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1 Summary and Acknowledgements 
Summary 
In order to increase drug safety we must better understand how medication interacts with the body of 
our patients and this knowledge should be made easily available for the clinicians prescribing the 
medication. This thesis contributes to how the knowledge of some drug properties can increase and 
how to make information readily accessible for the medical professionals. Furthermore it investigates 
the use of Therapeutic drug monitoring, drug interaction databases and pharmacogenetic tests in 
pharmacovigilance. 
Two pharmacogenetic studies in the naturalistic setting of psychiatric in-patients clinics have been 
performed; one with the antidepressant mirtazapine, the other with the antipsychotic clozapine. Forty-
five depressed patients have been treated with mirtazapine and were followed for 8 weeks. The 
therapeutic effect was as seen in other previous studies. Enantioselective analyses could confirm an 
influence of age, gender and smoking in the pharmacokinetics of mirtazapine; it showed a significant 
influence of the CYP2D6 genotype on the antidepressant effective S-enantiomer, and for the first time 
an influence of the CYP2B6 genotype on the plasma concentrations of the 8-OH metabolite was found. 
The CYP2B6*/*6 genotype was associated to better treatment response. A detailed hypothesis of the 
metabolic pathways of mirtazapine is proposed. In the second pharmacogenetic study, analyses of 75 
schizophrenic patients treated with clozapine showed the influence of CYP450 and ABCB1 genotypes 
on its pharmacokinetics. For the first time we could demonstrate an in vivo effect of the CYP2C19 
genotype and an influence of P-glycoprotein on the plasma concentrations of clozapine. Further we 
confirmed in vivo the prominent role of CYP1A2 in the metabolism of clozapine.  
Identifying risk factors for the occurrence of serious adverse drug reactions (SADR) would allow a 
more individualized and safer drug therapy. SADR are rare events and therefore difficult to study. We 
tested the feasibility of a nested matched case-control study to examine the influence of high drug 
plasma levels and CYP2D6 genotypes on the risk to experience an SADR. In our sample we compared 
62 SADR cases with 82 controls; both groups were psychiatric patients from the in-patient clinic 
Königsfelden. Drug plasma levels of >120% of the upper recommended references could be identified 
as a risk factor with a statistically significant odds ratio of 3.5, a similar trend could be seen for 
CYP2D6 poor metaboliser.  Although a matched case-control design seems a valid method, 100% 
matching is not easy to perform in a relative small cohort of one in-patient clinic. However, a nested 
case-control study is feasible. 
On the base of the experience gained in the AMSP+ study and the fact that we have today only sparse 
data indicating that routine drug plasma concentration monitoring and/or pharmacogenetic testing in 
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psychiatry are justified to minimize the risk for ADR, we developed a test algorithm named “TDM 
plus” (TDM plus interaction checks plus pharmacogenetic testing). 
Pharmacovigilance programs such as the AMSP project (AMSP = Arzneimittelsicherheit in der 
Psychiatrie) survey psychiatric in-patients in order to collect SADR and to detect new safety signals. 
Case reports of such SADR are, although anecdotal, valuable to illustrate rare clinical events and 
sometimes confirm theoretical assumptions of e.g. drug interactions. Seven pharmacovigilance case 
reports are summarized in this thesis.  
To provide clinicians with meaningful information on the risk of drug combinations, during the course 
of this thesis the internet based drug interaction program mediQ.ch (in German) has been developed. 
Risk estimation is based on published clinical and pharmacological information of single drugs and 
alimentary products, including adverse drug reaction profiles. Information on risk factors such as renal 
and hepatic insufficiency and specific genotypes are given. More than 20’000 drug pairs have been 
described in detail. Over 2000 substances with their metabolic and transport pathways are included 
and all information is referenced with links to the published scientific literature or other information 
sources. Medical professionals of more than 100 hospitals and 300 individual practitioners do consult 
mediQ.ch regularly.  Validations with comparisons to other drug interaction programs show good 
results.  
Finally, therapeutic drug monitoring, drug interaction programs and pharmacogenetic tests are helpful 
tools in pharmacovigilance and should, in absence of sufficient routine tests supporting data, be used 
as proposed in our TDM plus algorithm.  
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Résumé 
Pour améliorer la sécurité d’emploi des médicaments il est important de mieux comprendre leurs 
interactions dans le corps des patients. Ensuite le clinicien qui prescrit une pharmacothérapie doit avoir 
un accès simple à ces informations. Entre autres, cette thèse contribue à mieux connaître les 
caractéristiques pharmacocinétiques de deux médicaments. Elle examine aussi l’utilisation de trois 
outils en pharmacovigilance : le monitorage thérapeutique des taux plasmatiques des médicaments 
(« therapeutic drug monitoring »), un programme informatisé d’estimation du risque de combinaisons 
médicamenteuses, et enfin des tests pharmacogénétiques.  
Deux études cliniques pharmacogénétiques ont été conduites dans le cadre habituel de clinique 
psychiatrique : l’une avec la mirtazapine (antidépresseur), l’autre avec la clozapine (antipsychotique). 
On a traité 45 patients dépressifs avec de la mirtazapine pendant 8 semaines. L’effet thérapeutique 
était semblable à celui des études précédentes. Nous avons confirmé l’influence de l’âge et du sexe sur 
la pharmacocinétique de la mirtazapine et la différence dans les concentrations plasmatiques entre 
fumeurs et non-fumeurs. Au moyen d’analyses énantiomères sélectives,  nous avons pu montrer une 
influence significative du génotype CYP2D6 sur l’énantiomère S+, principalement responsable de 
l’effet antidépresseur. Pour la première fois, nous avons trouvé une influence du génotype CYP2B6 sur 
les taux plasmatiques de la 8-OH-mirtazapine. Par ailleurs, le génotype CYP2B6*6/*6 était associé à 
une meilleure réponse thérapeutique. Une hypothèse sur les voies métaboliques détaillées de la 
mirtazapine est proposée. Dans la deuxième étude, 75 patients schizophrènes traités avec de la 
clozapine ont été examinés pour étudier l’influence des génotypes des iso-enzymes CYP450 et de la 
protéine de transport ABCB1 sur la pharmacocinétique de cet antipsychotique. Pour la première fois, 
on a montré in vivo un effet des génotypes CYP2C19 et  ABCB1 sur les taux plasmatiques de la 
clozapine. L’importance du CYP1A2 dans le métabolisme de la clozapine a été confirmée.  
L’identification de facteurs de risques dans la survenue d’effets secondaire graves permettrait une 
thérapie plus individualisée et plus sûre. Les effets secondaires graves sont rares. Dans une étude de 
faisabilité (« nested matched case-control design » = étude avec appariement) nous avons comparé des 
patients avec effets secondaires graves à des patients-contrôles prenant le même type de médicaments 
mais sans effets secondaires graves. Des taux plasmatiques supérieurs à 120% de la valeur de 
référence haute sont associés à un risque avec « odds ratio » significatif de 3.5. Une tendance similaire 
est apparue pour le génotype du CYP2D6. Le « nested matched case-control design » semble une 
méthode valide qui présente cependant une difficulté : trouver des patients-contrôles dans le cadre 
d’une seule clinique psychiatrique. Par contre la conduite d’une « nested case-control study » sans 
appariement est recommandable.  
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Sur la base de notre expérience de l’étude AMSP+ et le fait que nous disposons que de peux de 
données justifiant des monitorings de taux plasmatiques et/ou de tests pharmacogénétiques de routine, 
nous avons développé un test algorithme nommé « TDMplus » (TDM + vérification d’interactions 
médicamenteuses + tests pharmacogénétique).   
Des programmes de pharmacovigilances comme celui de l’AMSP (Arzneimittelsicherheit in der 
Psychiatrie = pharmacovigilance en psychiatrie) collectent les effets secondaires graves chez les 
patients psychiatriques hospitalisés pour identifier des signaux d’alertes. La publication de certains de 
ces cas même anecdotiques est précieuse. Elle décrit des événements rares et quelques fois une 
hypothèse sur le potentiel d’une interaction médicamenteuse peut ainsi être confirmée. Sept 
publications de cas sont résumées ici. 
Dans le cadre de cette thèse, on a développé un programme informatisé sur internet (en allemand) – 
mediQ.ch -  pour estimer le potentiel de risques d’une interaction médicamenteuse afin d’offrir en 
ligne ces informations utiles aux cliniciens.  Les estimations de risques sont fondées sur des 
informations cliniques (y compris les profils d’effets secondaires) et pharmacologiques pour chaque 
médicament ou substance combinés. Le programme donne aussi des informations sur les facteurs de 
risques comme l’insuffisance rénale et hépatique et certains génotypes. Actuellement il décrit en détail 
les interactions potentielles de plus de 20'000 paires de médicaments, et celles de 2000 substances 
actives avec leurs voies de métabolisation et de transport. Chaque information mentionne sa source 
d’origine; un lien hypertexte permet d’y accéder. Le programme mediQ.ch est régulièrement consulté 
par les cliniciens de 100 hôpitaux et par 300 praticiens indépendants.  Les premières validations et 
comparaisons avec d’autres programmes sur les interactions médicamenteuses montrent de bons 
résultats. 
En conclusion : le monitorage thérapeutique des médicaments, les programmes informatisés contenant 
l’information sur le potentiel d’interaction médicamenteuse et les tests pharmacogénétiques sont de 
précieux outils en pharmacovigilance. Nous proposons de les utiliser en respectant l’algorithme 
« TDM plus » que nous avons développé.  
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2  Aims  
 
“Pharmacovigilance is the science and activities relating to detection, assessment, 
understanding, and prevention of adverse effects or any drug-related problems “   
(World Health Organisation 2002) 
 
The main and general aim of this thesis is a contribution towards improving drug safety for the 
psychiatric patient by finding means to minimize the risks of his or her drug treatment. Drug safety in 
psychiatry requires special attention: on the one hand, drugs are administered to patients who cannot 
always communicate their symptoms and who are sometimes treated against their will and in pressing 
situations of emergency, often involving polypharmacy and high doses. On the other hand, the 
pharmacology of psychotropic drugs and their interactions in drug combinations are still insufficiently 
known, as are the biological foundations of the diseases to be treated. 
In order to minimize risks, we have to be aware of them. Knowledge about drug characteristics and 
interactions with patient factors has to improve. To this goal, we performed two clinical studies in 
order to increase the clinically relevant pharmacokinetic knowledge about the antidepressant 
mirtazapine and the antipsychotic clozapine.  
Therapeutic Drug Monitoring, drug interaction checking programs and pharmacogenetic tests are in 
2011 considered to be useful tools for clinicians to minimize risks of drug therapies and help in 
causality assessment in pharmacovigilance. However, at the preparation of this thesis in 2001 
clinicians hardly used or even knew these tools. We implemented the use of Therapeutic Drug 
Monitoring (TDM) and pharmacogenetic tests in a clinical setting and in a case-control study 
evaluated the relationship between drug plasma levels, CYP2D6 genotypes and the risk of 
experiencing a serious adverse drug reaction. 
Furthermore, we developed a user-friendly drug interaction database that estimates the risk of drug 
combinations by taking into account pharmacokinetic and pharmacodynamic properties of the 
combined substances and some patient-related risk factors such as pharmacogenetics, diet and 
lifestyle. 
This thesis is structured as follows:  
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Introduction (chapter 3) 
In chapter 2 general considerations about pharmacovigilance in psychiatry and, more specifically, the 
drug safety project AMSP (Arzneimittelsicherheit in der Psychiatrie) will be presented, followed by an 
introduction to TDM, pharmacogenetics and drug-drug interactions. 
The pharmacogenetics of mirtazapine and clozapine (chapters 4 and 5) 
In chapters 4 and 5 the clinical trials with mirtazapine, in depressed, and clozapine, in schizophrenic 
patients, are presented, which examine the influence of pharmacogenetics and other factors on their 
pharmacokinetics and subsequent clinical consequences. Therapeutic drug monitoring and 
pharmacogenetic tests (genotyping and phenotyping) were used in connection with a clinical study 
protocol. These protocols, moreover, mimic the normal practice of a psychiatric in-patient clinic.  
Feasibility study AMSP+: a nested case­control study with psychiatric 
inpatients (chapter 6) 
Within the international quality assurance and research project AMSP the feasibility of using 
therapeutic drug monitoring and pharmacogenetic tests in the causality assessment of serious adverse 
reactions has been evaluated. In addition, a pilot nested case-control study was set up to test the 
feasibility of this design for a larger study examining the relationship between plasma levels and 
genotypes and the risk of developing a serious adverse drug reaction.  
Web­based  drug interactions database: mediQ.ch (chapter 7) 
Risk assessment in drug combination therapy is often very complex and time-consuming and, when 
this thesis was still in its preparatory phase in 2001, it was hardly part of clinical routine at all. Major 
risks were taken and serious adverse reactions resulted which could be have been avoided if such 
knowledge had been available more easily. A major part of this thesis consisted of creating an accurate 
and user-friendly drug interaction program offering clinicians this knowledge in an easily accessible 
and timely manner, always keeping in mind the time constraints of the clinical work context. 
Pharmacovigilance case studies (chapter 8) 
Anecdotal information from well-documented individual cases can be valuable for the detection of 
rare adverse drug effects and also for didactic purposes. A selection of such cases is presented in 
chapter 8. 
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Concluding remarks and outlook (chapter 9) 
Chapter 9, finally, looks back and summarizes the contributions of this thesis to improve drug safety 
for the psychiatric patient and provides an outlook on further activities planned in relation to this 
project. 
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3 Introduction 
Not only effective but also safe and well tolerated medication is one of the major goals of today’s drug 
development. In spite of all these efforts the number of serious and life threatening adverse drug 
reactions seems not to decrease. A meta-analysis from 1998 (1) showed an incidence of 6.7% serious 
adverse drug reactions (SADR), whereas fatal reactions involved 0.32% of hospitalized patients;  
calculated for the population of the United States of America (USA) meaning that about 2.2 Mio in-
patients suffer annually from SADR and 100 000 die from it. A study from the Food and Drug 
Administration (FDA) in the USA show a 2.6 fold increase in SADR and related deaths over the 
period from 1998 to 2005 (2). These numbers represent a serious medical and socio-economical 
problem (3-6).  
The majority of Adverse Drug Reactions (ADR) are predictable from the pharmacologic action of the 
drug (type A reactions, see also table 1) and are therefore considered at least partly avoidable. One 
strategy is to identify vulnerable individuals by biomarker tests (e.g. pharmacogenetic) (7), by taking 
into account co-morbidities and life style of the patient, and eventually by checking possible drug 
interaction potentials. Another strategy is intensified surveillance of the patient during treatment by 
e.g. Therapeutic Drug Monitoring (TDM), laboratory testing, electrocardiogram (ECG), and others for 
early detection and intervention to limit the extent of harm. Large pharmacovigilance surveillance 
programs such as the AMSP project (see page 17) help to detect adverse drug reactions and their risk 
factors. 
 
Pharmacovigilance in Psychiatry 
In psychiatry we are often confronted with chronic diseases requiring long term medication and with 
increasing polypharmacy (8-10). Polypharmacy is on average 3.5 and 5 drugs in patients  < 65 years 
and 65 years and older, respectively (AMSP (11) data on file, R. Grohmann personal communication). 
Psychotropic drugs have many side effects but the rate of serious adverse drug reactions seems with 
1.5 - 2% (data from the AMSP project) lower than in other medical disciplines with 6-7% (1;3). That 
could be explained by underreporting or because psychiatric patients are not always easy with 
expressing their suffering of side effects, and differentiation between adverse drug reactions and 
symptoms of underlying illness can be difficult. Data of the AMSP project show that a serious adverse 
drug reaction leads to a doubling of the hospitalisation duration which means a considerable burden, 
also economically, the average hospitalisation duration increasing from approximately 25 days to 50 
days (data from the AMSP project). 
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Type of Adverse Drug Reactions (12) 
When a causal relationship with the drug taken is established, an adverse drug event (ADE) is 
considered to be an adverse drug reaction (ADR). A serious adverse drug reaction meets one of the 
generally accepted following criteria: death, life threatening, causing permanent damage, leading to or 
prolonging hospitalisation (Definitions ICH E2A 1995 Step 5 revised in 2006).  
 
Two major classes of ADR exist: Type A and Type B (13).  Type A are common (> 80% of all ADR), 
predictable, and tend to be dose- or more exactly concentration-related and less serious than those 
aberrant effects of the Type B reactions. Type A reactions can result from too much of a drug (too 
high dosage, pharmacokinetic drug interaction, normal dosage but the person metabolises or excretes 
the drug only very slowly, normal dosage but the person absorbs more drug than common, normal 
dosage but the person is overly sensitive), but also by pharmacodynamic drug interactions (serotonin 
syndrome by combining several serotonin agonists) or in response to a secondary drug pharmacology 
(torsade de pointes in a patient with a long QT syndrome) (Table 1). 
 
Table 1:  Classification of adverse drug reactions 
Predictable  
(also known as Type A) 
Unpredictable  
(also known as Type B) 
• Overdosage/toxicity: e.g., nephrotoxicity 
caused by elevated aminoglycoside levels; 
coma because of elevated benzodiazepine 
levels  
• Side effects: e.g., constipation caused by 
chronic opiate use  
• Secondary or indirect effects 
o related to drug alone: e.g., 
disturbance of vaginal flora due to 
antibiotic use  
o related to both disease and drug: 
e.g., ampicillin rash in association 
with Epstein- Barr virus 
• Drug interactions: e.g., use of terfenadine 
(now withdrawn from the market) in 
combination with ketoconazole can result in 
torsade de pointes caused by elevated 
terfenadine levels; combination of 
fluvoxamine and clozapine can results in 
delirium due to very high clozapine plasma 
levels 
• Intolerance: e.g., tinnitus caused by small 
doses of aminosalicylic acid   
• Allergic (hypersensitivity or immunologic): 
result of an immune response to a drug, e.g., 
penicillin-induced urticaria  
 
• Pseudo-allergic (non-immunologic): 
immediate, generalized reaction involving 
mast cell mediator release, e.g., respiratory 
symptoms induced by non-steroidal anti-
inflammatory drugs  
 
• Idiosyncratic: unexpected response to a drug 
and differing from its pharmacological 
actions; not related to an allergic mechanism, 
e.g., anticonvulsant hypersensitivity 
syndrome reaction (characterized by fever, 
cutaneous eruption and internal organ 
involvement) 
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Since the majority of ADR are type A reactions, which tend to be concentration-dependent, one could 
hypothesize that (too) high plasma concentrations are a risk factor for an ADR and that by avoiding 
them a substantial amount of ADR could be prevented. This seems obvious when studying some 
individual cases but how relevant is this risk in a larger patient population?  
 
The Project „Arzneimittelsicherheit in der Psychiatrie“ AMSP 
Legislated pharmacovigilance took its beginning in the early1960ties with the invalidating thalidomide 
effects on babies of mothers who took this drug against morning sickness during pregnancy. The 
government of the USA decided to regulate Drug Safety within the FDA. Other countries followed 
with their own regulatory bodies and legislation, and post marketing surveillance was institutionalized. 
In 1973 a number of fatal cases of agranulocytosis cases occurred under treatment with clozapine 
which led to the withdrawal of this efficacious antipsychotic drug in several countries. As a reaction to 
that, in 1979, the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie) founded the 
pharmacovigilance working group AMÜP (Arzneimittelüberwachung in der Psychiatrie). The AMÜP 
study was a model for the continuous and systematic post marketing surveillance of psychiatric in-
patients collecting data on the nature and frequency of adverse drug reactions in a natural psychiatric 
setting (14;15). It was performed in the university clinics of Munich, Göttingen and Berlin and was 
supported by the former Bundesgesundheitsamt (federal office of health) of Germany. It lasted 20 
years.  
With the methodology and experience of AMÜP the AMSP project was developed from 1990 – 1993 
by Hans Hippius, Eckart Rüther, Rolf Engel and Renate Grohmann (16). Since 1993 AMSP surveys 
around 30’000 beds in approximately 57 psychiatric clinics in Germany, Austria and Switzerland. 
Serious adverse drug reactions (as defined by the AMSP project, table 2) are collected by AMSP drug 
monitors (medical doctors) in the naturalistic setting of the psychiatric inpatient clinic.  
Causality assessment is made by the drug monitor and the responsible treating doctor according to 
standard causality assessment criteria:  
1. Association in time between drug administration and event,  
2. Pharmacology (features, previous knowledge of side effects),  
3. Medical plausibility (characteristic sign and symptoms, laboratory assessments, pathological 
findings), and  
4. Likelihood of other causes, risk factors (17).  
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Table 2: Serious adverse drug reactions according AMSP criteria 
Life threatening or fatal, permanent disability, potentially life threatening, severely incapacitating. Examples by 
organ system: 
Psychic ADR: Suicide, suicide attempt, suicidal ideation, delirium, paranoid/hallucinatory or catatonic 
syndrome, depression, mania, coma, sopor, somnolence, aggressivity, obsessive compulsive symptoms, 
substance dependency, severe sedation, respiratory depression, frightening nightmares, severe psychomotor 
agitation,.. 
Neurological ADR: Incapacitating extrapyramidal-motor symptoms such as severe early dyskinesia, Parkinson 
syndrome, and akathisia; tardive dyskinesia, malignant neuroleptic syndrome, catatonic neuroleptic syndrome, 
Rabbit syndrome, atypical dyskinesia such as Pisa syndrome. Furthermore seizures, serotonin syndrome, ataxia, 
severe myocloni, severe tremor, speaking disorder, tinnitus, severe accommodation disturbances, diplopia, 
paraesthesia, restless legs. 
Cardiovascular ADR: Collapse, heart insufficiency, cardiac arrest, myocardial infarct, myocarditis, deep vein 
thrombosis, embolia, cerebrovascular disturbances, hypertension > 180/110 mmHg, symptomatic hypotension < 
90 mmHg, conduct disorders, arrhythmia, bradycardia < 40/min., tachycardia > 120/min, atriofibrillation, AV-
block II and III, QT-interval prolongation > 500ms or increase of > 25%, torsade de pointes, .. 
Liver disturbances: Liver value increase > 5 times the norm value, (AST, ALT, Y-GT, AP), severe cholestasis, 
hepatitis, ..  
Gastro-intestinal ADR: Severe vomiting or diarrhoea, severe nausea of longer than week, severe constipation, 
massive hypersalivation, pancreatitis, subileus and ileus, oesophagitis, .. 
Dermatological ADR: Allergic dermatological reactions, severe rash, Quincke oedema, allergic vasculitis, new 
manifestation or exacerbation of psoriasis, severe acne, severe hair loss, massive oedema, ..  
Haematological ADR: Neutropenia < 1500 neutrophiles/mm3 = <1,5/nl and agranulocytosis (< 500 
neutrophiles/mm3 = < 0,5/nl). Anaemia Hb < 8mg/dl, thrombopenia < 100.000/mm3 =< 100/nl, panzytopenia, 
coagulation disturbances, eosinophilia > 1500/mm³= > 1,5/nl absolute.  
Kidney and bladder disturbances: Disturbances of the kidney function, severe micturation problems (urine 
retention, pollakisuria), incontinence,... 
Sexual disturbances: Sexual disturbances which last > 4 weeks and are very bothersome for the patient, severe 
sexual disturbances, priapism,.. 
Endocrine and metabolic disturbances: Severe galactorrhoea, amenorrhoea > 6 months, symptomatic 
hypothyreosis, hyponatriemia <130 mmol/l; diabetes: new manifestation or exacerbation, hyperlipidemia which 
needs treatment, CK- increase > 2000 U/l, rhabdomyolysis.  
Respiratory disturbances: All forms of dyspnoea 
Other ADR: Weight increase > 10% body weight, metabolic syndrome, binging attacks, severe lasting cephalea, 
fever > 39°C. Loss of efficacy will only be taken into account as consequence of a drug interaction. 
Case and causality assessment are re-discussed in regional AMSP conferences and some complex 
cases in the international AMSP conferences as well. For estimation of the ADR frequencies, all 
medication from each surveyed patient is noted on 2 index days per year. 
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The AMSP project is a prospective multicentre dynamic cohort study under naturalistic conditions. Its 
aim is among others signal detection, in a case-by-case or qualitative analysis (18;19) as shown in 
figure 1. The signal can be a new ADR or a frequency change of an ADR associated to a certain drug 
or a change in severity.  
Figure 1: process of signal detection 
 
When a signal has been identified, a hypothesis is made which has to be verified in e.g. a case-cohort, 
case-control or other adequate epidemiological study (fig. 2). 
Figure 2: Potential Study designs in epidemiology. 
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Epidemiological studies allow calculating incidences, prevalence and risk ratios; risk factors such as 
age, certain genotypes, drug interactions or certain diseases can be identified. For risk calculations, 
incidence in the exposed population versus incidence in the non-exposed population is compared 
(table 3). 
Table 3: Two by two table for the calculation of risk ratios.  (RR = relative risk (for cohort studies); OR = 
odds ratio (for case-control studies); SAE = serious adverse event; Exposure: exposed to e.g. a drug; a = 
exposed and SAE, b = exposed no SAE, c = non exposed, but SAE, d = non exposed and no SAE.) 
 
For more detailed methodology of the AMSP project see www.amsp.ch and (16;20). Some case 
reports from the AMSP project are presented in Chapter 8, a case-control study from a sub-population 
of the AMSP project in Chapter 6. 
 
Inter- and intra-individual variations in drug plasma levels 
Drug plasma levels are determined by pharmacokinetic parameters (absorption, distribution, 
metabolism, elimination = ADME) that determine the amount of drug reaching the site of action. Drug 
transporting proteins (e.g. P-glycoprotein (Pgp)) and most important drug metabolising enzymes 
(e.g. Cytochrome P450 (CYP450)) are relevant factors determining the pharmacokinetic profile. Drugs 
may be metabolised by many different sequential and/or competitive chemical processes comprising 
phase I metabolic reactions (oxidation e.g. CYP450, reduction, hydrolysis) and/or phase II reactions 
(e.g. glucuronidation, acetylation). 
Inter- and intra-individual variations in drug plasma levels depend on biological variables and also on 
lifestyle and environmental factors.  Figure 3 illustrates examples of factors influencing plasma levels 
and subsequently the risk of developing adverse drug reactions. 
 
22 
   
Figure 3: Interaction of drug, patient and environmental factors 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic Drug Monitoring TDM 
TDM is based on the hypothesis that the concentration of a drug in the blood (plasma or serum) 
reflects - better than its dose - its concentration at target site. TDM is also based on the assumption that 
there is a definable relationship between drug plasma concentration and clinical effects (therapeutic 
effect and toxicity). In case of active metabolites the sum of the parent compound and the active 
metabolites (i.e. the active moiety) should be measured (e.g. venlafaxine and O-desmethylvenlafaxine 
ODV). This yields information on its contribution to the overall clinical activity of the compound, but 
also on the metabolism of the drug (e.g. ratio metabolite/parent compound). 
In psychiatry, these relationships have been mainly investigated for lithium, tricyclic antidepressants 
and antipsychotic drugs (the latter with inconsistent results) (21-31). Methodological limitations of 
many studies might be the reason for the lack of an evident relationship between concentration and 
effects or side effects (32-36). However,  systematic reviews and meta-analyses (37) based on 
adequately designed studies have produced convincing evidence for this relation. A correlation 
between plasma levels, dopamine D2 receptor occupancy and extrapyramidal side effects could be 
demonstrated for antipsychotic medication, e.g. for haloperidol (38;39). For drugs with a wide 
therapeutic index such as SSRIs, TDM is mainly used as a basis to adapt doses for special populations 
Environmental  
Diet 
Smoking 
Alcohol, Drugs 
Cultural factors 
Patient 
Genetics 
Age 
Gender 
Disease 
Interaction 
Drug 
Dose 
Exposure 
Route of administration 
Galenic formulation 
Frequency of drug intake 
Absorption, Distribution, 
Metabolism, Excretion 
Variability in drug response 
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such as the elderly, patients with hepatic impairment or patients with a known pharmacogenetic 
polymorphism affecting the metabolism of the prescribed drug (40).  
Indications 
Table 4 outlines indications where TDM is useful in relation to drug safety. In psychiatry, monitoring 
of substances with a narrow therapeutic index, especially when used in long term treatment and 
compliance control are probably dominant; TDM in particularly vulnerable patient populations may 
prevail in other medical specialities. TDM gains importance in the presence of unexpected adverse 
drug reactions.  
Table 4: List of indications for TDM in relation with pharmacovigilance 
o In case of adverse drug reaction type A 
o Monitoring of substances with a narrow therapeutic window 
o Combination therapy with pharmacokinetic drug-drug interaction potential   
o Known pharmacogenetic polymorphisms (drug metabolic enzymes, transporter proteins) 
o Pharmacotherapy in special patient populations (elderly, children, pregnant women, patients 
with renal or hepatic insufficiency) 
o Problems occurring after switching different preparations of the same compound (e.g. original 
preparation versus generic) 
 
Consensus guidelines for the use of TDM 
In 2004, the first international Consensus Guidelines for TDM of psychopharmacological agents were 
published by the interdisciplinary TDM expert group of the Arbeitsgemeinschaft für 
Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) (41), an update will be published in 
the fall of 2011. These guidelines cover indications for TDM, levels of recommendation, practical 
guidelines for clinicians and laboratories, and importantly, give reference plasma levels for the 
therapeutic window, as well as expected dose-dependent plasma levels under steady state conditions. 
Where therapeutic ranges are missing, target ranges corresponding to the normally observed plasma 
levels at therapeutic drug doses are given. 
Sometimes, individual optimal serum concentrations seem to be preferred over consensus values, 
especially for long term and combination treatments (42;43).  This is supported by studies on 
predicting relapse or rehospitalisation of patients under clozapine treatment; it was found that the 
variability in plasma levels in an individual patient seems to be predictive for a psychotic exacerbation 
(44;45).  
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In the difficult situation of a relative overdose (e.g. a very high plasma concentration due to a genetic 
deficiency for a metabolic enzyme or due to a drug-drug interaction (DDI)), it is important to know the 
toxic plasma levels of a drug. However, these are unknown for many, especially newer drugs, which in 
general have wider therapeutic indexes. Some listings of toxic drug concentrations exist (46;47); they 
have been generated by reviewing case reports of intoxications. A laboratory alert level has been 
included in the consensus guidelines 2011 indicating potentially harmful drug concentrations.  
Reference plasma levels are generally based on trough steady-state concentrations. The difference 
between peak and trough levels can be very important, as e.g. in the case of quetiapine (fig. 4). Special 
attention is necessary when comparing results from immediate release galenic forms and extended 
release forms (48). Methylphenidate (49;50), atomoxetine (51;52) and agomelatine (CHMP 
assessment report of Valdoxan Procedure No. EMEA/H/C/000915) are exceptions, such that steady 
state peak plasma levels have to be measured. Methylphenidate and agomelatine have a very short half 
life, so inter-individual variability in drug pharmacokinetics and trough plasma concentrations are 
difficult to detect. In the case of atomoxetine the peak compared to trough plasma concentrations are 
less affected by the CYP2D6 genotype-dependent inter-individual variability. In patients treated with 
an intramuscular depot preparation of an antipsychotic drug, blood should be sampled immediately 
before the next injection and also during steady state conditions (often only reached after 2 - 4 months) 
(53). 
 
Figure 4: peak (blood sampling 90 minutes after drug intake) and trough plasma concentrations of 
quetiapine immediate release of 13 patients participating in a multicentre pharmacogenetics study on 
quetiapine (manuscript in preparation) 
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TDM is a valid tool to optimise pharmacotherapy, but it does not replace clinical judgement. Since the 
majority of adverse drug reactions is dose-dependent, measuring drug plasma levels seems to be a 
highly rational approach to prevent these reactions, to reveal possible causes and, subsequently, to take 
steps to adjust drug treatment.  
 
Pharmacogenetics 
 
Definition 
Pharmacogenetics describes hereditary factors influencing the response to drug treatment - therapeutic 
effect and potential side effects - either dealing with the fate of drugs in the body (ADME) or the 
interaction of the drug with the body at the target site (pharmacodynamics, e.g. neurotransmitter 
transporter polymorphism). “Genetic polymorphism” refers usually to genetic loci for which variants 
occur with a frequency of at least 1% (54).  
Cytochrome P450 polymorphisms 
Genetic polymorphisms of drug metabolising enzymes and their effects on treatment response for 
certain patients have been extensively studied since the late 1970s (55-57). Individual genetic 
disposition determines their activity, and the number of active alleles in a gene determines to a great 
extent how much enzyme will be produced. Some Cytochrome P450 isozymes are primarily involved 
in phase I reactions of psychoactive drugs, most importantly CYP2D6, but also CYP1A2, CYP2B6, 
CYP2C19 and CYP3A. CY2D6 and CYP2C19 are genetically polymorphic, some genotypes leading 
to complete enzyme deficiency. CYP3A as well as CYP1A2 are largely influenced in activity by 
enzyme induction or inhibition but genetic polymorphisms in these two CYP enzymes are less 
important for the phenotype. From a genetic point of view, four types of drug metabolisers have been 
identified, which are not found with all drug metabolising CYP450 enzymes. The most 
comprehensively studied CYP isoform is CYP2D6 and the following definitions are established 
mainly on the basis of observations about the metabolism of substrates by this enzyme.  
1. ”Poor metaboliser” (PM) carry two alleles predicting a low (e.g. CYP2D6*10 or *17)(58) or 
no enzyme activity (e.g. CYP2D6*3, *4, *5);  
2. “intermediate metaboliser” (IM) are normally referred to individuals being heterozygous 
carriers of one inactive allele or have two alleles with reduced activity, leading to a reduced 
enzyme activity;  
3. ”extensive metaboliser” (EM) are carriers of two active alleles having a normal activity; 
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4. ”ultra-rapid metaboliser” (UM) have a very high enzyme activity which is genetically caused 
by gene duplication expressed as 2XN (so far found for CYP2D6). Recently rapid 
metabolisers for other CYP450 enzymes have been found, e.g. in patients carrying the 
CYP2C19*17 allele (59;60) .  
The phenotypes reflecting the actual enzyme activity still show high inter-individual variation 
especially within the intermediate and extensive metaboliser groups. Thus, genetic prediction of 
enzyme activity is best possible for the poor and ultra-rapid genotypes but poor or ultra-rapid 
metabolizing activity can also be caused by enzyme inhibition or induction (61;62).  Instead of this 
classical approach of attributing phenotypes to genotypes, efforts have been made to predict a CYP450 
enzyme activity score by genotype (63). Figure 5 illustrates genotype dependent plasma concentrations 
and expected therapeutic and toxic effects.  Extensive information on the activity of different CYP450 
alleles can be found on www.imm.ki.se/CYPalleles.  
 
Figure 5: Schematic illustration of CYP2D6 genotype-based plasma concentration differences and 
therapeutic consequences (64) (wt = wild type, mut = mutant;      = genotype based plasma 
concentration at steady state). In the case of a person with the wild type genotype there is an optimal 
balance between drug efficacy and toxicity, in the case of a person with homozygote mutant genotype 
the risk for toxicity is high.   
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The prevalence of different types of metabolisers varies greatly between ethnic groups (table 5) (65).  
Table 5: Estimate of the prevalence of relevant CYPP450 polymorphisms in different ethnic populations 
Ethnicity CYP450 Poor metaboliser Ultra rapid metaboliser 
Various* 1A2* Rare (66-68) Induction polymorphism (68-72)  
Clinical relevance unclear 
- Caucasian (73-75) 
- Asian (76;77) 
- African (78) 
2C8/9 1-10%  
0-2% 
up to 4% 
None 
- Caucasian (75;79), African 
(80), Saudi Arabia (81) and   
Turkish (82)  
- Asian (77;83-85) 
2C19 1-5%, 
 
13-23% 
CYP2C19*17 (59;60) 
Various 2B6 High inter-ethnic differences (86-
92)  
CYP2B6*4 (93) 
- Asian (79;94) 
- Turkish (82)  
- African (80;94) and   Afro 
American 
- Caucasian (75;95-99)  
 
-Saudi Arabia (81;100) 
- Aethiopian 
 
- Asian (101) 
- African (80) 
 
2D6 
 
1-2%                                                   
.                                                            
2-4 %                                                 
.       
5-7% 
 
 
 
Carrier of an allele with reduced 
activity(102-104) 
up to 50% (CYP2D6*10)  
up to 30 % (CYP2D6*17)  
up to 2%                                        
5-10% 
2%                                                    
.  
1-2 % North Europe 
5-10% South Europe 
20% 
up to 29% 
 
 
 
 
- Caucasian (105) 
- Afro Americans (105) 
- Japanese (106) 
- Chinese (107) 
3A5 About 70 % 
About 40% 
30-40% 
about 50% 
 
Various (108) 3A** Wide variability in metabolic 
capacity, few functional 
polymorphisms identified. 
Wide variability in metabolic 
capacity, few functional 
polymorphisms identified. 
* The inter-individual variability of the CYP1A2 metabolic capacity is wide, with a bi- or tri-modal distribution 
depending on the population; only few functional genes have been identified to date. 
**The inter-individual variability in the CYP3A metabolic capacity is wide but no bi- or multimodal distribution 
has been found, indicating that most probably several genes contribute to the function.  
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CYP2D6 and CYP2C19 show a polymodal distribution of activity in the population. For CYP2D6 
which catalyses the oxidative biotransformation of many tricyclic antidepressants and other 
psychotropic drugs, 5 to 8% poor metabolisers and 1 to 10 % ultra-rapid metabolisers have been found 
in Caucasians. CYP2C19 polymorphisms are less prevalent in Caucasians and seem to be therefore 
less important (109) although several tricyclic antidepressants and citalopram are catalysed by this 
enzyme. In Asians, however, about 20% of the population are poor metabolisers. The unimodal 
distribution of large inter-individual variability of CYP3A4 activity suggests multiple influence factors 
on enzyme activity of this important enzyme which is highly expressed in human liver. Two other 
CYP3A enzymes are existing, CYP3A5 for which genetic polymorphisms have been detected to 
predict enzyme expression, and CYP3A7 which is mainly expressed during foetal life and later in a 
low percentage of adults (110;111). CYP3A5 is only expressed in 10-30% of the Caucasians and their 
contributing effect to overall CYP3A activity is low. The clinical relevance of the CYP1A2 
polymorphism (C->A) (66;70) associated with high inducibility is unclear and conflicting results have 
been reported (69;71;112). Genetic and environmental factors can interact synergistically or in an 
antagonistic way by e.g. adding a CYP2D6-blocking agent in pharmacological treatment with a 
CYP2D6 substrate taken by a CYP2D6 ultra-rapid metaboliser (113). 
Recent investigations indicate that drug transporters, such as P-glycoprotein (Pgp) and organic anion-
transporting polypeptides (OATP), in the intestinal mucosa and the blood brain barrier are also 
relevant for the pharmacokinetic variability of many drugs (114-119). 
P-glycoprotein, coded by the MDR-1 (multi-drug resistance, also known as ABCB1) gene, is an 
adenosine triphosphate (ATP)-dependent efflux pump for xenobiotic compounds with broad substrate 
specificity (120;121).  A model of Pgp-mediated substrate transport (fig. 6) can be found in recent 
publications (122). Pgp plays an important role in drug absorption, disposition and excretion, and is 
found in several organs such as the gut, liver, gonads, kidneys, brain and others (116;117;123;124) 
(fig. 7). Reported genetic polymorphisms of MDR-1 show high inter-ethnic variability and appear to 
play a role similar to that of drug-metabolizing enzymes (114;125-129). Pgp function can be 
influenced by drugs, food, smoking, age and gender, and it can be inhibited or stimulated. 
Interestingly, Pgp and CYP3A4 are often co-expressed in the same cells and they share a large number 
of substrates and modulators (inhibitor and inducer). The disposition of such drugs is influenced by 
both drug transport and metabolism, and the interaction with modulators acting on both systems will 
multiply the effect; for example, cyclosporine is a substrate of CYP3A4 and Pgp (130-132), whilst St. 
John’s wort is an inducer of both (133-135). 
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Figure 6:  Model of substrate transport by the efflux pump Pgp (lilac), membrane between two 
horizontal lines. Pgp-substrates (pink) enter a cavity of the P-glycoprotein lined up with amino acids 
(blue) which can bind to many different molecules.  ATP (adenosine triphosphate) binds to two 
nucleotide-binding domains which causes a conformational change ejecting the substrate to the 
outside. Adapted from (122) 
 
 
Figure 7: Pgp acts as an efflux pump for xenobiotics at the brain, the liver, the intestine, the gonads, 
the kidney, and at the placenta in order to protect vital organs. Adapted from (136) 
                                         
With regard to the occurrence of wanted or unwanted clinical effects, the contribution of drug 
transporters is less well understood than that of drug metabolising enzymes. Digoxin is a typical Pgp 
substrate with a narrow therapeutic index that can be affected by Pgp inhibition or induction. Certain 
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phenotypes of Pgp can lead to increased plasma levels of digoxin (125) and subsequently to serious 
adverse drug reactions. Another example is the Pgp substrate loperamide, a potent opiate anti-
diarrhoea drug that has limited access to the brain due to Pgp activity. When combined with the Pgp 
inhibitor quinidine, it can enter the brain and cause respiratory depression (137) without any change in 
plasma levels of loperamide.  
Pharmacogenetic tests 
Depending on the particular CYP450 enzyme, different geno- or phenotyping methods are today 
available for the clinician. Genotyping and phenotyping differ in their clinical significance. 
Genotyping is considered as a “trait marker” and its result does not depend on environmental factors, 
meaning that it has only to be performed once in a person’s lifetime. In general a DNA probe is 
extracted from a non-centrifuged whole blood sample, but buccal swabs or saliva samples may also 
serve. Most laboratories analyse only the most common alleles for which a functional significance is 
known. Standard methods such as real-time polymerase chain reaction (PCR) (138) are mainly used 
for rapid and inexpensive genotyping of the common alleles. More than 95% prediction of the poor 
metaboliser of CYP2D6 is possible with genotyping of the (few) alleles predicting deficient enzyme 
activity such as CYP2D6*3, *4, *6 and *5 (104;139-141), and for CYP2C19 80% and almost 100% of 
the poor metaboliser can be predicted in analysing CYP2C19*2 and *3 (142) in Caucasian and Asian 
respectively. In cases where many alleles of more than one gene should be analysed, microarray-based 
genotyping devices (“gene chips”) (143;144) are recommended. Unfortunately the costs for gene chip 
analysis are still relatively high. A very short time lag between collecting a DNA probe and obtaining 
the results is a prerequisite if genotype-based dosing is applied.  
 
Phenotyping tests exist for more CYP450 enzymes but they represent “state markers” meaning that 
they are situation dependent. This carries the advantage of reflecting the metabolic situation of the 
patient at a specific moment, and allows its evolution to be followed. Some persons especially among 
psychiatric patients experience the fact that they have to ingest a test substance which will be later 
analysed in a blood or urine sample together with its metabolites as disadvantage. Phenotyping test 
probes should be isozyme specific such as dextromethorphan (145), sparteine/desbrisoquine for 
CYP2D6 (146;147), mephenytoin (145) or omeprazole for CYP2C19 (148), tolbutamide or 
flurbiprofen for CYP2C9 (149;150), caffeine for CYP1A2 (69) and midazolam for CYP3A (151;152). 
However, some of these probes lack enough specificity as is the case for dextromethorphan to clearly 
distinguish ultra-rapid from extensive metaboliser (and intermediate metabolisers).  
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Genetic association - haplotype analysis (153) 
Single nucleotide polymorphisms (SNPs) in a gene can be analysed either considering them each as a 
separate predictor or by haplotypes. A haplotype is a combination of alleles or SNP’s, a set of DNA 
variations, located on the same chromosome and which tend to be inherited together. Special statistical 
methods exist for inferring haplotypes and population haplotype frequencies from the genotypes of 
unrelated individuals. These methods, and the software that implements them, rely on the fact that in 
region of low recombination relatively few of the possible haplotypes will actually be observed in any 
population. True haplotypes are more informative than genotypes, but inferred haplotypes are typically 
less informative because of uncertain phasing. However, the information loss that arises from phasing 
is small when linkage disequilibrium is strong (153).  
These complex statistical methods are commonly applied when studying the association of ABCB1 
SNPs to e.g. drug plasma concentrations or drug effects (see e.g. chapter 5). 
 
Pharmacogenetic Studies in Pharmacovigilance 
Sufficient clinical data are missing to give clear cut recommendations concerning pharmacogenetic 
testing before initiating treatment. Kirchheiner et al (154-156) developed a scheme for genotype-based 
dose adjustments. They recommend genotyping for drugs where a minimum 2 fold difference in AUC 
for the active moiety has been observed between poor metabolisers and ultra-rapid or extensive 
metabolisers and/or for which a twofold or more risk for an adverse drug reaction or therapy failure 
exists. Some clinical studies in psychiatry found a higher number of patients not tolerating treatment as 
a consequence of a genetically deficient drug metabolism (157-164). In case of genotype-based dose 
adjustments the drug plasma concentrations will be controlled by TDM since most genotype-based 
dose recommendations are based on calculations rather than on clinical data. 
TDM and pharmacogenetic tests can advantageously be combined, and TDM can to a certain extent be 
considered as a phenotyping procedure. A valuable strategy is proposed in the algorithm in chapter 6 
“TDM plus” (65). It reflects a pro-active and systematic approach to a situation of treatment failure or 
intolerability where pharmacogenetic tests are performed based on unexpected plasma levels and after 
exclusion of pharmacokinetic drug interactions. Pharmacogenetic tests might also be indicated in the 
case of unusual plasma concentration to dose relations or when the ratio of parent substance to 
metabolite is distorted. 
Polymorphic drug metabolising enzymes represent some of the most common genetic risk factors 
associated with adverse drug reactions (165-169) but may also be the reason for non-response. In poor 
metabolisers increased plasma concentrations can reach toxic levels and lead to serious adverse drug 
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reactions, in ultra-rapid metabolisers on the contrary, non-response might occur due to subtherapeutic 
plasma concentrations. Differences in drug clearance between poor and rapid metabolisers sometimes 
vary up to 20-fold which certainly has an influence on drug efficacy and adverse drug effects. 
However, if analyzing phenotypes such as drug responders or occurrence of adverse drug effects, a 
simple monogenic association between a single polymorphic drug metabolising enzyme and response 
or an adverse event, seems in many cases not evident. Therefore new high-dimensionality analysing 
methods like “combinatorial pharmacogenetics” (170) which allow an insight in the complexity of 
possible metabolic processes and pathways in the human body are necessary. Other for the 
pharmacokinetic variability of many drugs relevant systems such as phase II enzymes (e.g. UDP-
glucuronosyltransferases UGT), N-acetyltransferases (NAT)) and drug-transporting-proteins, e.g. P-
glycoprotein and organic anion-transporting polypeptides (OATP), show genetic polymorphisms as 
well. The clinical relevance of phase II enzyme polymorphisms such as UGT polymorphisms in 
pharmacopsychiatry seems to be far less pronounced than those of CYP450 isozymes (171).  Genetic 
polymorphisms of the drug transporter Pgp have been studied extensively, but the functional 
significance of genotypes or haplotypes remains controversial (136;172).  
No doubt, pharmacodynamic parameters are important and clinically relevant genetic polymorphisms 
for receptor proteins or neurotransmitter transporters have been described (173-176). For instance 
numerous studies show a robust association between  the serotonin transporter gene promoter 
polymorphism and the therapeutic effect of SSRI (177). Therefore, results of pharmacogenetic tests for 
pharmacokinetic and –dynamic variables should - where possible - be analysed together. However, the 
use of pharmacogenetic tests for pharmacodynamic parameters is not yet validated in clinical practice. 
 
Drug-Drug Interactions 
Drug-drug interaction means a change of the drug’s effect as a result of the presence of another drug. 
Considering pharmacokinetic and pharmacodynamic drug interactions including the risk increase for 
serious adverse reactions due to similar side effect profile, the risk estimation of a certain drug 
combination can become very complex. Classical information sources on drug interactions such as 
Pharmavista (http://www.pharmavista.net) or Drugdex (http://www.thomsonhc.com) give risk 
estimations based on clinical observations, and deducted from these class effects. However, this 
method is often not accurate and incomplete. Another more precise approach would on one hand 
include – if available - clinical observations of a specific drug combination and on the other hand look 
at the pharmacokinetic and pharmacodynamic properties of the combined drugs as well as at their side 
effect profile and make then risk estimation.  
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Pharmacokinetic interactions 
Pharmacokinetic interactions are due to the effect of drug A on drug B’s movement through the body. 
Alterations can occur during absorption, distribution, metabolism and elimination. They are expressed 
by a change in the expected concentration of one or both substances at the target site, and often also in 
the blood. TDM is therefore a valuable instrument in controlling the effect of a pharmacokinetic drug 
interaction, even if it is not a direct measure of the drug concentration at the target site. The usefulness 
of TDM may be limited in situations where drug transport through the blood brain barrier shows high 
inter-individual variability and is determined by active transport mechanisms (116;123). Information 
on mechanisms of metabolic interactions can be found in text books (178) or other literature 
(179;180). 
Drugs can be substrates for one or several metabolic enzymes, which contribute to their 
biotransformation using major and minor pathways (e.g. clozapine (181), see Fig. 8) and drug 
metabolism can be stereoisomer specific (e.g. mirtazapine, see chapter 4) . This is important when 
estimating the effects of inhibition or induction of one of these pathways. The extent of an interaction 
is dependent on the baseline enzyme activity. No inhibition occurs in people with almost no enzyme 
activity (e.g. in the situation of a genetic deficiency of this enzyme), whilst the inhibitory effect may 
be pronounced in people with high baseline activity.  
It is not an easy task to estimate the interaction potential of a particular combination therapy. 
Numerous tables listing drugs as substrates and inhibitors/inducers for different metabolic enzymes, 
mostly CYP450 enzymes exist. Many do not differentiate between major and minor pathways, and 
many translate in vitro results into in vivo data, which can lead to misinterpretation. Clozapine in vitro 
is metabolised by almost all relevant CYP450 enzymes (fig.8 (181)). However, in vivo (see chapter 5), 
it appears that CYP1A2 is the major pathway, CYP2C19 plays a relevant role (182) and CYP3A4 is 
probably involved in a concentration-dependent manner, while CYP2D6 plays a negligible role 
(181;183-186).  
Predicting in vivo interactions from in vitro data is difficult; a number of reviews have been published 
on the impact of various factors on the accuracy of such an extrapolation and on prediction models 
(187-191). There is great need for data on drug metabolism and transport in vivo and where possible in 
patient populations. With newer drugs this information becomes more accessible since more 
pharmacokinetic data are requested from the authorities. But with older substances these data are not 
available.  
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Figure 8: Dose dependent CYP450 mediated metabolism of clozapine in vitro (181), reaction rates in 
mol/h per mole CYP450 isoform. (Reproduction of the figure with kind permission of “Drug 
Metabolism and Disposition”) 
 
Some drug interaction lists give the interaction potential of drug classes, such as found for the SSRIs, 
but SSRIs form a very heterogeneous group especially concerning their CYP450 enzyme inhibiting 
properties. Fluvoxamine is a potent inhibitor of CYP1A2, but not of CYP2D6. Paroxetine and 
fluoxetine are potent inhibitors of CYP2D6, but not of CYP1A2, and so forth.  The thesis author, 
recognising these shortcomings, developed an online interaction program, mediQ.ch, which is 
described in greater details in chapter 7. Table 6 indicates some Internet sites with clinically relevant 
information on drug interactions, cytochrome P450 and other drug metabolising and transporter 
systems. 
Table 6: Examples of Internet sites providing information on drug-drug interactions, CYP450 enzymes 
and drug-transporting proteins (retrieved 2011) 
www.mediQ.ch  www.psiac.de   http://medicine.iupui.edu/flockhart  
www.genemedrx.com    www.imm.ki.se/CYPalleles   www.themedicalletter.com 
www.drugs.com   www.druginteractioninfo.org  http://www.thomsonhc.com 
http://www.pharmavista.net   http://www.hiv-druginteractions.org 
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Since the extent of a specific drug-drug interaction is not easy to predict, TDM should be used in drug 
combinations where affected drugs have a narrow therapeutic index. Figure 9 shows that the clinical 
consequences strongly depend on the therapeutic index of the drug. It would not be wise to avoid 
combinations when they appear to be of little risk and promising from a therapeutic point of view. 
Inhibition can last for several weeks after discontinuation of the inhibiting agent, as is the case with 
fluoxetine, and especially its metabolite norfluoxetine, which has a very long elimination half-life. In 
cases of a rapid change of medication from fluoxetine to another serotonergic compound, an increased 
risk for serotonergic side effects, including serotonin syndrome (192-195) has been reported.  
Figure 9: The importance of a drug-drug interaction or a drug metabolising enzyme polymorphism 
depends on the therapeutic index of the affected drug (adapted from (196)) 
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For drugs with active metabolites, the active moiety has to be considered, especially when the active 
metabolite is formed by the affected enzyme. In a study with 12 schizophrenic patients (197) 
risperidone was shown to be inhibited by paroxetine in a dose-dependent manner. Daily doses of 10, 
20 or 40 mg paroxetine resulted in a 3.8- to 9.7- fold increase in the concentration of risperidone. The 
concentration of the “active moiety” (risperidone + 9-OH-risperidone) was not significantly increased 
by low doses of paroxetine, but a 1.8-fold increase occurred after 40 mg/day paroxetine. However, 
extrapyramidal side effect scores increased significantly also with 20 mg/day paroxetine. 
Modulation of drug metabolism can be enantioselective, as is the case for warfarin, methadone, some 
antidepressants (e.g. venlafaxine, citalopram, mirtazapine) and other substances (198-206). Since in 
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many cases the effect of each enantiomer is distinct, it is important to know which metabolic pathway 
is affected.  
In addition, it should be noted that an inhibitory effect occurs as soon as the inhibitor is introduced and 
disappears – with exception of mechanism based inhibition - as soon as the interacting compound is 
eliminated from the body, which implies that the time course depends on the elimination half-lives of 
the drugs (and metabolites) implicated in the interaction. 
The induction process takes time since more, new enzyme has to be synthesized. As a rule of the 
thumb, one could say the induction effect can generally be expected after one week and the full effect 
might take several weeks. This has to be kept in mind when applying TDM. When an inducer is 
removed from treatment (207), plasma levels of the substrate will increase with about the same lag 
time until a new equilibrium is reached. 
Pharmacodynamic interactions 
Pharmacodynamic interactions are due to the influence of drug A on drug B at the target site of drug 
action (end organ, receptor site). Serious complications such as serotonin syndrome, resulting from a 
combination of several serotonin agonistic drugs (e.g. SSRI plus the analgesic tramadol or the 
anorectic sibutramin) (208-210), or delirium caused by a combination of drugs with anticholinergic 
properties, are examples. Pharmacodynamic interactions are not easily measured in vivo. 
 
Other Interactions 
Individual drug response is also dependent on factors, such as age, gender, organ function (especially 
renal and hepatic), co-morbidity but also lifestyle or environmental factors like diet or smoking. These 
factors certainly affect CYP450 enzyme function but glucuronidation and the expression of drug 
transporters also seem to be sensitive.  
Smoking 
Smoking induces CYP1A2 which means that smokers are likely to have lower plasma levels of 
CYP1A2 substrates than non-smokers. Importantly, the tar particles in the smoke rather than nicotine 
are responsible for this effect. A similar effect is also seen when consuming barbecued meat, for 
instance. Smoking also slightly induces glucuronidation, as seen with codeine (211). Environmental 
and genetic factors can produce either synergistic or antagonistic effects. It appears that there is also a 
genetic polymorphism for inducibility (e.g. by tobacco smoke) of CYP1A2 (66;70). 
Smoking cessation in patients on drugs like clozapine, olanzapine, tacrine or theophylline, which are 
mainly metabolised by CYP1A2, can lead to drug intoxication. Several cases have been described for 
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clozapine and olanzapine, (212-214) with adverse drug reactions including seizures, heavy sedation, 
cardiac problems and delirium. The induction effect of smoking seems to have a mean elimination half 
life of about 39 hours (range 27 - 54h) (207); a new steady state could be expected after about 2 
weeks. De Leon in his study overview (213) suggests a mean dose correction factor of 1.5 for change 
in smoking behaviour. In individual patients, however, smoking cessation may lead to a more marked 
increase in plasma levels. Other authors refer to mean correction factors of up to 5 (71;215). A 
stepwise dose reduction with TDM control is strongly recommended. 
Food 
Recently there has been increased awareness that grapefruit juice can have an important interaction 
with as many as 40 orally taken drugs (216;217). In particular, interaction with certain HMG-CoA 
reductase inhibitors (statins), such as simvastatin, atorvastin and lovastatin, can lead to serious 
complications such as rhabdomyolysis (217;218); with some antihypertensive agents (e.g. felodipine 
or nifedipine) it might result in excessive vasodilatation. For drugs with a narrow therapeutic index 
such as the immunosuppressant cyclosporine or the antimalarial agent halofantrine special attention is 
necessary. In psychiatry, drugs such as midazolam, triazolam, buspirone, carbamazepine or quetiapine 
are affected. The type of interaction consists mostly in an increase in drug plasma levels, seen in either 
the area under the concentration-time curve (AUC) or the maximum plasma concentration (Cmax). The 
main mechanism is the inhibition of the intestinal CYP3A4 pathway, inhibition of P-glycoprotein 
might play a role as well. A review on pharmacokinetic interactions with citrus juices (mainly 
grapefruit) (216) gives more insight in possible mechanisms of action. 
Interactions with other food constituents (caffeine, cabbage, chargrilled food, water cress, and others) 
exist but, with the exception of the combination of clozapine and caffeine (219;220), seem to play a 
less important role. 
Age and gender 
Divergent responses to drug treatment are often observed between the elderly, young and adult 
population. In children, some clinical studies indicate that higher doses (on a weight-adjusted basis) 
are often needed, as compared with adults, to reach therapeutic drug concentrations (221;222). This 
seems to be based on an increased clearance of the drug in younger children. In contrast, in elderly 
patients, impaired renal and sometimes hepatic function often leads to a decrease in drug elimination 
and reduced drug metabolism, respectively, and therefore dose adaptation may be recommended 
(196;197). It is also probable that the therapeutic index of some drugs in some individuals is narrower, 
due to an increased sensitivity to drugs in the elderly (223). 
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Men and women often differ in their response to drug treatment. Gender differences in subjective 
tolerability might account for part of this (224), but biological factors are certainly also important 
(225). An extensive overview of gender-specific factors such as body build, hormonal transitions, diet 
and other environmental or cultural factors was recently presented in relationship to antipsychotic 
therapy (226). The author states that, for a given dose, the mean plasma levels in men tend to be lower 
than in women and concludes that the evidence collected suggests that women need lower doses than 
men. Another review (227) mentions that the adverse drug reaction risk for women is about 1.5-fold 
greater compared to men. Own data from a naturalistic cohort study including 165 psychiatric in-
patients with a severe adverse drug reaction showed that women (n=79) were more likely to have 
unexpectedly high plasma drug levels than men (n=82) (36% versus 22% (228). This gender 
difference has been demonstrated previously and the findings have been reviewed by Pollock et al 
(229). The use of TDM rather than adoption of a standard recommended dose could help optimise 
individual doses of therapeutic agents. 
Pronounced gender differences are, for example, described for clozapine (230;231) and olanzapine 
(232), both of which are mainly metabolised by CYP1A2. Perry et al (230) developed a clozapine 
dosing model comprising the variables dose, smoking and gender. To reach therapeutic plasma levels, 
smoking men may need twice the dose required by non-smoking women (fig. 10).  
Figure 10: Gender-related dose differences for clozapine (adapted from (230)) 
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Gender differences are observed in drug metabolizing enzymes and drug transporter proteins 
(233;234). Men appear to have higher CYP1A2 activity, and maybe also CYP2E1, as well as of some 
UGTs and Pgp, while women may have higher CYP2D6 activity (235). Of course there are other 
physiological differences between women and men: women have generally lower bodyweight and 
organ size, a higher percentage of body fat, lower glomerular filtration rate and different gastric 
motility than men.  
In general, however, gender-based pharmacokinetic differences account for only subtle changes in 
drug response; gender-based pharmacodynamic processes such as QTc prolongation seem to be more 
important (234). 
Co-morbidity 
The effect of renal or hepatic insufficiency on the fate of a drug may be dramatic, but it depends on the 
means of elimination. Not widely known is that plasma levels of CYP1A2 substrates can vary in the 
presence of an inflammatory process and lead to an intoxication with drugs such as clozapine. The 
hypothesis is that cytokines (e.g. interleukin-6) inhibit CYP1A2 activity (236).  Several animal studies 
have shown that different CYP450 enzymes are down-regulated during sepsis (237) or after 
endotoxin-induced inflammation, but the mechanism for this reduction is still under debate.  
 
In this introductory chapter, present knowledge is summarized about the basics of 
pharmacovigilance, TDM and pharmacogenetics, as well as of drug-drug interactions and other 
factors influencing the drug concentration in our patient’s body. 
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4  Multicentre study on the clinical effectiveness, pharmacokinetics and 
pharmacogenetics of mirtazapine in depression 
Summary 
Pharmacogenetic tests and therapeutic drug monitoring may considerably improve the 
pharmacotherapy of depression.  The aim of this study was to evaluate the relationship between the 
efficacy of mirtazapine (MIR) and the steady-state plasma concentrations of its enantiomers and 
metabolites in moderately to severely depressed patients, taking their pharmacogenetic status into 
account.  In- and out-patients with major depressive episode (17-item Hamilton Depression Rating 
Scale (HAMD) total score ≥18 points and Mini-Mental State Examination score ≥24) received MIR 
for 8 weeks (30 mg/day on days 1-14 and 30-45 mg/day on days 15-56).  A total of 45 patients (mean 
age 51 years; range 19-79) were included.  MIR treatment resulted in a highly significant (p < 0.0001, 
Wilcoxon test) improvement in mean HAMD total score at the end of the study. The analysis of the 
enantiomers of MIR and its hydroxylated (OH-MIR) and demethylated (DMIR) metabolites in non-
hydrolysed and hydrolysed plasma samples on days 14 and 56 showed a clear influence of gender and 
age on these parameters. Moreover, non-smokers had higher MIR plasma levels than smokers: S-
MIR: 9.40±3.85 vs. 6.15±5.50 (p = 0.005); R-MIR: 24.4±6.54 vs. 18.5±4.06 (p = 0.003). Only in non-
smokers, plasma levels of S-MIR and metabolites depended on the CYP2D6 genotype. In patients 
presenting the CYP2B6 *6/*6 genotype (n = 8), S-OH-MIR concentrations were higher than in the 
other patients (n = 37), and the reduction of the HAMD scores was significantly more pronounced in 
the CYP2B6 *6/*6 genotyped patients at the end of the study. However, it is not known, if S-OH-MIR 
is associated to the therapeutic effect of mirtazapine. 
 
Introduction 
Pharmacogenetic tests and therapeutic drug monitoring of psychotropic drugs are increasingly 
recommended for the optimization of the pharmacological treatment of depression (41;64;154;238).  
Many antidepressants are chiral drugs in that they possess one or several asymmetric centres which 
give rise to enantiomers differing by their metabolism, pharmacokinetics and pharmacological 
properties. However, the majority of studies on the drug plasma concentration - clinical effectiveness 
relationship of chiral antidepressants were usually carried out using achiral analytical methods, which 
are unsuitable for the assay of the individual enantiomers (199;239).  
Many studies have documented the clinical effectiveness of the chiral antidepressant drug mirtazapine 
(MIR) in the treatment of depression (240), including in elderly patients (241;242).  It has an unusual 
pharmacological profile (table 7) (243), acting as an antagonist at central presynaptic α2-adrenergic 
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inhibitory autoreceptors and heteroreceptors, thereby causing an increase in the release of 
noradrenaline. The subsequent excitation of postsynaptic α1-receptors, which mediate serotonin (5-
HT) cell firing, and the direct blockade of inhibiting α2-heteroreceptors located on 5-HT terminals, 
possibly lead to an increase in the release of 5-HT. The effect of the released 5-HT is exerted mainly 
via 5-HT1 receptors, since 5-HT2 and 5-HT3 receptors are blocked directly by the drug (244-246). The 
extent of the serotonergic effect of MIR is, however, somewhat controversial (243;247;248).  The S(+) 
enantiomer of MIR (S-MIR) is a more potent α2-receptor antagonist than the R(-) enantiomer (R-
MIR), whilst the inverse is true regarding 5-HT3-antagonism (246;249;250).  Contrary to other chiral 
antidepressants, the differential receptor affinity profile of both MIR enantiomers seems to lead to an 
advantage of the racemate over a single enantiomer (199). Probably, the antidepressant effect of MIR 
resides mainly in the S-enantiomer, while the R-enantiomer may prevent some adverse effects such as 
nausea, due to stimulation of 5-HT3-receptors. A small study comparing cerebrospinal fluid (CSF) 
concentration with plasma levels of MIR and its enantiomers in MIR treated patients evinced much 
lower S-MIR than R-MIR CSF concentrations (251). Interestingly, Brockmöller et al (252) found 
enantioselective differences regarding adverse drug effects, with the effect of MIR on the heart rate 
and blood pressure correlating more strongly with the R-enantiomer than with the S-enantiomer.  
Table 7: Pharmacological profile of mirtazapine with some enantioselective differences. In case of the 
α1- antagonistic property it is speculated that the R-enantiomer might be more potent since it is more associated 
with orthostatic hypotension and tachycardia. 
receptor             mirtazapine 
5HT2 Potent antagonist (S-enantiomer >> R) 
5HT3 Potent antagonist (S-enantiomer << R) 
H1 Potent antagonist 
M Moderate antagonist 
α1 Moderate antagonist (S-enantiomer << R?) 
Presynaptic α2 Antagonist (S-enantiomer >> R) 
 
MIR kinetics is linear within the dose range 15 to 80 mg, but shows gender and age effects (253-257). 
Plasma levels in males are, independent of age, reportedly lower than those of females, and the plasma 
half-life is significantly shorter in adults than in the elderly (20 and 40 hours, respectively) (253). 
Renal and hepatic insufficiency can also result in substantially reduced clearance (253).  Several 
isoforms of cytochrome P-450 (CYP) contribute in vitro to the enantioselective biotransformation of 
MIR: CYP1A2, CYP2D6 and CYP3A (258;259). For CYP2C19 no significant contribution has been 
found in vitro, a possible role of CYP2B6 has not been studied. The main metabolites are 8- 
hydroxymirtazapine (8-OH-MIR), N-desmethylmirtazapine (DMIR) and mirtazapine-N-oxide (MIR-
N-oxide).  N-demethylation and N-oxidation are catalysed by CYP3A (253;260). The 8-hydroxylation 
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process (followed by glucuronidation) is under the control of CYP2D6 and, to some extent, CYP1A2 
(more important at higher MIR concentrations) and it is essentially associated with the S-enantiomer.  
For the R-enantiomer, (reversible) N-ammonium glucuronidation is the main metabolic step 
(259;261). A study in healthy volunteers did not suggest differences in the pharmacokinetics of MIR 
between extensive (EM) and poor metabolisers (PM) (CPY2D6) (260).  However, a reanalysis of the 
samples using a stereoselective method showed that the elimination half-life of the R-enantiomer was 
longer than that of the S-enantiomer in EM (22.5 and 13.2 hours, respectively), and that the half-life of 
the S-enantiomer was increased in PM (18.8 hours) (253). A population pharmacokinetic analysis of 
MIR (262) found a distinct difference in clearance between CYP2D6 EM and intermediate 
metabolisers (IM), the clearance being reduced by 26% in IM. No other factor had a significant 
influence on MIR clearance. The similarity between CYP2D6 PM and EM might be related to a 
relatively lower importance of CYP2D6 in favour of CYP1A2 with increasing MIR exposure (262). 
One may then postulate that with low CYP2D6 activity, other pathways become more important. 
Wide inter-individual variability in MIR plasma concentration in relation to dose has been found (255) 
and no drug plasma concentration-clinical effectiveness relationship has been demonstrated. The 
recommended therapeutic doses of 15-45 mg/d result in plasma levels ranging from 5-100 ng/ml 
(253); the recommended target range is 40-80 ng/ml (41). 
The aim of this study was to evaluate the relationship between steady-state plasma concentrations of 
the enantiomers of MIR and its metabolites and the clinical effectiveness of MIR in moderately to 
severely depressed and CYP genotyped patients, including in elderly patients, taking their 
pharmacogenetic status into account. 
 
Materials and Methods 
 
Patients 
This multicenter study recruited in- and out-patients (aged ≥18 years) with a primary diagnosis of 
major depressive episode (DSM-IV), unipolar or bipolar II (296.2, 296.3 or 296.89 according to the 
DSM-IV checklist), in one French (Besançon) and in 6 Swiss (Adult psychiatric and psychogeriatric 
university hospitals, Prilly-Lausanne; Königsfelden; Brig; Herisau; psychogeriatric university hospital 
Chêne-Bourg (Geneva)) psychiatric hospitals. Patients were scheduled according to age: 18-39 y (n = 
20), 40-64 y (n = 30) > 64 y (n = 30).  They were required to have a 17-item Hamilton Depression 
Rating Scale (HAMD) (263) total score of ≥18 points at baseline and a Mini-Mental State 
Examination MMSE (264) score of ≥24 at screening (day -3 to -1). Exclusion criteria included: 
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unacceptable severe cognitive impairment (defined as <24 on the MMSE); duration of current 
depressive episode >12 months; known or suspected active suicidal tendencies; a history of or current 
schizophrenia or organic mental disorders; current primary anxiety disorders (according to DSM IV), 
epilepsy, a history of seizure disorders or prior treatment with anticonvulsant medication for epilepsy 
or seizures; any clinically meaningful non-stable renal, hepatic, cardiovascular, respiratory or 
cerebrovascular disease or other serious progressive physical diseases; participation in other trials in 
the last 30 days; and pregnancy or lactation.  Patients were also excluded if they had received MAO 
inhibitors of any type within 2 weeks of the start of treatment, fluoxetine within 5 weeks, and 
electroconvulsive therapy within 3 months or other psychotropic drugs within 2-3 days. 
After procedures and possible side effects had been explained, all patients gave written informed 
consent prior to entering the study. The study was conducted according to Good Clinical Practices and 
the Declaration of Helsinki. In particular, the protocol was accepted by the corresponding local ethical 
committees. All investigators (one per centre) met twice for an inter rater’s training. 
Treatment 
After a 3-day wash-out period, patients received oral MIR for 8 weeks. MIR was dispensed as 30 mg 
tablets to be taken as a single night-time dose of 30 mg/day on days 1-14 and 30-45 mg/day on days 
15-56. The dose could not be modified between visits, but could be adapted on days 15, 28 and 42. 
Deviations from this dosing schedule, such as dose reductions below 30mg or at other time points, 
were only allowed in case of emergence of intolerable adverse events. Any unessential concomitant 
medication and the use of alcohol were discouraged. Concomitant medication for physical illnesses 
other than those specified by the exclusion criteria was permitted.  In cases where sleeping problems 
persisted or were aggravated during the course of treatment, zopiclone (maximum 7.5 mg/day), 
zolpidem  (maximum 10 mg/day) or chloral hydrate (maximum 2,000 mg/day) were allowed for night-
time sedation. The following co-medications were not permitted: any other psychotropic drug, 
including short- and long-acting benzodiazepines (stable benzodiazepine users were allowed to remain 
on the same dose during the study - a maximum 30% change in dose was allowed); sedative drugs 
(including sedative antihistaminergics and antiemetics); antiepileptic drugs (including carbamazepine 
and valproate); and thyroid hormones. 
For the evaluation of an interaction between MIR and co-medications, the interaction program used 
was: http://www.mediq.ch/ (retrieved March 2010). 
Clinical assessments 
Assessments were performed at screening (day -3 to -1), baseline (day 0) and days 7, 14, 21, 28, 42 
and 56 of treatment or at endpoint. Clinical assessments comprised the 17-item HAMD (Hamilton 
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Depression Scale) (263) and the clinical global impression (CGI), vital signs, spontaneous adverse 
events, the UKU (Udvalg for Klinske Undersogelser) side effect rating scale (265), and smoking 
behaviour, alcohol and caffeine consumption. An ECG was recorded at screening and on day 56. 
Biological assessments 
Steady state trough plasma concentrations of the enantiomers of MIR, DMIR and 8-OH-MIR, were 
measured on days 14, 28, 42 and 56 using a recent stereoselective LC-MS method (200), after a 3-step 
extraction of the compounds. The limit of quantification (LOQ) for all enantiomers was 0.5ng/ml, and 
the intra- and inter-day coefficients of variation (CVs) were within 3.3% to 11.7% (concentration 
ranges 5-50 ng/ml). All plasma levels are expressed in ng/ml; for conversion in nmol/l: 1 ng/ml is 
equivalent to 3.774 nmol/l. Total (free and glucuroconjugated) concentrations of MIR and metabolites 
were also determined after submitting the plasma samples to enzymatic hydrolysis (hydrolysed 
samples). If not otherwise specified, drug concentrations mentioned in the text are those of non 
hydrolysed samples. As on day 14, all patients were medicated with the same mirtazapine dose 
(30mg/day), absolute plasma concentrations are given. For drug plasma concentrations measured on 
days 28, 42 or 56, dose corrected concentrations (ng/ml/mg dose) are presented or used for statistical 
comparisons. 
At the end of the wash-out period, patients were phenotyped with dextromethorphan (CYP2D6) and 
mephenytoin (CYP2C19) (145).  Dextromethorphan and its metabolite dextrorphan, and S- and R-
mephenytoin were assayed in urine as previously described (145). Patients were also genotyped for 
CYP2D6 (alleles *1, *3, *4, *5, *6,*16 2XN (amplified)), CYP2C19 (alleles *1, *2, *3), CYP2B6 
(alleles *1, *4, *5, *6, *7, *9) and CYP1A2 (allele *1F) as previously described (138). The patients 
were classified according to their CYP2D6 and CYP2C19 genotypes (ref. (138) and cf. Table 1): 
ultrarapid (UM), intermediate (IM), extensive (EM) and poor (PM) metabolisers.  
Standard clinical chemistry (sodium, potassium, calcium, chlorine, inorganic phosphate, fasting 
glucose, total cholesterol, high-density lipoprotein (HDL)- cholesterol, triglycerides, albumin, total 
protein, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, γ-glutamyl 
transpeptidase, urea, creatinine, lactate dehydrogenase, total bilirubin, triiodothyronine (T3), thyroxine 
(T4), thyroid stimulating hormone (TSH)) and haematology (haemoglobin, haematocrit, mean 
corpuscular volume, erythrocytes, leucocytes, platelets) parameters were measured at baseline and at 
the end of the study. 
Statistical analysis 
The dependence of genotypes, sex, age and plasma levels of MIR enantiomers and metabolites were 
analyzed by the Kruskal Wallis test for >2 groups and the Mann Whitney test for two groups. All 
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values were reported as mean ± SD or median (minimum- maximum). A p-value < 0.05 was 
considered to indicate statistical significance.  Confidence interval was 95%. Correlations were 
assessed by Spearman`s test. The same analysis was performed for the dependence of genotypes, 
HAMD total score, and change in HAMD score during the study, and plasma levels of MIR 
enantiomers and metabolites. In this exploratory study no corrections for multiple comparisons were 
made. Efficacy was assessed using the CGI and HAMD scales and the results were analyzed 
descriptively and graphically over time. The two-sample Wilcoxon test for paired data was applied to 
compare the CGI and HAMD scores at the beginning and end of the study.  A responder was defined 
as a patient whose HAMD score fell by >50% compared with baseline at some time during the study. 
The rate of responders was displayed graphically over time both for the study completers and using the 
last observation carried forward (LOCF) method. Side effects measured with the UKU side effect 
scale were analyzed descriptively. Changes in weight and plasma levels of total cholesterol, HDL-
cholesterol, triglycerides, glucose, T3, T4 and TSH over time were analyzed graphically and 
descriptively.  The Wilcoxon test for unpaired data was applied to compare laboratory parameters in 
responders and non-responders. For detection of optimal cut-off values regarding responders/ non-
responders receiver operating characteristic (ROC) curves were applied and the area under the curve 
(AUC) was calculated. For ROC- derived optimal cut-off values sensitivity, specificity, positive (PPV) 
and negative (NPV) predictive value were calculated. Optimal cut-off values are values corresponding 
with the highest accuracy. SPSS 16.0 (SPSS Inc. Chicago, IL) was used to perform the statistical 
analysis.  
 
Results 
 A total of 45 patients (32 females (f)) were included in the study. The mean age was 51 years (range 
19-79) and the age distribution was: 18-39 years n=13 (8 f), 40-64 years n=19 (13 f), and >64 years 
n=13 (11f). All patients were diagnosed with unipolar depression (13 with DSM296.2, 32 with 
DSM296.3). Twenty eight patients were non-smokers (22f), and 17 smokers (10f). One patient had a 
HAMD score of 17 at baseline (20 at screening), but was nevertheless included in the analyses because 
this protocol violation was considered non significant. Thirty one patients (69%) completed the study.  
The rate of study completion increased with age: 18-39 y: 54% (n=7); 40-64 y: 68% (n=13); > 64 y: 
85% (n=11).  Reasons for drop-out were loss to follow up (n=5), withdrawal of consent (n=5), 
protocol violation (n=1), inefficacy (n=1) and combined inefficacy/intolerability (n=2).  A 37 year-old 
male patient was unable to tolerate the higher dose of 45 mg/d because of restless legs, sweating and 
agitation; he was switched back to the 30 mg dose, which proved ineffective, and then withdrawn from 
the study. Then 0.5 mg/d alprazolam and 5 mg/d olanzapine were added to his treatment with MIR. 
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Seven days later, during a family fight, he committed suicide by shooting himself. The investigators 
attribute causality for this suicide to the underlying disease that did not respond to treatment. 
Co-medications 
Anxiolytics/hypnotics were the most frequent co-medications: 58 times a drug of this class has been 
mentioned as co-medication, sometimes for the whole study period, sometimes for some days only; 
most frequently zolpidem, zopiclone and chloralhydrate for nighttimes’ sedation, and lorazepam as 
anxiolytic stable co-medication. None of these drugs interferes pharmacokinetically with MIR. 
Cardiovascular drugs were co-prescribed 25 times.  Twelve times an analgesic has been given, 3 times 
rofecoxib.  In 2 patients rofecoxib was present on day 14. These patients showed higher plasma levels 
of S-MIR (median 17.4 ng/ml (15.9-18.9) versus 7.1 ng/ml (0.6-18.9), p = 0.029) and a higher ratio 
SMIR/SDMIR than the rest (median 9.9 (9.6-10.2) versus 2.6 (0.6-6.8), p = 0.018). Other medications 
included mainly vitamins, minerals, contraceptives, and drugs acting on the gastrointestinal tract. 
None of them were identified interacting with MIR metabolism.  
Efficacy 
All patients started their MIR treatment with 30mg/d for a minimum of 14 days. Thereafter the dose 
was either 30mg or 45mg daily; mean dose on day 56 was 38mg/d. The treatment resulted in a 
significant (p < 0.0001, Wilcoxon test) improvement in mean ± SD HAMD total score from 24.8 ± 4.9 
at baseline to 9.8 ± 7.9 at the end of this open, not placebo controlled study (LOCF analysis). The 
response rate as assessed by the HAMD scale increased from 22.7% (confidence interval: 0.355, 
0.099) at week 1 to 80.7% (confidence interval: 0.951, 0.662) at week 8, when 23 out of 31 patients 
were considered as responders. This clinical improvement was reflected by the CGI severity scale that 
showed a clear shift from mainly moderately to extremely ill patients at baseline to mainly not ill or 
borderline ill patients by the end of the study. Some patients showed a rapid improvement from week 
1 onwards. 
Drop-outs 
14 patients dropped out during the study. Reasons and moments of drop out are found in table 8, 
further characteristics in table 9. 
Table 8: Reason and moment of study drop out 
Number of patients per reason of drop out Last visit Remark 
1 protocol violation Base line for clinical values, day 14  
3 inefficacy/intolerability 1 day 14, 2 day 28  
5 withdrawal of informed consent 2 day 7, 2 day 14, 1 day 21 2 (day 7) without laboratory 
5 loss of follow up 1 day 7, 1 day 14, 2 day 28, 1 day 42  
14 Total (7 responder, 7 non responder)   
47 
   
Table 9: Characteristics of study completers and dropouts.  
 Completers (n= 31) Dropouts (n=14) 
Mean age (years) 52.8 45.7 
Sex 23f, 8m: f:m=2.9 9f, 5m: f:m=1.8 
CYP1A2 4 *1/*1 =13% 
7*1F/*1F 23% 
3  *1/*1 =21% 
6 *1F/*1F = 42% 
CYP2B6 6 *6/*6 = 19% 2 *6/*6 = 14% 
CYP2D6 1 PM = 3% 
2UM = 6% 
2 PM = 14%  
1 UM = 7% 
 
Tolerability and safety 
No serious adverse drug reactions were reported during the study. The doctor’s and patient’s global 
assessments of side effects according to the UKU side effect rating scale were strikingly similar at all 
assessment points.  Baseline and reported treatment emergent complaints were partly identical but at 
baseline more patients reported complaints than during the study period (fig. 11); > 50% suffered from 
asthenia/lassitude, concentration difficulties, tension/inner unrest, reduced sleep, sexual disturbances, 
failing memory, emotional indifference, all symptoms of a depressive illness. During the study the 
following adverse events, rated as possible or probable, were mentioned in >10% of the patients (by 
their decreasing frequency (LOCF)): asthenia/lassitude, weight gain, concentration difficulties, 
increased dream activity, headache, failing memory, increased sweating and decreased salivation. Side 
effects were mostly mild to moderate. Sedation and increased duration of sleep were more often 
reported at the start of treatment. Restless legs were spontaneously reported by 11% of the patients 
outside the UKU scale. When comparing side effects with baseline complaints weight gain was clearly 
associated to the treatment with MIR. 
There was a weight gain during the study of 2.7 ± 2.9 kg (p<0.001; ANOVA Chi2 test) (range -1.1 kg 
to 11.0 kg), with weight gains > 4 kg in 15.6%, and > 2 kg in 29% of the patients.  The patient with a 
weight gain of 11 kg experienced deterioration of pre-existing dyslipidemia, dry mouth and restless 
legs, which were not associated with unusual plasma levels of MIR.  There were four patients (9%) 
who had a weight gain of >10% during the study (a weight gain of >10%, according the AMSP criteria 
(16;266) (Arzneimittelsicherheit in der Psychiatrie (Drug Safety in Psychiatry)), is considered to be 
medically significant).  There were no clinically significant overall changes in any laboratory 
parameters during the study.  
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Figure 11: Baseline and reported treatment emergent complaints as rated by the UKU scale 
 
 
Cytochrome P-450 genotypes (Table 10) and phenotypes 
None of the 45 genotyped patients presented a genetic deficiency of CYP2C19 (PM), but 9 and 36 
subjects were classified as CYP2C19 IM (CYP2C19 *1/*2) or EM, respectively. The mephenytoin test 
demonstrated that all patients were EM or IM (as the mephenytoin test does not allow discriminating 
EM from IM). CYP2D6 genotyping showed that 3 patients (6.7%) were PM, 3 patients were ultrarapid 
metabolisers (UM), 14 patients (31%) were IM, and 25 subjects were classified as EM. The phenotype 
predicted by the genotype was not congruent in all cases with the observed phenotype characterized by 
the dextromethorphan test.  Four patients (2 IM and 2 EM by genotype) were identified as PM by 
phenotyping with dextromethorphan.  Thirteen patients (29%) were homozygote for the CYP1A2 
allele *1F. In this study group, 14 subjects (31%) had the *1/*1 wild type CYP2B6 genotype and 8 
(18%) the *6/*6 genotype (Table 10). 
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Table 10. Cytochrome P-450 genotypes and the predicted phenotypes of the patients treated with 
mirtazapine (MIR) 
          
Genotype  n Frequency (%) Predicted phenotype 
          
CYP1A2 CYP1A2*1F   
 *1/*1 7 15.6% 
 *1/*1F 25 55.6% 
 *1F/*1F 13 28.9% 
    
CYP2B6 alleles *4/*5/*6/*7/*9   
 *1/*1 14 31.1% 
 *1/*4 1 2.2% 
 *1/*5 4 8.9% 
 *1/*6 12 26.7% 
 *1/*7 4 8.9% 
 *4/*6 1 2.2% 
 *5/*5 1 2.2% 
 *6/*6 8 17.8% 
    
    
CYP2C19 alleles *2/*3   
 *1/*1 36 80.0% EM 
 *1/*2 9 20.0% IM 
    
CYP2D6 alleles 
*3/*4/*5/*6/*16/*XN 
  
 *1/*1 24 53.3% EM 
 *1/*4 10 22.2% IM 
 *1/*5 4 8.9% IM 
 *1/*xN 3 6.7% UM 
 *3/*4 1 2.2% PM 
 *4/*6 1 2.2% PM 
 *4/*xN 1 2.2% EM 
 *5/*16 1 2.2% PM 
          
Classification of the patients according to their genotypes and predicted phenotypes (35): 
UM: ultrarapid metabolisers; IM: intermediate metabolisers; EM: extensive metabolisers; 
PM: poor metabolisers 
 
 
 
Pharmacokinetics 
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Only the pharmacokinetic data of day 14 will be presented here extensively, as all 45 patients were 
treated with the same daily dose of MIR (30 mg/day): Median (range) MIR plasma concentration 
reached 30.4 ng/ml (13.2-53.4) and in hydrolysed samples, this value increased drastically to 70.1 
ng/ml (21.2-117.7). Complete data for plasma levels and geno- and phenotypes were available for 40 
patients. 
There were important stereoselective differences in the pharmacokinetics of MIR (Table 11). R-MIR 
and R-DMIR concentrations were about 2.8 and 6.5 times higher than their corresponding S-
enantiomers, but this stereoselectivity almost disappeared when the enantiomers of OH-MIR were 
compared (when not otherwise specified, non-hydrolysed samples are meant). The situation was 
similar when hydrolysed samples were compared, except for the metabolite OH-MIR: the mean 
concentration of S-OH-MIR was almost 5 times higher than that of R-OH-MIR. While hydrolysis of 
the samples increased drastically the concentrations of the enantiomers of MIR and OH-MIR, this 
treatment had apparently only a small but nevertheless significant effect on R-DMIR (p = 0.026) but 
not S-DMIR (ns) plasma concentrations. 
Table 11: Median (ranges) plasma concentrations (ng/ml) of the enantiomers of mirtazapine (MIR), 
desmethylmirtazapine (DMIR) and 8-hydroxymirtazapine (OH-MIR) on day 14 in CYP2D6 genotyped 
patients 
 
Plasma levels of MIR and metabolites were higher in non-smokers (n = 28) than in smokers (n = 17). 
Most comparisons reached statistical significance (median plasma levels (min-max), not dose 
corrected): S-MIR: 9.4 ng/ml (1.8-16.2) vs. 4.3 ng/ml (0.6-18.9) (p = 0.014); R-MIR: 24.1 ng/ml 
(11.5-37.2)  vs. 18.6 ng/ml (12.2-27.8)  (p = 0.007); S-DMIR 3.5 ng/ml (1.1-7.9) vs. 2.0 ng/ml  (1.0-
4.9)  (p = 0.006); but R-DMIR 19.0 ng/ml (7.3-41.7) vs. 16.5 ng/ml (7.4-25.7) (p = 0.053; ns). The 
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ratio S-/R-MIR was higher in non smokers with 0.41(0.15-1.06) vs. 0.25(0.04-1.01) in smokers 
(p=0.025 Mann-Whitney). Such significant differences were not observed in hydrolysed samples (not 
shown).  
Significant positive correlations were observed between age and plasma concentrations of MIR 
enantiomers and metabolites, in the samples submitted to hydrolysis: (S-MIR: r = 0.377 (p = 0.018); 
R-MIR: r = 0.576 (p = 0.0001); S-DMIR: r = 0.618 (p = 0.001); R-DMIR: r = 0.503 (p = 0.001); R-
OH-MIR: r = 0.331 (p = 0.04)). Similar significant correlations were obtained at weeks 4, 6 and 8 (not 
shown). Inconsistent results were obtained by the statistical analysis of non-hydrolysed samples as at 
week 2, significant correlations were only observed for R-MIR: r = 0.398 (p = 0.01) and R-DMIR: r = 
0.328 (p = 0.04), and only for R-MIR, significant correlations were also observed on weeks 4 and 8. 
Age and smoking status were not significantly correlated (r = -0.205, p = 0.177), and therefore the 
effect of smoking was not confounded by age.  
The study of the relationship between gender and MIR kinetics (table 12) showed that female had 
significantly higher median R-MIR, R-DMIR and S-MIR plasma levels than male patients, both in 
samples without and with hydrolysis.  
Table 12: Significant differences in plasma concentrations of MIR enantiomers and metabolites 
between female and male patients.  
 non- hydrolysed  hydrolysed  
gender R- MIR R- DMIR S- MIR R- MIR R- DMIR S- MIR 
female 23.46±6.87  20.23±7.25  9.47±4.91 57.36±16.75  23.29±21.17  16.47±9.00  
male 19.31±3.39 15.00±4.88  5.79±3.89  43.21±18.81 13.97±10.58  10.34±6.42  
p 0.029 0.015 0.029 0.022 0.024 0.035 
 
Pharmacokinetics – pharmacogenetics relationships 
Relationships between the pharmacogenetic status of the patients regarding CYP2C19 polymorphisms 
and plasma concentrations of MIR and its metabolites as measured on day 14 (but also at weeks 4, 6, 
and 8) were calculated. There was apparently no evidence for a direct effect of the CYP2C19 
pharmacogenetic status of the patients on MIR kinetics (not shown).  
A statistically significant influence of the CYP2D6 genotype (PM, IM, EM, UM) on plasma levels of 
MIR enantiomers or metabolites was only observed for S-DMIR plasma concentrations at almost all 
data points (p= 0.09, 0.014, 0.02, 0.006 respectively) after 2, 4, 6, and 8 weeks (data not shown).  
Ratios between the concentrations of the parent compound and the metabolite, as well as between the 
enantiomers, which could be formed by a particular enzyme, were calculated in order to examine 
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pharmacogenetic relationships (table 13): In the whole patient population, the ratios S-MIR/S-OH-
MIR (p = 0.014) and S-MIR/R-MIR (p = 0.043) in the hydrolyzed samples showed a statistically 
significant CYP2D6 dependence, S-DMIR/R-DMIR showed a trend (Kruskal Wallis test, data not 
shown). Analyzing smokers and non-smokers separately, these effect could only be confirmed in non-
smokers (S-MIR/S-OH-MIR (p = 0.023); S-MIR/R-MIR (p = 0.015)) (Table 14a and b).   
Table 13: Median (ranges) ratios of the enantiomers of MIR, DMIR and OH-MIR on day 14 in plasma 
of CYP2D6 genotyped patients treated with mirtazapine 30mg/d. 
 
 
Table 14a: Median (ranges) concentrations and ratios of the enantiomers of MIR, DMIR and OH-MIR 
on day 14 in non-hydrolysed plasma samples of CYP2D6 genotyped patients treated with mirtazapine 
30mg/d: smokers vs. non- smokers. 
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Table 14b: Median (ranges) concentrations and ratios of the enantiomers of MIR, DMIR and OH-MIR 
in hydrolysed plasma samples of CYP2D6 genotyped patients treated with mirtazapine 30mg/d: 
smokers vs. non-smokers  
 
For CYP1A2*F we found some significant influence on day 14 for D-MIR (p = 0.039), in smokers for 
the ratio S-DMIR/R-DMIR (p = 0.039), and in non-smokers for the ratio R-MIR/R-DMIR (p = 0.047). 
For the distribution of CYP1A2*1F genotypes cf. table 15.  
 
 Table 15: CYP1A2*1F genotypes in smokers and non smokers 
  CYP1A2       
  *1/*1 *1/*1F *1F/*1F total 
smoker 1 11 5 17
non smoker 6 14 6 31
 
One patient treated throughout the study with 30 mg/day MIR had consistently high plasma levels of 
enantiomers of MIR and its metabolites. Her racemic MIR plasma levels rose steadily from 41ng/ml 
after 2 weeks to 91ng/ml after 8 weeks. Her dose-corrected plasma MIR levels rose steadily from <1.5 
ng x day /ml x mg after 2 weeks of treatment to 3.0 ng x day /ml x mg after 8 weeks.  In contrast, the 
remaining patients had dose-corrected levels of <1.5 ng x day /ml x mg at almost all time points for 
the entire duration of the study.  She weighed 48 kg, was 157 cm tall and smoked around 20 cigarettes 
per day.  She was an ex-alcohol abuser and had high levels of liver enzymes (γ-GT consistently >100 
U/L).  As well as receiving MIR, at a dose of 30 mg/day, she was also taking concomitant vitamin B, 
calcium, acamprosate and propranolol.  The fact that propranolol is a moderate inhibitor of CYP2D6 
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(267) may have contributed to the higher than expected MIR plasma levels.  Her genotype for 
CYP2D6 was determined as IM *1/*5 (*5 a deficient allele); however her observed phenotype as 
characterized by the dextromethorphan test was not a PM which is against the hypothesis above. Her 
other genotypes were: CYP1A2 *1/*1F, CYP2B6 *6/*6, CYP2C19 *1/*1. 
Patients with the genotype CYP2B6 *6/*6 (n=8) compared with those presenting another CYP2B6 
genotype (n = 37) had similar plasma concentrations of R-MIR: 24.0 ng/ml (16.2 -37.2) (median, 
range) vs. 22.0 ng/ml (11.5-36.4) and S-MIR: 7.2 ng/ml (2.6-18.9) vs. 7.2 ng/ml (0.6-18.9), but 
somewhat higher levels of R-DMIR: 21.9 ng/ml (8.8-25.3) vs. 16.7 ng/ml (7.3-41.7); S-DMIR: 3.2 
ng/ml (1.3-4.4) vs. 2.6 ng/ml (1.0-7.9); R-OH-MIR: 5.8 ng/ml (5.8) vs. 1.0 ng/ml (0.5-1.2); they were 
significantly higher only for S-OH-MIR (1.7 ng/ml (1.2-3.5) vs. 0.9 ng/ml (0.6-1.6) (p = 0.01)). In 
patients displaying the CYP2B6 *6/*6 genotype, the sum of the two enantiomers of MIR (and that of 
its metabolites) were also somewhat higher but without reaching statistical significance (results not 
shown). 
Pharmacokinetics, pharmacogenetics, clinical outcome 
On day 56, at the end of the 8-week study period, the mean dose of mirtazapine was 38.5 ± 7.6 and 
37.5 ± 8.0 mg/day in responders (n = 23) and non responders (n = 8) respectively. The plasma (not 
dose corrected) concentrations (median (min-max)) of MIR and its metabolites were: R-MIR: 25.2 
ng/ml (15.0-65.2) and 25.1 ng/ml (8.5-40.3), S-MIR: 9.7 ng/ml (0.8-49.1) and 5.8 ng/ml (0.5-14.2), R-
MIR + S-MIR: 34.9 ng/ml (17.4- 108.2) and 31.6 ng/ml (9.0-54.5). There was no evidence for a 
significant plasma concentration – clinical effectiveness or tolerability relationship regarding any 
pharmacokinetic parameter. Although plasma concentrations of the enantiomers of MIR and MIR 
metabolites did not differ between responders and non-responders, a ROC-analysis of our data 
indicates that patients with a plasma concentration of S-MIR ≥ 5 ng/ml will be responders with a 
probability of 77% (sensitivity 91%, specificity 50%). Also in the Chi square test this difference is 
statistically significant (table 16). 
 
Table  16: Study completers divided in responders and non responders and S-MIR plasma 
concentration. Chi square is 4.64(p= 0.031) 
S‐MIR   Responders  Non responders All
> 4.96ng/ml  20  4  24 
< 4.96ng/ml   3  4  7 
Total  23  8  31 
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With the exception of CYP2B6 there were no significant relationships between CYP genotypes, 
HAMD total scores or change in HAMD total scores. Patients with the CYP2B6 *6/*6 genotype had a 
higher reduction in HAMD scores (p = 0.016, Mann-Whitney test) than the patients presenting another 
CYP2B6 genotype (Table 17).  
 
Table 17: Association between CYP2D6 genotype and HAMD scores at baseline/study end 
 
 
Discussion 
Clinical outcome 
Although this was not a blind, placebo controlled study design, the results confirm the clinical 
response of MIR in patients (19-79 years old, 13 being >64 years old) suffering from an episode of 
major depression, resulting in a significant improvement in HAMD and CGI severity score (240;268). 
In this 8-week study, there was a mean decrease of 15 points on the HAMD scale, in comparison to a 
mean 11.5 points decrease found in a meta-analysis of 5 randomized, double-blind trials with 5 – 60 
mg/d MIR administered during 5 – 6 weeks (240). In another analysis of MIR studies in patients with 
moderate to severe depression, response rate varied from 51 to 80 % after a 4 – 7-week treatment 
(240) – the response rate was 81% in the present study.  The tolerability and safety profile was also as 
expected, with sedative effects and body weight increase being the most common adverse events.  One 
patient committed suicide some days after being withdrawn from the study because of lack of 
therapeutic effect. Although in some cases a causal relation to antidepressant treatment has been 
suggested, this was not the case with this patient, and furthermore a recent analysis of 15 pooled 
studies with mirtazapine showed no increased but a lowered risk (269).     
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Cytochrome P-450 genotypes/phenotypes 
The patients were phenotyped and/or genotyped for some (CYP2D6, CYP1A2) but not for all 
(CYP3A) enzymes known to be implicated in the metabolism of MIR (258;260). In particular, it was 
found that the percentage of patients (29%) homozygote for the CYP1A2 allele *1F was lower than 
expected from the incidence of around 50% seen in the general population (70), but that could be a 
chance finding due to the low number of our study population.  Homozygote subjects for this allele 
might show higher inducibility of CYP1A2 (70). The allele frequency for CYP2C19*2 was low in our 
population with no PM, neither by genotype nor by phenotype (64;140;270). This makes it difficult to 
identify a possible effect of this enzyme but anyway, available literature on this subject does not 
suggest a relevant role of CYP2C19 in the metabolism of MIR (258;259). Regarding CYP2D6, no co-
medication was identified that could sufficiently explain the difference between the predicted and 
observed phenotypes. It is known that the UM phenotype cannot be identified by the 
dextromethorphan test, and genotyping reveals only about 30% of UM (271;272). For statistical 
comparisons with clinical and pharmacokinetic parameters, only genotyping data were used. On the 
other hand, for the first time, a possible contribution of CYP2B6 in the biotransformation of MIR has 
been examined in this study, where 15% of the 45 patients presented the genotype CYP2B6 *6/*6 
(CYP2B6 G to T polymorphism at position 516). 
MIR pharmacokinetics 
The concentrations of the enantiomers of MIR and its metabolites (Tables 11-14) can only to a limited 
extent be compared with data from the literature. All previous measurements of the enantiomers of 
MIR and its metabolites in steady-state conditions were performed by the same laboratory, using the 
same method ((200;251;257), as in this study. In all these investigations, R-MIR concentrations were 
generally higher than those of S-MIR, both in hydrolysed and non-hydrolysed samples (including in 
those from CYP2D6 PM), except in those from patients co-medicated with CYP2D6 inhibitors such as 
fluoxetine (200). However, it seems probable, that the antidepressant effect of MIR is mainly exerted 
by S-MIR, due to its preferential affinity for α2-receptors (243;246;250).  
This study also confirms that R- and S-MIR, R- and S-OH-MIR are largely conjugated (200;251), but 
as these conjugated products were apparently never synthesised as pure compounds, no data are 
available on their pharmacological profile and therefore, on their possible clinical contribution.  
Mainly after hydrolysis, significant positive correlations were observed between almost all drug or 
metabolite levels and age and as well non-conjugated as total drug or metabolite concentrations were 
significantly higher in females than in males. The data suggest that these age and gender effects may 
probably be more pronounced with regard to the pharmacokinetics of the R-enantiomer. In the already 
mentioned study which reported only non-conjugated levels of MIR and DMIR (257), the 
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concentrations of the enantiomers of MIR and DMIR were also found to be higher in elderly (> 65 y) 
than in younger patients, but on the other hand, these levels only tended to be higher in females than in 
males. Finally, in the therapeutic drug monitoring study (with the same patients as reported in (257)), 
where only achiral methods were used, both higher age and female gender were related with higher 
levels of dose corrected MIR and DMIR (256). In summary, after taking into account also some single 
dose studies (273), higher plasma concentrations of MIR and its metabolites are rather expected in 
elderly patients and in female subjects, but the mechanism is not clear (metabolism by cytochrome P-
450 isozymes or conjugating enzymes, liver blood flow, renal elimination) (253). 
Smokers had significantly lower plasma concentrations of S-MIR (p = 0.014), R-MIR (p = 0.007) and 
S-DMIR (p = 0.006) than non-smokers, their ratio S-/R-MIR was lower as well (p=0.025). These 
findings, to some extent, are in line with previous publications (257). Using an achiral method, dose 
corrected MIR and DMIR concentrations were found to be lower in smokers than in non-smokers in 
the 6-month therapeutic drug monitoring study (256). A reanalysis of the samples of this investigation 
(256) by a stereoselective method (200) revealed that S-MIR (p = 0.026) and R-DMIR (p = 0.036), as 
well as the ratio S-/R-MIR were lower in smokers than in non-smoking patients (257).  This suggests 
that CYP1A2, which is induced by smoke (274), contributes to the biotransformation of MIR. 
However, as already discussed earlier (256;257), in vitro studies with recombinant enzymes suggest 
that CYP1A2 may dose-dependently be involved in N-demethylation, hydroxylation and N-oxidation 
of MIR (258). In another in vitro study, limited methodologically by the fact that only the decrease of 
substrate but not the formation of a metabolite was measured, CYP1A2 preferentially but only 
marginally (in comparison to CYP2D6) metabolised S-MIR (S-(+)-MIR), while it was found to be 
inactive towards R-(-)-MIR (259). 
Only few of co-medicated drugs can be considered as potentially interfering with the metabolism of 
MIR: The 2 β -blocking drugs metoprolol (275) and propranol (267) have some inhibitory potential on 
CYP2D6, and rofecoxib inhibits CYP1A2 activity (276;277). In 2 patients co-medicated with this 
analgesic drug, which in the meanwhile is not any more available on the market, S-MIR 
concentrations were higher than in the other patients (p = 0.026). Actually, in a patient treated with 
MIR (200), co-medication with several psychotropic and somatic drugs including omeprazole (a 
CYP1A2 inducer and CYP2C19 inhibitor) and rofecoxib, a ratio S/R-MIR = 9.4 could be observed in 
plasma, which seems to be the highest ratio ever reported.  
Pharmacokinetic-pharmacogenetic relationships 
While these comparisons between the smoking status of the patients and drug plasma concentrations 
show the influence of environmental factors on the stereoselective biotransformation of MIR, genetic 
factors also play an important role, which may be partly masked in smokers. Indeed, considering the 
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non-hydrolysed samples only, there is some evidence of a control of the metabolism of S-MIR (p = 
0.031) and S-DMIR (p = 0.025) by CYP2D6 (Table 14a) only in non-smokers. Probably due to the 
low number of CYP2D6 PM, the ratio S-MIR/S-OH-MIR only shows a tendency to vary with the 
pharmacogenetic status of the patients (p = 0.093). These relationships appear more clearly when total 
(conjugated and non-conjugated) concentrations of S-MIR (p = 0.003), S-DMIR (p = 0.008) and S-
MIR/S-OH-MIR (p = 0.023) are considered (Table 14b). In addition, CYP2D6 also contributes to 
some extent to the metabolism of R-MIR (p = 0.04). Again, CYP2D6 effects were stronger in non-
smokers. These observations confirm those obtained earlier in 95 patients, which showed a 
relationship between the CYP2D6 genotype and S-MIR concentrations and with the S/R-ratio (257). 
The MIR plasma concentrations from the 3 UM (CYP2D6) did not significantly differ from the EM 
(CYP2D6). It might be assumed that UM undergo a risk of therapeutic failure due to low tissue 
concentrations as CYP2D6 accounts for about a third to half of their total MIR biotransformation 
(278).  However, of the 3 UM in this study, two responded well and the third withdrew prematurely.  
Similarly, in a previous study conducted in healthy volunteers, the impact of this genotype on MIR 
pharmacokinetics was less than expected (278). Definite conclusions cannot be drawn due to the low 
number of subjects, but S-MIR in the only smoking UM was considerably lower than in the 2 UM 
non-smokers, both in hydrolysed and non-hydrolysed plasma samples (Tables 14 a and b). This 
supports again the hypothesis that CYP1A2 activity, mainly in smokers, masks that of CYP2D6. 
CYP1A2*1F has been associated with increased CYP1A2 activity in smokers, possibly because of 
increased inducibility (69;70). The CYP1A2*F polymorphism believed to enhance the inducibility of 
CYP1A2 did show some significant influence on enantiomeric MIR and metabolites plasma 
concentrations. However, these findings are difficult to interpret, since also non-smokers seemed to 
show some CYP1A2*F genotype dependency; but also for clozapine, mainly metabolised by CYP1A2, 
findings were contradictory (71;182;279).  
The finding that the plasma concentrations of S-OH-MIR are significantly higher (p = 0.01) in patients 
presenting the genotype CYP2B6 *6/*6 (CYP2B6 G to T polymorphism at position 516) than in the 
other patients is highly interesting, however also difficult to interpret. It is to note that the 
concentrations of the other metabolites were also higher in the CYP2B6 *6/*6 patients, but these 
differences did not reach statistical significance, possibly due to the low number of tested subjects. 
Nevertheless, this suggests the hypothesis that in CYP2B6 *6/*6 patients, metabolism of S- and 
possibly also of R-MIR is enhanced, but the question remains open whether both hydroxylation and N-
demethylation are concerned. Only a few other psychotropic drugs were as yet shown to be substrates 
of CYP2B6, including bupropion (93), sertraline (280;281) and methadone (with a stereoselectivity in 
favour of S-methadone) (138).  Most often, the presence of the CYP2B6 *6/*6 genotype is 
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synonymous with decreased enzymatic activity as a consequence of a decreased enzyme protein 
expression, but with some substrates, increased metabolism has also been observed (282). 
MIR pharmacokinetics and pharmacogenetics relationship with clinical outcome 
Steady-state plasma concentrations of the enantiomers of MIR and its metabolites were dependent on 
age, gender, smoking, and they were related with the pharmacogenetic status of the patients regarding 
CYP2D6 and probably also CYP2B6 genotypes, but not regarding  CYP2C19 or CYP1A2*F 
genotypes. However, there was no significant relationship between plasma concentrations of MIR or 
its metabolites, or the pharmacogenetic status of the patients and clinical outcome, except that patients 
presenting the CYP2B*6/*6 genotype had a better clinical response than the other patients (Table 17). 
The question arises if S-OH-MIR contributes to the therapeutic effect of MIR. No similar studies were 
previously published, but a clinical study with depressive patients treated with MIR for a varying 
period suggests that MIR plasma concentrations < 30 ng/ml represent a risk for decreased 
response(283). Unfortunately, no enantioselective methods were used to allow comparison with the 
present study, where concentrations of S-MIR > 5 ng/ml were synonymous with a higher response 
rate. Although recommended doses of MIR were given in this study, mean or median plasma 
concentrations hardly met the recommended target of 40-70ng/ml (41).  
In summary, several forms of cytochrome P-450 are involved stereoselectively in the metabolism of 
MIR: CYP2D6, CYP3A, CYP1A2 and, as shown in this study, possibly also CYP2B6. Dose 
dependently, the contribution of the various enzymes varies, but also in relationship with the 
pharmacogenetic status of the patient (CYP2D6, CYP2B6), his phenotype with respect to CYP1A2 
(e.g. induction by smoking) and probably also to CYP3A; gender and age affect also MIR plasma 
concentrations.  Hedlund et al. (284) formulated the question: "2B or not 2B" with regard to its 
possible presence in the brain. This question is also justified considering the preliminary findings in 
this study about the metabolism of MIR by CYP2B6. In order to clarify this very complex situation, in 
vitro studies would be helpful as those carried out for sertraline (280) and clozapine (181), which 
allowed presenting the relative activity of each CYP isoform in function of the drug dose. In figure 12 
a hypothesis is presented, how these different CYP450 enzymes could be involved in the metabolism 
of mirtazapine. Studies with larger groups of patients are needed in order to ascertain the role of 
CYP2B6 in the metabolism of MIR and its implication in the clinical response of the patients to this 
antidepressant. Indeed, the relatively small study size must be borne in mind and it is possible that a 
larger sample size may reveal more significant correlations. Moreover, neither CYP3A genotypes nor 
phenotypes have been examined and, in addition to rofecoxib and some β-blockers, other co-
medications may also have influenced MIR pharmacokinetics.  
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Figure 12: Possible metabolic pathways of mirtazapine 
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5 Pharmacogenetic study of clozapine 1 
Summary 
In order to examine the genetic factors influencing clozapine kinetics in vivo, 75 patients treated with 
clozapine were genotyped for CYPs and ABCB1 polymorphisms, and phenotyped for CYP1A2 and 
CYP3A activity. CYP1A2 activity and dose corrected trough steady-state plasma concentrations of 
clozapine correlated significantly (r=0.61; p=1x10-6), with no influence of the CYP1A2*1F genotype 
(p=0.38). CYP2C19 poor metabolisers (*2/*2 genotype) had 2.3-fold higher (p=0.036) clozapine 
concentrations than the extensive metabolisers (non *2/*2). In patients co-medicated with 
fluvoxamine, a strong CYP1A2 inhibitor, clozapine and norclozapine concentrations correlated with 
CYP3A activity (r=0.44, p=0.075; r=0.63, p=0.007, respectively). Carriers of the ABCB1 3435TT 
genotype had 1.6 fold higher clozapine plasma concentrations than non-carriers (p=0.046). In 
conclusion, this study showed for the first time a significant role of CYP2C19 and the Pgp transporter 
in the in vivo pharmacokinetics of clozapine. CYP1A2 is the main CYP isoform involved in clozapine 
metabolism, with CYP2C19 contributing moderately, and CYP3A4 contributing only in patients with 
reduced CYP1A2 activity. In addition, ABCB1, but not CYP2B6, CYP2C9, CYP2D6, CYP3A5 nor 
CYP3A7 polymorphisms, influence clozapine pharmacokinetics. 
Introduction 
The first atypical antipsychotic drug clozapine is still considered superior in its efficacy to that of other 
antipsychotics (285), but because of its side effect profile (with amongst other the risk of severe 
haematological problems) it is mainly used in difficult to treat patients who failed to respond to other 
medication. However, about 30% of the patients do not respond adequately (286), one of the reasons 
could be too low plasma levels in spite of normal dosing. The well defined therapeutic window of 
clozapine of 350 – 600 ng/ml has been found in several studies (287;288); high plasma concentrations 
(>1000 ng/ml) are associated with a higher risk for serious adverse reactions such as generalised 
seizures, delirium, confusion (289). 
The therapeutic effect of the drug clozapine is mainly attributed to the parent compound but the main 
active metabolite N-desmethyl clozapine (norclozapine) might have antipsychotic properties as well 
and beneficial effects on cognition (290;291) attributed to the M1 partial agonistic activity.  In some 
studies a higher metabolic ratio of norclozapine/clozapine showed to be associated to a higher 
response rate (292;293). Norclozapine is, as the antipsychotic aripiprazole, a partial agonist for D2 and 
D3 receptors (294) which could explain the low incidence of EPS and maybe also positive effect on 
                                                            
1 This study contributed also to the medical thesis of Branka Knezevic 2009 
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the negative symptoms of schizophrenia. Clozapine N-oxide seems not to have a significant clinically 
relevant activity (291;293;295;296). A comparison of the pharmacological profile of clozapine and 
norclozapine shows many similarities but also some striking differences (table 18). 
Table 18: Pharmacological profiles of clozapine and norclozapine (291;293;297;298) 
receptor clozapine norclozapine
D2 inverse agonist/antagonist middle potent partial agonist 
D3 inverse agonist/antagonist middle potent partial agonist 
D4 antagonist antagonist 
5HT1a weak partial agonist weak partial agonist 
5HT2a inverse agonist, high affinity inverse agonist, high affinity 
5HT2c inverse agonist inverse agonist, high affinity, higher potency 
5HT6 middle potency inverse agonist,  middle potency inverse agonist, high affinity 
5HT7 middle potency inverse agonist, high middle potency inverse agonist, high affinity 
H1 high potency inverse agonist inverse agonist, but << than clozapine 
H3 antagonist, middle affinity antagonist, low affinity 
M1 antagonist potent partial agonist 
M2 agonist partial agonist 
M3 - partial agonist 
M4 agonist partial agonist 
M5 - partial agonist 
α1A antagonist, high affinity antagonist, but lower affinity than clozapine 
 
Considering side effects, M1 agonistic activity of norclozapine explains the observed sialorrhea, the 
M2 antagonism of the parent compound clozapine the relative protection against extrapyramidal 
symptoms. The H1 antagonistic activity of clozapine and norclozapine could explain the weight gain 
observed with clozapine, clozapine being more potent. This seems contradictory to the clinical 
observations of less weight gain with lower norclozapine plasma levels. However, the different inverse 
agonistic potency at the 5HT2c receptor could explain this association (298-301). 
Clozapine displays a high inter-individual variability in dose-corrected plasma concentrations which 
might be explained by the influence of genetic and environmental factors on the metabolism and drug 
transport of clozapine (112;302;303).  
In vitro studies suggest the contribution of several Cytochrome P450 enzymes (CYP) in the 
metabolism of clozapine (181;186;304): CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A, with 
CYP1A2 having a major role in the N-demethylation of clozapine to its main active metabolite 
norclozapine (304). Figure 13 illustrates probable metabolic pathways of clozapine. In vivo the role of 
CYP1A2 has been confirmed (69;305), and it explains the lower plasma levels in smokers compared 
to non-smokers  (306) since CYP1A2 is induced by smoking (307). A small pharmacogenetic study 
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did not find a significant influence of CYP2D6 nor CYP2C19 in the in vivo metabolism of clozapine 
(308). CYP3A could play a significant role since clozapine plasma concentration is lowered in 
presence of carbamazepine, a strong CYP3A inducer (309) but it is not known which CYP3A isoforms 
are implicated. 
Figure 13: Possible metabolic pathways of clozapine (304;310-312) 
 
Clozapine could be a substrate of the P-glycoprotein (Pgp), encoded by the ABCB1 gene, as found in 
one in vitro study (313) but not found in another (314).  
The aim of this study was to examine the in vivo influence of genetic polymorphisms of CYP isoforms 
(CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and CYP3A7) and ABCB1 on 
the steady state plasma concentrations of clozapine. Patients were also phenotyped with the caffeine 
test for CYP1A2 and the midazolam test for CYP3A since genotyping reflects only partly the activity 
of these two CYP enzymes. Further environmental factors such as smoking and co-medication were 
investigated.  Finally, we examined a possible causal association of clozapine plasma concentrations 
with side effects, especially with weight gain (315;316). 
Methods 
Seventy-five in-patients of 2 psychiatric clinics aged 18 years and older, on stable clozapine treatment 
and unchanged co-medication for at least 2 weeks (4 weeks for fluoxetine) were included in the study. 
Serious uncontrolled illnesses, organic psychiatric illness, or substance dependence were exclusion 
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criteria. To ensure compliance the patients took their medication under the supervision of a nurse, 
clozapine being dissolved in the four days before blood sampling. Patients or their legal representative 
signed the written informed consent, and the study was approved by the local ethics committees of the 
2 clinics (Königsfelden and Prilly-Lausanne). 
Blood sampling: on the morning of day 1, before first drug intake, 75µg oral midazolam diluted in a 
glass of water was given to the patient for CYP3A phenotyping (152). A blood sample was taken 30 
minutes later for the determination of the 1’OH-midazolam/midazolam plasma ratio (152) and trough 
clozapine and norclozapine plasma concentrations. Thereafter the patients received their usual 
medication together with 200mg caffeine for CYP1A2 phenotyping (317). 6 hours later a second 
blood sample was taken for the determination of the paraxanthine/caffeine plasma ratio (317). No 
caffeine containing food or beverage was allowed on the test day until after the second blood 
sampling. All the samples – plasma after centrifugation and K-EDTA whole blood – were kept frozen 
at -20ºC until analysis. To control compliance, plasma concentration measurements of clozapine and 
norclozapine were repeated on day 7. Since there were no significant differences between them, results 
are expressed as the mean of the 2 blood samplings. 
Assays of drugs:  Clozapine and norclozapine concentrations were determined by gas chromatography 
with a nitrogen-phosphorus detector (69). Fluvoxamine (318), midazolam and 1′OH-midazolam 
(151;152) caffeine and paraxanthine (69) were measured by gas chromatography-mass spectrometry. 
Measured clozapine and norclozapine plasma concentrations were corrected by clozapine daily dose, 
and hereafter are referred to as plasma concentrations. 
Genotyping: Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA Kit 
(Qiagen, Hombrechtikon, Switzerland). All the SNPs, with the exception of CYP2D6*5 and 
CYP2D6*xN, were detected by real-time PCR with 5’-nuclease allelic discrimination assays (ABI 
PRISM 7000 Sequence Detection System, Applied Biosystems, Rotkreuz, Switzerland) with primers 
and probes obtained from Applied Biosystems. The CYP1A2*1F, CYP2B6*4, CYP2B6*5, 
CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, 
CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP3A4*1B, CYP3A5*3, ABCB1 61A>G, 2677G>T and 
3435C>T SNPs were analyzed as previously described (69;138). CYP2D6 gene deletion (allele *5) 
and duplication/multi-duplication (allele *xN) were analyzed by quantitative real-time PCR and long 
PCR, respectively (138). CYP3A7*1C (-262T>A and -270T>G) allele was determined as previously 
described (319). CYP2C19*17 (-806C>T) allele was determined using the following primers, 
GTTTGGAAGTTGTTTTGTTTTGCTAA (forward), CATCGTGGCGCATTATCTCTT (reverse), 
and labelled probes, 6-FAM-TTCTCAAAGcATCTCT-MGBNFQ, and VIC–
TTCTGTTCTCAAAGtATCT-MGBNFQ. The 25µl PCR mixture contained 12.5µl TaqMan Universal 
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PCR Master Mix (Applied Biosystems), 900nM of each primer, 200nM of each TaqMan minor groove 
binder non-fluorescent quencher probe, and 40ng (100ng for CYP2C19*17) of genomic DNA. After 
an activation step comprising AmpErase (50°C for 2 min) and AmpliTaq Gold enzyme activation 
(95°C for 10min), 60 PCR cycles (50 cycles for CYP2C19*17) were performed with 15s at 92°C and 
1min at 58°C (1.5min at 60ºC for CYP2C19*17). CYP3A4 rs4646437C>T were analyzed with 
commercial TaqMan® Drug Metabolism Genotyping Assays according to the manufacturer’s 
instructions (Assay Ids C_32306227_10; Applied Biosystems).  
Clinical assessments: At baseline all patients underwent a physical examination and routine 
haematological and chemistry parameters were measured. Their medical history was recorded and 
their psychiatric and somatic diagnoses were confirmed. On days 1 and 7, weight, vital signs, adverse 
events and lifestyle factors such as smoking, caffeine consumption and grapefruit intake were noted. 
Weight gain data during the entire clozapine treatment were collected from the patient’s medical files. 
Statistical Analysis:  Clozapine and norclozapine blood concentrations were compared between 
different genotypes by non-parametric analyses (Kruskal-Wallis for >2, Mann-Whitney U Test for 2 
groups). Correlations between plasma concentrations and CYP1A2 or CYP3A activity were assessed 
by Spearman’s test, and multivariate analyses were performed using linear regression (backward 
method). A p-value <0.05 was considered to indicate statistical significance. All statistical tests were 
performed in the whole group of patients and in the two subgroups with and without fluvoxamine as 
inhibition by fluvoxamine could mask the potential influence of other factors. Statistical analyses were 
performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, USA). For ABCB1 polymorphisms, 
Hardy-Weinberg equilibrium was tested and linkage disequilibrium (Lewontin’s D’coefficient) was 
estimated with STATA (version 10, StataCorp, College Station TX, USA). Haplotypes were inferred 
using the haplo.em function in R (http://www.r-project.org/), which uses expectation-maximization 
algorithm. As none of the inferred haplotypes had a posterior probability below 98%, haplotype 
uncertainty can be considered as minimal. Genetic association studies were conducted using the 
haplo.score function in R (which uses generalized linear models and takes haplotype uncertainty into 
account) with an additive effect and a Gaussian distribution for the trait.  
Results  
Seventy-five patients (39 men/36 women; 73 Caucasian/1 Asian/1 Black African) participated in the 
study. Their median age was 44 years (mean 48; SD 17; range 20-90). The majority were diagnosed 
with schizophrenic disorders (n=73), one with bipolar disorder, and one with dementia. 
Table 19 gives an overview of the observed genotype frequencies of CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7 and ABCB1.  They are similar to those previously 
described in Caucasian populations (http://www.cypalleles.ki.se) (64;139)and all the SNPs are in 
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Hardy-Weinberg equilibrium for the Caucasian sub-sample (n=73). All 3 SNPs of the ABCB1 genes 
are in strong linkage disequilibrium, as previously reported (136). 
Table 19: Frequency of CYP1A2*1F, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, 
CYP3A7 and ABCB1 genotypes in 73 white patients treated with clozapine 
Genotype n Frequency (%) 95% Cl (%) 
 CYP1A2*1F    
 *1/*1 8 10.9 4.8-20.5 
 *1/*1F 31 42.5 31.0-54.6 
 *1F/*1F 34 46.6 34.8-58.6 
 CYP2B6    
 *1/*1 30 41.1 29.7-53.2 
 *1/*4 1 1.4 0.03-7.4 
 *1/*5 8 10.9 4.8-20.5 
 *1/*6 20 27.4 17.6-39.1 
 *1/*7 4 5.5 1.5-13.4 
 *5/*5 2 2.7 0.3-9.5 
 *6/*6 8 10.9 4.8-20.5 
 CYP2C9    
 *1/*1 51 69.9 58.0-80.1 
 *1/*2 11 15.1 7.8-25.4 
 *1/*3 8 10.9 4.8-20.5 
 *2/*2 1 1.4 0.03-7.4 
 *2/*3 2 2.7 0.3-9.5 
 CYP2C19    
 *1/*1 24 32.9 22.3-44.9 
 *1/*2 17 23.3 14.2-34.6 
 *1/*17 18 24.6 15.3-36.1 
 *2/*2 4 5.5 1.5-13.4 
 *2/*17 4 5.5 1.5-13.4 
 *17/*17 6 8.2 3.1-17.0 
 CYP2D6    
 *1/*1 40 54.8 42.7-66.5 
 *1/*3 4 5.5 1.5-13.4 
 *1/*4 16 21.9 13.1-33.1 
 *1/*5 3 4.1 0.9-11.5 
 *1/*6 1 1.4 0.03-7.4 
 *1/*xN 4 5.5 1.5-13.4 
 *4/*4 4 5.5 1.5-13.4 
 *4/*xN 1 1.4 0.03-7.4 
CYP3A CYP3A5*3    
 *1/*1 1 1.4 0.03-7.4 
 *1/*3 8 10.9 4.8-20.5 
 *3/*3 64 87.7 77.9-94.2 
 CYP3A7*1C    
 *1/*1 66 90.4 81.2-96.1 
 *1/*1C 6 8.2 3.1-17.0 
 *1C*1C 1 1.4 0.03-7.4 
 CYP3A4 rs4646437 (intron 7)   
 CC 58 79.4 68.4-88.0 
 CT 14 19.2 10.9-30.1 
 TT 1 1.4 0.03-7.4 
ABCB1 61A>G (exon2)    
 AA 71 97.3 90.5-99.7 
 AG 2 2.7 0.3-9.5 
 2677G>T (exon 21)   
 GG 25 34.2 23.5-46.3 
 GT 38 52.1 40.0-63.9 
 TT 10 13.7 6.8-23.8 
 3435C>T (exon 26)   
 CC 18 24.6 15.3-36.1 
 CT 40 54.8 42.7-66.5 
 TT 15 20.5 12.0-31.6 
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Dose-plasma level relation 
The median clozapine daily dose was 250mg (range: 25-800mg). Six patients received clozapine 
mono-therapy; 17 patients (23%) had co-medication with the strong CYP1A2 and moderate CYP3A 
and 2C19 inhibitor fluvoxamine (dose range: 25-300mg/day) (320;321). The dose corrected median 
trough plasma concentrations of clozapine and norclozapine were 1.14ng/ml*mg (0.15-6.24) and 
0.60ng/ml*mg (0.04-2.36) in the whole group of patients and 0.99ng/ml*mg (0.15-2.88) and 
0.49ng/ml*mg (0.04-1.28) in the group of patients without fluvoxamine, respectively. The median 
clozapine, norclozapine, and clozapine + norclozapine plasma concentrations were 3.5-, 2.4- and 3.3-
fold higher, respectively, in the group with as compared to the group without fluvoxamine (p=4.9 x  
10-7, p=1.3x10-5 and p=1.1x10-6, respectively). Correlations (logarithmic regressions) were calculated 
between fluvoxamine plasma concentrations and clozapine (r2=0.65), norclozapine (r2=0.11) and 
clozapine + norclozapine (r2=0.52) plasma concentrations (fig. 14). In addition, this figure suggests 
saturation of inhibition in the range 50 to 100ng/ml of fluvoxamine. In agreement with a strong 
inhibition of CYP1A2 activity by fluvoxamine, the median paraxanthine/caffeine ratios were 0.72 
(0.19–3.12) and 0.33 (0.08–3.49) in the groups of patients without and with fluvoxamine, respectively. 
Flattening of the correlation curve (power regression, r2=0.71) between fluvoxamine plasma 
concentrations and paraxanthine/caffeine ratios suggests saturation of the inhibition of CYP1A2 
activity with increasing fluvoxamine plasma concentrations (fig. 15). 
Figure 14: Correlations (logarithmic regressions) between fluvoxamine plasma levels and (■) 
clozapine (y=0.84Ln(x) +0.88, r2=0.65), (▲) norclozapine (y=0.11Ln(x) +0.85, r2=0.11) and (○) 
clozapine + norclozapine (y=0.96Ln(x) +1.73, r2=0.52) dose normalised plasma levels. 
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Figure 15:  Correlation between fluvoxamine plasma levels and CYP1A2 activity measured by the 
paraxanthine/caffeine ratio (power regression: y=1.62x-0.51, r2=0.71). The outlier corresponds to a 
patient with a CYP2D6 ultra rapid metaboliser polymorphism with very low fluvoxamine plasma 
levels. 
 
 
 
 
 
 
 
 
 
A group of patients was identified with other possibly relevant co-medications (maximal dose; number 
of patients): sertraline (322) (150mg/day; 6), paroxetine (323) (40mg/day; 3), fluoxetine (324) 
(20mg/day; 1), levomepromazine (325) (150mg/day; 3), amlodipine (10mg/day; 2), phenytoin (326) 
(300mg/day; 1) and omeprazole (327) (20mg/day; 1). There was no significant effect of these co-
medications on clozapine (p >0.3), norclozapine (p ≥0.9) or clozapine + norclozapine (p >0.6) 
concentrations when considered individually or as a group. Gender and age in the total study 
population did not appear to influence clozapine plasma concentrations (p=0.34, p=0.43 respectively, 
data not shown). However, when excluding patients taking fluvoxamine, women had significantly 
higher clozapine but not norclozapine (p=0.12, data not shown) plasma concentrations (median: 1.11 
(0.18–2.88) ng/ml*mg versus 0.61 (0.15-2.72) ng/m*mg, in women and men respectively, p=0.027).  
Forty-five patients were smokers (26 men/19 women) and 30 were non-smokers (13 men/17 women). 
The number of cigarettes smoked per day ranged from 1 to 60 (median 20). Smoking induces 
CYP1A2 as shown by the 1.5-fold higher median paraxanthine/caffeine ratio (p=0.031) in smokers 
(0.74 (0.08–3.49)) compared with non-smokers (0.50 (0.09–1.15)). Lower norclozapine (median of 
0.49 versus 0.67 ng/ml*mg, p=0.039), but not clozapine (1.03 versus 1.30 ng/ml*mg, p=0.175), 
plasma concentrations were measured in smokers compared with non-smokers. As expected, this 
effect was more pronounced in the group without fluvoxamine, where the influence of smoking was 
also significant on clozapine plasma concentrations (median of 0.72 versus 1.21ng/ml*mg, in smokers 
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and non-smokers, respectively, p=0.011). The effect of smoking on clozapine or norclozapine plasma 
concentrations was not related to the number (>20, 11 to 20, 6 to 10, ≤5) of cigarettes smoked per day 
(data not shown). 
Since only three patients drank grapefruit juice, and all but two had regular caffeine intake, the effect 
of grapefruit and caffeine on clozapine plasma concentrations could not be determined. In contrast to 
two previous studies (315;316), there was no significant correlation between norclozapine plasma 
levels (not corrected by dose) and weight gain (r=0.11, p=0.38), nor after subgroup analysis of non-
smokers (r=0.28, p=0.14) and smokers (r=-0.07, p=0.65). 
Plasma level and side effects 
Clozapine treatment was in general well tolerated at the time of the study; the most frequent 
complaints were hyper-salivation and weight gain. Four patients developed diabetes in the course of 
their clozapine treatment, but all before this study. 
The median weight at entry to the study was 79 kg (range: 52-128 kg; 74.5 kg and 83 kg, for women 
and men, respectively). The median body mass index (BMI) was 27.4 kg/m2 (range: 19.1-36.6). 
Thirty-two (43%) patients gained 10% or more of their starting body weight during the course of 
clozapine treatment, with the maximum increase being 97% over 15 years for a male aged 32 with a 
BMI of 36.6 kg/m2. Three patients lost weight, 25 remained stable, 13 increased their weight slightly 
to moderately (<10% of body weight), and for 2 patients the initial body weight was unknown. 
In contrast to two previous studies (315;316), there was no significant correlation between 
norclozapine plasma levels (not corrected by dose) and weight gain (r=0.11, p=0.38), nor after 
subgroup analysis of non-smokers (r=0.28, p=0.14) and smokers (r=-0.07, p=0.65). 
Hyper-salivation did correlate with neither clozapine nor norclozapine plasma levels. 
Cytochrome 1A2: 
Induction polymorphism CYP1A2*F 
Genetic polymorphisms for the CYP1A2*F allele were without influence on clozapine, norclozapine 
or clozapine + norclozapine plasma levels: CYP1A2 (p=0.386, 0.632, 0.533), in the whole group (and 
in the patients without fluvoxamine (data not shown)).  
Phenotyping with the caffeine test 
A strong correlation was observed between CYP1A2 activity and plasma concentrations of clozapine, 
norclozapine and clozapine + norclozapine in the whole population (r=-0.61, p=1·10-6; r=-0.48, 
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p=2·10-5; r=-0.59, p=1·10-6), in the subgroup without fluvoxamine (n=58) (r=-0.51, p=5·10-5; r=-0.41, 
p=0.001; r=-0.50, p=1·10-4), and in the fluvoxamine subgroup (n=17) (r=-0.69, p=0.002; r=-0.39, 
p=0.12; r=-0.64, p=0.006).  
Cytochrome 2C19 polymorphism 
In the whole patient group (n=75) CYP2C19 genotypes significantly influenced clozapine (p=0.036) 
but not norclozapine (p=0.185) plasma concentrations (Fig. 16a and b), with a 2.3-fold higher median 
clozapine concentrations in poor metabolisers (*2/*2 genotype, n=5, 2.58ng/ml*mg (1.10-5.98)) than 
in extensive metabolisers (non-*2/*2 genotypes, 1.11ng/ml*mg (0.15-6.24)) and 1.9-fold (p=0.057) 
higher clozapine + norclozapine levels. Similarly, between carriers of the *17 allele associated with an 
increased CYP2C19 activity (*17/*17, *1/*17) and poor metabolisers the differences were 2.3-, 1.9-, 
and 1.6-fold respectively for clozapine p=0.033, clozapine + norclozapine 0.039, and norclozapine 
0.112. On the other hand, no significant differences in clozapine (p=0.558), norclozapine (p=0.186) 
and clozapine + norclozapine (p=0.407) plasma levels were found between the carriers of the *17 
allele (*17/*17, *1/*17) and extensive metabolisers (*1/*1, *1/*2, *2/*17; data not shown). In the 
smaller group of patients without fluvoxamine, significant differences were observed between 
CYP2C19 *1/*1, *1/*17 or *17/*17 and *2/*17, *1/*2 or *2/*2 individuals for clozapine (p=0.027), 
norclozapine (p=0.074) and the sum of both (p=0.042). 
Figure 16 a: Boxplot with median and interquartile range of clozapine plasma concentration 
(ng/ml x mg) according to CYP2C19 genotypes. (Patient nr. 38’: clozapine plasma levels not 
detected). 
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Figure 16 b: Boxplot with median and interquartile range of norclozapine plasma concentration 
(ng/ml x mg) according to CYP2C19 genotypes. (Patient nr.1’: norclozapine plasma levels not 
detected) 
 
 
Cytochrome 2D6 polymorphism 
The CYP2D6 pharmacogenetic status of the patient had no influence on the plasma concentration of 
clozapine, norclozapine, and of the sum clozapine + norclozapine: (p=0.464, 0.696, and 0.718). The 
frequency of the different CYP2D6 genotypes was as expected in a white population (64). 
Cytochrome 3A:  
CYP 3A4, 3A5 and 3A7 polymorphisms 
The CYP3A pharmacogenetic status of the patient was without influence on clozapine, norclozapine 
or clozapine + norclozapine plasma levels: CYP3A4 (p=0.355, 0.341, 0.444), CYP3A5 (p=0.865, 
0.206, 0.627), and CYP3A7 (p=0.586, 0.384, 0.493), in the whole group (and in the patients without 
fluvoxamine (data not shown)). 
CYP3A phenotyping with the Midazolam Test  
No correlation was found between clozapine (r=-0.16, p=0.16), norclozapine (r=-0.07, p=0.58), and 
clozapine + norclozapine (r=-0.161, p=0.172) plasma concentrations and CYP3A activity in the whole 
group. In the fluvoxamine subgroup, however, a weak correlation was found between CYP3A activity 
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and clozapine + norclozapine (r=0.51, p=0.038), a moderate correlation with norclozapine (r=0.63, 
p=0.007), and a trend with clozapine concentrations(r=0.44, p=0.075).  
Other CYP450 isozyme polymorphism 
Finally, other genetic polymorphisms were without influence on clozapine, norclozapine or clozapine 
+ norclozapine plasma levels: CYP2B6 (p=0.664, 0.540, 0.522), CYP2C9 (p=0.252, 0.344, 0.370), in 
the whole group (and in the patients without fluvoxamine (data not shown)).  
ABCB1 polymorphism 
In the whole patient group (n=75) ABCB1 3435 C>T polymorphism significantly influenced clozapine 
plasma concentrations (p=0.046), with a 1.6-fold higher median clozapine concentrations in 3435TT 
genotype (n=16, median=1.6 ng/ml*mg (0.27–5.98) in TT genotypes; n=59, median=1.1ng/ml*mg 
(0.15-6.24) in CC/CT genotypes). Statistical analysis on the 61 A>G polymorphism was not performed 
due to the low observed genetic variability (table 22). No significant influence of the 2677 G>T 
polymorphism on clozapine plasma concentration was observed (data not shown). In addition, 
norclozapine and clozapine + norclozapine plasma concentrations did not differ significantly between 
different genotypes (2677G>T and 3435C>T) (data not shown). Haplotype analysis revealed a trend 
towards higher clozapine concentration for carriers of 2677G-3435T haplotype (global score: 0.1, 
haplotype specific score: 0.01). Because of the small sample size when considering haplotypes, we 
also computed permutation tests (global empirical p-value: 0.10; haplotype-specific empirical p-value: 
0.01), which are in very close agreement with the asymptotic p-values based on a chi-square 
distribution. Similar results were obtained after adjusting for sex and age (data not shown).  
Multivariate Analysis 
Multivariate analyses between clozapine, norclozapine and clozapine + norclozapine plasma 
concentrations and the main factors potentially influencing their kinetics yielded the following models 
in the whole group of patients. For clozapine, presence of fluvoxamine (p<10-8), high fluvoxamine 
concentrations (p=0.0001), low CYP1A2 activity (p=0.0001) and absence of CYP2C19 *17*17 or 
*17/*1 genotype (p=0.008) were predictive of higher plasma concentrations (r=0.84, p<10-17). Other 
variables such as fluvoxamine dose (p=0.88), gender (p=0.19), smoking (p=0.29), CYP3A activity 
(p=0.67), CYP3A4 rs4646437 allele T (p=0.69), CYP1A2*1F/1F genotype (p=0.32), ABCB1 2677TT 
genotype (p=0.22) and ABCB1 3435TT genotype (p=0.17) did not significantly contribute to the 
model. For norclozapine, presence of fluvoxamine (p<10-8), non-smoking (p=0.004), low CYP1A2 
activity (p=0.025) and absence of CYP2C19 *17*17 or *17/*1 genotype (p=0.036) were predictive of 
higher plasma concentrations (r=0.72, p<10-9). For clozapine + norclozapine, presence of fluvoxamine 
(p<10-8), high fluvoxamine concentrations (p=0.004), low CYP1A2 activity (p=0.0001) and absence 
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of CYP2C19 *17*17 or *17/*1 genotype (p=0.012) were predictive of higher plasma concentrations 
(r=0.82, p<10-15). Similar models can be built including presence of CYP2C19 *2/*2 or *2/*1 
genotype instead of absence of CYP2C19 *17*17 or *17/*1 genotype as a significant covariate for 
higher clozapine (p=0.017) and clozapine + norclozapine (p=0.030) plasma concentrations. 
Discussion 
The measured trough plasma concentrations of clozapine, norclozapine, and clozapine + norclozapine 
corrected by daily dose showed very wide inter-individual variability, with a 41-, 59-, 23-fold 
variation, respectively. Determination of genetic and environmental factors contributing to this 
variation is therefore of clinical relevance, considering the narrow therapeutic window of clozapine 
(350-600ng/ml) (287); plasma levels over 800-1000ng/ml are associated with an increased risk of side 
effects such as convulsions (289). Previous in vitro and in vivo studies suggested that the main CYP 
isoform mediating the metabolism of clozapine is CYP1A2 (112;186;305). Therefore, modulation of 
CYP1A2 activity will have a major influence on clozapine plasma levels and its effects. We examined 
4 factors believed to have a relevant influence on CYP1A2 activity: CYP1A2*1F polymorphism, the 
effect of smoking and caffeine consumption, and co-medication with fluvoxamine. 
CYP1A2*1F has been associated with increased CYP1A2 activity in smokers, possibly due to 
increased inducibility (69;70). Contrary to two previous studies (69;70), but in accordance with two 
other (71;279), we could not confirm an influence of CYP1A2*1F polymorphism on clozapine plasma 
concentrations or CYP1A2 activity, either in the whole group or in the subgroup of smokers; a strong 
influence of this polymorphism on clozapine plasma concentrations appears therefore unlikely. On the 
other hand, the important inducing effect of smoking on CYP1A2 activity and clozapine metabolism 
(306) has been confirmed in our study by the 1.5-fold higher CYP1A2 activity in smokers compared 
with non-smokers in all patients and in those without fluvoxamine as co-medication. Measured 
clozapine and norclozapine plasma levels in smokers compared with non-smokers were 93% (ns) and 
77% (p=0.039) in the whole group, and 67% (p=0.011) and 64% (p=0.003) in the group without 
fluvoxamine. Interestingly the number of cigarettes seemed to be of little relevance. The demonstrated 
decrease in clozapine plasma concentrations in smokers is in accordance with most other studies 
(71;306;328;329). Considering the narrow therapeutic window of clozapine, therapeutic drug 
monitoring is recommended when smoking habits are changed, as cessation of smoking can lead to a 
significant rise in clozapine concentrations and the risk of overdose (212).  
In the present study, 23% of the patients were co-medicated with the antidepressant fluvoxamine. Such 
high proportion is explained by the fact that in one study centre (Königsfelden) patients not 
responding and/or intolerant to high doses of clozapine are switched to a combination of low dose 
clozapine and fluvoxamine (– of course with therapeutic drug monitoring to adapt clozapine doses 
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(69;315;330)). Fluvoxamine is a strong CYP1A2 inhibitor, which is confirmed by the 2.2-fold higher 
paraxanthine/caffeine ratios determined in the patients without fluvoxamine compared to those with 
fluvoxamine. Accordingly, fluvoxamine markedly increases clozapine (3.5-fold) and norclozapine 
plasma concentrations (2.4-fold), indicating that it blocks the metabolism of both clozapine and 
norclozapine. The question arises whether the blocking effect of fluvoxamine on CYP1A2 is dose-
dependent or is saturable at low doses. We investigated this in an earlier case series and the conclusion 
was that co-medication with 150mg/day fluvoxamine has the same blocking effect as 300mg/day 
(331). This is confirmed by the relationship between fluvoxamine, clozapine and norclozapine plasma 
concentrations (Fig.14) suggesting saturation of inhibition at low fluvoxamine plasma levels (around 
50-100ng/ml). Thus, a daily dose of about 100mg fluvoxamine (41) would be sufficient to have a 
major blocking effect on the metabolic pathways of clozapine and norclozapine. Saturation of the 
inhibitory effect on CYP1A2 activity is also observed with paraxanthine/caffeine ratios at around 
50ng/ml fluvoxamine (fig. 15). Finally, published studies have suggested that caffeine consumption, in 
particular when consumption fluctuates over time, can influence clozapine plasma concentrations, 
possibly by inhibition of CYP1A2 (219). In the present study, since all but two patients had regular 
intake of caffeine, the influence of caffeine on clozapine plasma concentrations could not be verified. 
Conflicting results have been published on the implication and relative importance of other CYP 
isoforms besides CYP1A2 in the metabolism of clozapine and norclozapine (304;308;312;332). We 
found no evidence of an effect of CYP2B6, CY2C9, CYP2D6, CYP3A5, or CYP3A7 on the steady-
state kinetics of clozapine or norclozapine. On the other hand, this seems to be the first study to 
demonstrate a significant in vivo involvement of CYP2C19 in the pharmacokinetics of clozapine, 
previously suggested by an in vitro study (304) but challenged by an in vivo study with a single oral 
low dose of clozapine (308). Thus, in the present study, CYP2C19 poor metabolisers had 2.3-fold 
higher plasma concentrations of clozapine than patients with other CYP2C19 genotypes (fig. 16a). The 
absence of a significant influence of the CYP2C19*17 allele could be attributed to its limited effect 
especially when present in one copy only (60). A possible explanation for the negative results 
observed in the single dose (10 mg) study is that, with such a low oral dose (308), only CYP1A2 was 
responsible for the metabolism of clozapine.  
Fluvoxamine is also a CYP2C19 inhibitor (320;333;334). One can hypothesise that only the 
metabolism of clozapine but not norclozapine is affected. That could explain the different impact of 
fluvoxamine metabolic inhibition on clozapine and norclozapine plasma levels (fig. 14). 
The effect of CYP3A4 has been previously examined in interaction studies with CYP3A4 inhibitors 
and inducers (309;332). Based on in vitro data, it has been suggested that its role becomes increasingly 
relevant with higher doses of clozapine (304). In our study, the dose ranged from 25 to 800mg/day, 
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with a median of 250mg/day. In the whole study population, there was no correlation between CYP3A 
activity and clozapine or norclozapine plasma concentrations. On the other hand, the observed 
correlation between 1-OH-midazolam/midazolam ratios and clozapine plasma concentrations in the 
fluvoxamine co-medication group probably reflects the increasing importance of CYP3A4 in patients 
with blocked CYP1A2 activity. The formation of clozapine N-oxide is CYP3A4 dependent but this 
metabolite is less important than norclozapine (295) and its conversion back to clozapine is 
hypothesised (296;304). 
The very strong inhibition of clozapine metabolism by fluvoxamine can be explained by the fact that 
fluvoxamine is not only a strong CYP1A2 inhibitor but also a moderate inhibitor of CYP3A4 
(321;335) and CYP2C19 (320;333;334).  
Finally, the present study was the first, to our knowledge, to suggest that clozapine plasma 
concentration is significantly influenced by the genetic polymorphism of the ABCB1 gene, with higher 
concentrations measured in the 3435TT genotype, a genotype previously associated with lower Pgp 
expression (136). The result of a clinical trial with 40 male and 20 female schizophrenic patients 
(published at the same time as our study) confirmed our findings (336). Interestingly, in their study, 
patients with the ABCB1 3435CC or C/T genotype needed higher clozapine daily doses than patients 
with the 3435TT genotype in order to reach satisfactory therapeutic results. Since these ABCB1 
genotypes have an influence on clozapine plasma levels we can assume that Pgp plays a role in the 
intestinal absorption process of clozapine, regulating its bioavailability. A role of Pgp at the blood 
brain barrier has been evaluated earlier with negative results (314). 
No serious adverse drug reactions were reported, but hyper-salivation and weight gain were frequently 
reported to be troublesome and difficult to manage. Sialorrhea is a consequence of the M1 agonistic 
properties of norclozapine, weight gain can be attributed to the H1 and 5HT2 inverse agonistic 
properties of both clozapine and norclozapine (table 18). Weight gain is considered one of the major 
side effects of clozapine and it is an important risk factor for developing a metabolic syndrome. In our 
study 43 percent of patients gained 10% or more body weight during clozapine treatment. Some 
authors found a reduced risk for weight gain when combining fluvoxamine with clozapine (315). 
Another group found a correlation between norclozapine plasma concentrations and weight gain in 
non-smoking patients (316). These results could not be confirmed in our study probably because of the 
small number of non-smokers included. Another limitation is that the duration of clozapine treatment 
and the nature of pre-treatment could not be determined for all patients and that some patients were co-
medicated with valproic acid and lithium which are also associated with weight gain. Due to the 
important clinical problems associated with weight gain in patients treated with atypical antipsychotics 
(337), the role of norclozapine should be examined further in prospective longitudinal studies.  
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It would be interesting to compare the metabolic ratio of patients with a clozapine monotherapy with 
patients taking a combination of fluvoxamine and clozapine to search for differences in efficacy and 
tolerability as done by other authors (292;293).  
In conclusion, our study examined thoroughly the in vivo implications of drug metabolizing enzymes 
and transporters in clozapine kinetics with the aim to explain its large inter-individual variability. 
CYP1A2 is the major CYP isoform involved in clozapine metabolism in vivo, with CYP2C19 
contributing to a moderate extent and CYP3A4 contributing in the presence of co-medications that 
induce activity of this isozyme or when CYP1A2 is blocked by drugs such as fluvoxamine. ABCB1 
genetic polymorphism also contributes to clozapine pharmacokinetic variability. To our knowledge, 
this is the first study showing a significant in vivo role of CYP2C19 and the Pgp transporter in 
clozapine kinetics. Besides these genetic factors, environmental factors such as smoking or co-
medications (e.g. fluvoxamine) markedly influence the kinetics of clozapine. Finally, because of the 
limited sample size, the results of the present study should be replicated by another study with a larger 
number of patients. 
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6 Nested case-control study in psychiatric in-patients: AMSP+ 
Summary 
From experiences with individual cases we learned that high drug plasma concentration and certain 
CYP450 genotypes seem to be associated with an increased risk for (S)ADR.  However, there exist no 
studies in psychiatry which confirm these risk factors for a patient population and which might justify 
routine TDM and/or routine pharmacogenetic testing.  
We therefore performed a nested case-control study in the psychiatric in-patient clinic Königsfelden 
comprising 62 SADR cases and 82 matched controls in order to examine the feasibility of a nested 
matched control study design. Firstly, in an open cohort, SADR according to the AMSP criteria were 
collected and analyses of the plasma concentrations of suspected drugs made. In this phase of the 
AMSP+ project, correct TDM but also pharmacogenetic tests were introduced to the clinicians of the 
clinic. In a second phase 62 SADR cases were collected, their drug plasma levels analysed, a CYP2D6 
genotyping and a midazolam test performed.  These cases would be matched with 3 controls each, 
matching for the imputed drug (combination), gender and age group (< 65 or ≥ 65 years old).  
Matching proved to be more difficult than expected and the original study design was changed to a 
non matched case-control study. Some of the reasons were the very heterogeneous patient population, 
drug combinations which were difficult to match because unusual or rare, and the difficult recruitment 
of controls.  
Preliminary results showed that the group of SADR patients and the group of controls were similar in 
age, gender, medication (matching criteria) but also in weight, BMI, renal function and smoking 
behaviour. However, the odds ratio for drug plasma levels ≥ 120% of the upper reference limit was 
3.49 CI95: 1.42-8.57 (p=0.005) in SADR patients compared to the control patients.  
SADR patients had more often a CYP2D6 poor metaboliser genotype, controls more often a CYP2D6 
ultra rapid genotype; however that was statistically no significant. Larger studies with more patients 
have to show if these results can be confirmed. 
For future studies the difficulties of a nested matched control design has to be considered. A non-
matched case-control study in a large cohort study seems more realistic and feasible. A multi-centre 
approach would help finding SADR cases and controls in a timelier manner. 
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Introduction 
The usefulness of TDM and pharmacogenetic tests in single cases can be shown.  However, larger 
clinical trials are needed to answer the question “in which situation or for which drug should we apply 
TDM and/or pharmacogenetic tests?” or “should we routinely measure plasma levels and/or perform 
pharmacogenetic tests in order to improve drug safety?”  
Such large studies will in general exceed the possibilities of one study centre and are very cost 
intensive.  
Fewer resources are needed for a nested case-control study which we performed within the dynamic 
AMSP cohort of the clinic Königsfelden: AMSP+. In a first phase TDM and Pharmacogenetic Tests 
were introduced in association with the causality assessment of serious adverse drug reactions. In the 
second phase a patient with a SADR (= case) was matched with control patients. The AMSP+ study 
must be seen as a feasibility study, because within this field of TDM and pharmacogenetics no 
previous case control studies have been carried out. Ethics approval from the local ethics committee 
has been obtained for both phases. Two questions were addressed in the AMSP+ study: 1) Do patients 
with a SADR have higher drug plasma levels? 2) Are certain CYP450 enzyme genotypes associated 
with an increased ADR risk? 
Do ADR patients have higher drug plasma levels? 
The majority of ADR are of type A, i.e. mostly drug concentration dependent. Better than the 
administered dose, drug plasma levels reflect the concentration of the drug at target site, in psychiatry 
mostly the brain. Although we know that in an individual patient the ADR risk with increasing drug 
plasma level will increase, clinical experience shows us that the threshold for developing an ADR is 
different between patients and that several other factors play a significant role as well. Establishing a 
therapeutic index of drug plasma levels is not for every drug possible. The question remains: do 
patients with an ADR have higher drug plasma levels?  
Are certain CYP450 enzyme genotypes associated with an increased ADR risk? 
Some authors found an increased risk in small clinical studies (see chapter “Pharmacogenetic Studies 
in Pharmacovigilance”). Interestingly, certain CYP450 enzyme genotypes predicting a decreased 
enzyme function seemed to show an increased ADR risk, but a connection with increased drug plasma 
concentrations was not always shown. A large case-control study might be an adequate study design to 
further examine these relationships. 
Collaborations 
For the pharmacovigilance parts of the AMSP+ study a close collaboration with the leaders of the 
AMSP project: Dr. Renate Grohmann, Prof. Rolf Engel (both university of Munich), Prof. Eckart 
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Rüther (university of Göttingen), Prof. Waldemar Greil (university Munich and Sanatorium 
Kilchberg), and Dr. Andreas Horvath (Sanatorium Kilchberg) were important. 
Drug plasma levels have been analysed in the laboratories of Prof. Pierre Baumann and Prof. Dr. Chin 
Eap from the University of Lausanne and of Prof. Dr. Katharina Rentsch from the University of 
Zurich, both laboratories granting research prices for the analyses. 
Pharmacogenetic tests have been done in the laboratory of Prof. Pierre Baumann and Prof. Dr. Chin 
Eap at the University of Lausanne, within the common research project free of charge.  
Advice on the study design and methodology has been given by Prof. Richard Farmer, University of 
Surrey, Prof. Sammy Suissa, University of Montreal, and by Jan-Willem van der Velden, MD, all 
pharmacoepidemiologists and experts in Drug Safety studies. Literature searches and discussions with 
these three experts made clear that before initiating any large case-control study, we need feasibility 
studies. 
Method: Feasibility study   
Phase I Awareness - collection of SADR and plasma level analysis of imputed 
drugs 
In a first phase, serious ADR cases from the clinic Königsfelden were collected within the AMSP 
project and blood samples for plasma level analysis of the medication involved were taken. 
Pharmacogenetic testing was only performed in cases where the presence of a particular 
pharmacogenetic status was suspected. This first phase was necessary to introduce the notion of TDM 
and pharmacogenetic testing in relation to the causality assessment of serious ADR in the daily 
clinical routine and to obtain the cooperation of the clinicians.  
Phase II nested matched control study 
In the second phase the aim was to test the feasibility of using a nested case-control study to 
investigate possible associations between drug plasma concentrations and/or CYP2D6 genotypes and 
the event of a serious adverse drug reaction. 
For this purpose 1 SADR case was matched with 3 control patients for the same imputed drug 
(combination), gender and age group (< 65 or ≥ 65 years old). Plasma levels of the imputed drugs 
were analysed and CYP2D6 genotyping and CYP3A phenotyping were routinely performed in all 
cases. 
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Stimulated spontaneous ADE reporting 
Systematic ADE reporting where every ADE is captured is very resource intense and only possible 
within a delimited research project. Stimulated spontaneous ADE reporting is also feasible in the 
context of the naturalistic setting of a large psychiatric hospital. The stimulation consisted in 
explaining the research and quality assurance project AMSP+ to all parties involved: in the first line to 
the clinicians, but also the nurses and the laboratory personnel. This procedure was repeated several 
times per year, combining it with AMSP case presentations. Furthermore, posters with the AMSP 
criteria for SADR and what to do in case such an SADR is found were posted in every ward office, 
easy to fill in forms were distributed to all clinicians and the wards to announce such cases to the 
AMSP drug monitors. In order to further motivate the clinicians, all AMSP cases were thoroughly 
documented for them and for the patient history. 
Collection of SADR according to the AMSP definition 
The AMSP+ study was performed in close collaboration with the clinicians of the 400 beds psychiatric 
in-patient hospital Königsfelden in Switzerland, medically directed by Dr.med. Mario Etzensberger 
(till end of 2008 and time of data collection), and member of the AMSP project since 2001. Three 
medical doctors (Patrik L. Stephan most of the cases, Lukas Ritz, and Evelyne Rechsteiner) acted as 
AMSP drug monitors coordinating the collection of the SADR, and making the first causality 
assessment after seeing the patient themselves and after taking the relevant patient history and further 
development of the ADR into consideration. This causality assessment was discussed with the treating 
clinicians and the author of the thesis before entering them in the central AMSP database at the 
University of Munich. There all entries were controlled for completeness of the case, inconsistencies 
and plausibility. Finally the cases were discussed at one of the Swiss case conferences with the other 
participants of the Swiss AMSP project (currently 13 psychiatric inpatient clinics, 13 manufacturers of 
psychotropic drugs, and members of the regional pharmacovigilance centres). If during this conference 
the causality was assessed differently, changes were added in the central database. Difficult cases were 
further discussed in one of the international conferences which participants of the different countries 
attend (mainly Germany, Austria and Switzerland). Again, if amendments to the cases are made, these 
are entered in the central database. All case reports including all amendments were also sent to the 
pharmacovigilance authorities and to the relevant pharmaceutical company. 
Blood sampling for drug plasma level analysis  
Blood samples were taken in the morning before any drug intake in order to obtain drug trough plasma 
concentrations, knowing that the drug free interval would vary between about 12 to 24 hours (for 
twice respectively once daily administration, evening respectively morning intake). 
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Blood samples were immediately centrifuged and serum was sent in the morning per priority mail to 
the laboratory. Blood samples obtained during the weekend were kept in the refrigerator till Monday 
morning when they were treated as described before. 
All the samples were analysed under routine conditions when received and the results were sent back 
to the clinician. This procedure allowed the clinician to adjust their treatment and reflects a naturalistic 
study design. 
Pharmacogenetic testing 
Pharmacogenetic testing was not readily accepted by the clinicians in the beginning of the study. In 
phase I pharmacogenetic testing was only done in case of strong suspicion of an unusual genotype. 
In Phase II every ADR patient and all matched control patients were genotyped for CYP2D6 (138), 
alleles *1,*3, *4, *5 and 2XN and wildtype, and phenotyped for CYP3A with the midazolam test 
(151;152;338). The results were sent to the clinician as soon as available, again in order to be of 
clinical help. This clearly was a motivation for them to collaborate in the study. 
For every pharmacogenetic test, for research purpose or for diagnostic reasons, a written informed 
consent by the concerned person or his or her tutor has to be obtained. Not only for doctors not 
familiar with this kind of tests can it be challenging to explain to psychiatric ill patients what a 
pharmacogenetic test means for them. Further to the informed consent the treating or research 
physician has to explain the results of the test to the patient, unless he or she explicitly refuses this 
knowledge. For every patient the pharmacogenetic test results were interpreted for the treating 
clinicians in the test report, put in the patient history and a personal genetic pass in credit card format 
was given to the patient explaining very briefly the test results as well (fig. 17).  
Figure 17: Example of short genetic information given to the patient in credit card format 
 
 
  
   
mediQ 
 
Zentrum für 
Medikamentensicherheit 
und Diagnostik 
 
Tel  056 462 23 21 
Fax 056 462 27 66 
mediQ@pdag.ch 
 
Ausweis 
Pharmakogenetik 
 
  
 Anna Muster 
 11.11.1941 
 
   CYP2D6 Genotyp *4/*4 = keine Aktivität 
 
   CYP2C19 Genotyp*1/*1= unauffällig 
   (untersucht Allele *2, *3) 
    
  
 
  Therapie-Empfehlung: 
  Medikamente, die v.a. über  CYP2D6  
  abgebaut werden vorsichtig dosieren. Grosszügige   
  Indikation für Kontrolle von Plasmaspiegel, v.a. bei   
  enger therapeutischer Breite und Nebenwirkungen.                
                                                               . 
                                                                 16.2.2006 
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Matching criteria for the control group 
Three patients of the dynamic cohort of the patient population of the clinic Königsfelden, without an 
ADR at the time of selection, were matched for gender, age group (< 65 or ≥ 65 years old), and 
imputed drug (combination) of the SADR case. Concerning the drug treatment they had to have the 
same drug(s) but were allowed to have other drugs besides as well. We did not match for the duration 
of drug intake with exception of the cases of weight gain where the controls had to have at least a 
month drug intake. 
Collection of control patients 
Ideally controls are selected shortly after the case is identified. Although lists with matching criteria 
were distributed to all wards, this did not always work. On one hand there were not enough patients 
fulfilling all criteria and on the other hand not all potential controls gave informed consent.  Therefore 
we tried to form a pool of potential control patients to be matched with later cases. Regular meetings 
were arranged in the wards explaining the research project and recruiting control patients.   
Statistical analysis 
This feasibility study is primarily analysed descriptively. Odds ratios have been calculated between 
cases and controls (see also table 2). 
 
Preliminary Results 
From 62 collected SADR cases only 20 could be matched with 3 controls, 8 cases with 2 controls, 7 
with 1 control, and 27 cases could not be matched at all. 5 SADR cases were 65 or more years old. 
None of them could be matched with control patients. 
Patient characteristics AMSP+ phase II 
37 (60%) SADR cases were female, 25 (40%) were male, mean age was 44 ±11 years, median 44 (20-
80) years. 31 (50%) were smokers, 23 (37%) non smokers, and in the remaining 7 cases smoking 
behaviour is unknown. 
All patients in the clinic Königsfelden are diagnosed according to the ICD-10 International 
Classification of Diseases. 29 (46%) patients suffered from a schizophrenic disorder (ICD10 - F2), 14 
(23%) from an affective disorder (F3), 10 had a neurotic disorder (ICD10-F4), 4 a personality disorder 
(ICD10-F6), 3 a substance abuse disorder (ICD10-F1), and 2 an organic mental disorder (ICD10-F0).  
Type of SADR were: 9 weight gain, 4 each for serotonin toxicity, exanthema, 3 each for somnolence, 
liver enzyme increase, hyponatremia, hair loss, 2 each for tachycardia, seizures, oedema, hypotension, 
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hypersalivation, extrapyramidal syndrome, delirium, and 1 each for vomiting, urinary retention, 
tremor, taste distortion, tardive dyskinesia, singultus, priapism, pericarditis, night mares, neutropenia, 
metabolic syndrome, intoxication due to a drug interaction, ileus, galactorrhoea, eosinophilia, 
dizziness, diarrhoea, bleeding, amaurosis. 
Weight and body mass index (BMI) were: mean weight was 75 ± 15kg, median weight 72 (47-128); 
mean BMI 26.1 ± 4.6, median BMI 24.4 (17.2-38.1). 
For the measure of the renal function, creatinine clearance was calculated: mean clearance was 113 ± 
28 ml/min; median was 116 (40-197) ml/min. 
Results of the CYP3A activity or midazolam test (ratio 1’OH midazolam/midazolam ) were: for 50 
patients results from the midazolam were obtained with a mean of 6.8 ± 5.7, median of 3.6 (0.28-
68.4); as reference: After oral administration of 75 µg midazolam, the 30-min total 1’OH-
midazolam/midazolam ratios measured without co-medication, with ketoconazole (a strong CYP3A-
inhibitor) and with rifampicin (a strong CYP3A-inducer) were (mean ± SD): 6.23 ± 2.61, 0.79 ± 0.39 
and 56.1 ± 12.4, respectively (152).  
CYP2D6 genotype frequencies were as follows: 42 EM (68%), 14 IM (23%), 4 PM (6.5%), 1UM 
(1.6%), and 1 unknown. The PM had the following SADR and imputed medication: 
1) Liver enzyme increase, tachycardia, hypotension, dizziness under clomipramine 300mg/d 
(plasma level of clomipramine + desmethyl clomipramine: 1228ng/ml; ref: 175-450ng/ml) and 
quetiapine 700mg/d (plasma level: 826ng/ml; ref. 70-300ng/ml). This same patient had also a 
low CYP3A activity in the midazolam test with a value of 1.1. 
2) Metabolic syndrome under olanzapine 30mg/d (99ng/ml; ref: 20-80ng/ml) and valproate 
1500mg/d (66ng/ml; ref: 50-100ng/ml), (additionally the antihypertensive combination 
atenolol/chlortalidone 50mg/ 12.5mg/d). The result of the midazolam test was 2.56. 
3) Abnormal bleeding under acetyl salicylic acid 100mg/d (no plasma levels) and fluoxetine 
40mg/d (total 1054ng/ml, ref. 120-300ng/ml; fluoxetine  667 ng/ml ; norfluoxetine 386ng/ml), 
(additionally olanzapine 10mg/d (plasma level 15ng/ml, ref. 20-80ng/ml), enalapril 2.5mg/d, 
torasemide 20mg/d, potassium, vitamin D). The result of the midazolam test was 4.06. 
4) Hair loss under lithium (0.78 mmol/l, ref. 0.5-1.2 mmol/l), venlafaxine (total 206ng/ml; ref. 
195-400ng/ml; venlafaxine 111ng/ml; O-desmethylvenlafaxine 95ng/ml). No result of the 
midazolam test was available. 
35 drugs were imputed in the SADR cases (table 20). 
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Table 20: Listing of the imputed drugs of the SADR cases (several drugs per case possible). n.d. = non 
detected; nc = non compliant 
drug Imputed 
with 
SADR 
SADR only 
attributed 
to this drug 
Reference plasma 
levels in ng/ml 
(including active 
metabolites, other 
units mentioned) 
Cases with high 
plasma levels (% 
of recommended 
upper limit) 
Cases with low 
plasma levels (% 
of recommended 
lower limit) 
Plasma 
level 
missing 
Acetyl salicylic 
acid 
1 0 no ref value - - 1 
Alprazolam 1 0 20 - 40  - n.d. - 
Aripiprazol 2 1 150 - 250  118, 120 - - 
Biperiden 3 0 no ref value - n.d.  2 
Buspirone 1 0 1 – 5  - - 1 
Carbamazepine 4 3 4-10 µg/ml 113, 120, 125 - 1 
Chlorprothixene 1 0 20 – 200  - - - 
Citalopram 1 1 30 – 130  - - - 
Clomipramine 1 0 175 – 450  273 - - 
Clotiapine  2 0 no ref value no ref value no ref value 1 
Clozapine 13 8 350 – 600  109, 111 257,120,     
186 
14 (nc), 57, 66 - 
Diclofenac  1 0 No ref value - - 1 
Fluoxetine 1 0 120 – 300  351 - - 
Flupentixol 1 1 2 – 15  127 - - 
Fluvoxamine 5 2 150 - 300 494, 284 8 (nc) - 
Haloperidol  4 0 5 – 17  - 68, 64, 68, 33 - 
Lamotrigine 1 0 3 -14 μg/ml -  - 
Levomepromazine 1 0 15 – 60  -  - 
Lithium 4 1 0,5-1,2 mmol/l 139 - - 
Lorazepam 1 0 10 – 15  - - 1 
Methadone 2 0 400 – 600  - 31 1 
Mianserin 1 0 15 – 70  204  - 
Mirtazapine 2 1 30 – 80  -  1 
Olanzapine 4 0 20 – 80  124  20, 97 - 
Oxcarbazepine 2 0 10-35 µg/ml - - - 
Paroxetine 2 0 30 – 120  - - - 
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Promazine 2 0 no ref value no ref value no ref value 1 
Quetiapine 5 2 70 – 300  275  - 1 
Risperidone 2 2 20 – 60  - - - 
Sertraline 2 1 10 – 50  - - - 
Trazodone 1 1 700 – 1000  - 57 - 
Valproate 13 2 50-100 μg/l - 28, 86, 44 - 
Venlafaxine 5 1 195 – 400  135, 571, 237 - - 
Zolpidem 1 0 80 – 150  - 69 - 
Zuclopenthixol 6 2  4 – 50  182 - 1 
 
99 times a drug has been imputed in our SADR cases, in 13 cases drug plasma levels are missing; 
from the rest (n=86): 23 (27%) had levels above the upper limit of the TDM reference level (41), 19 
(22%) had drug plasma levels of 120% or more of this upper limit. 18 (21%) had drug plasma levels 
below the lower limit of the TDM reference level, 16 (19%) had drug plasma levels of  80% or less of 
this lower limit. 
43 of the imputed drugs were antipsychotics, 24 were mood stabilising drugs, 21 antidepressants, 4 
anxiolytics/hypnotics, 3 anticholinergic drugs, 2 analgesics and 2 methadone. 
Control group characteristics 
82 control patients could be matched to the 62 SADR cases, 47 (57%) females and 35 males. Mean 
age was 42 ± 9 years, median 44 (20-64) years. 46 (56%) were smokers, 34 were not smoking, and 
from 2 the smoking data are missing.  
44 (53%) suffered from a schizophrenic disorder (ICD10-F2), 21 (26%) from an affective disorder 
(ICD10-F3), 8 had a substance abuse disorder (ICD10-F1), 7 a neurotic disorder (ICD10-F4, and 1 
each had an organic disorder (ICD-10-F0), a behavioural disorder (ICD10-) F5, and a disorder of the 
psychological development (ICD10-F8). 
Mean weight was 75 ± 13kg, median 72 (50 – 127) kg. Mean BMI was 26.1 ± 4.1, median 25.3 (18.5-
39.5). 
Mean creatinine clearance was 117 ± 29 ml/min, median was 112 (55-220) ml/min. 
For 78 out of the 82 controls results from the midazolam test were available. Mean was 8.9 ± 6.8, 
median 5.4 (0.25-69.6). 
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The CYP2D6 genotype frequencies were: 51 EM (62%), 25 IM (30%), 2 PM (2.4%), 4 UM (4.9%), 
and 1 unknown. The two PM had the following medication: 
1) Trazodone with plasma levels of 283 ng/ml (40% of the lower reference limit) 
2)  Clozapine with 595 ng/ml (within the recommended reference plasma levels) 
Table 21: Drug levels analysed in the control patients 
drug Number 
of plasma 
levels 
Reference plasma 
levels in ng/ml 
(including active 
metabolites, other 
units mentioned) 
Reference 
plasma 
levels 
Controls with high 
plasma levels (% 
of recommended 
upper limit) 
Controls with low 
plasma levels (% 
of recommended 
lower limit) 
Plasma 
level 
missing 
Acetyl salicylic 
acid 
- no ref value no ref 
value 
- - - 
Alprazolam - 20 - 40  20 - 40  - - - 
Aripiprazol 6 150 - 250  150 - 250  160 45, 77 - 
Biperiden 2 no ref value no ref 
value 
- - - 
Buspirone - 1 – 5  1 – 5  - - - 
Carbamazepine 1 4-10 µg/ml 4-10 µg/ml 113 - - 
Chlorprothixene - 20 – 200  20 – 200  - - - 
Citalopram 3 30 – 130  30 – 130  - - - 
Clomipramine + 
metabolite 
- 175 – 450  175 – 450  - - - 
Clotiapine  - no ref value no ref 
value 
- - - 
Clozapine 19 350 – 600  350 – 600  114, 137, 155 50, 90, 65, 65, 31, 
17 
- 
Diclofenac  - No ref value No ref 
value 
- - - 
Fluoxetine - 120 – 300  120 – 300  - - - 
Flupentixol - 2 – 15  2 – 15  - - - 
Fluvoxamine 9 150 - 300 150 - 230 182, 207, 193 85, 90, 82, 47 - 
Haloperidol  1 5 – 17  5 – 17  199 - - 
Lamotrigine - 3 -14 μg/ml 3 -14 
μg/ml 
- - - 
Levomepromazine - 15 – 60  15 – 60  - - - 
Lithium 5 0,5-1,2 mmol/l 0,5- 1,2 
mmol/l 
- - 1 
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Lorazepam - 10 – 15  10 – 15  - - - 
Methadone 2 400 – 600  400 – 800  - 14, 89 - 
Mianserin 3 15 – 70  15 – 70  180 86 - 
Mirtazapine 3 30 – 80  40 – 80  - 96, 66 - 
Olanzapine 5 20 – 80  20 – 80  - 88 - 
Oxcarbazepine - 10-35 µg/ml 10-35 
µg/ml 
- - - 
Paroxetine - 30 – 120  70 – 120  - - - 
Promazine - no ref value no ref 
value 
- - - 
Quetiapine 9 70 – 300  70 – 170  107 74, 74, 46, 87 - 
Risperidone + 
metabolite 
6 20 – 60  20 – 60  - 55, 70, 35, 45 - 
Sertraline 2 10 – 50  10 – 50  - 90 - 
Trazodone 3 700 – 1000  650 – 1500 - 44, 40 - 
Valproate 21 50-100 μg/l 50-100 
μg/l 
105, 110, 115, 111 20, 92, 82 2 
Venlafaxine + 
metabolite 
5 195 – 400  195 – 400  186, 117 96 - 
Zolpidem - 80 – 150  80 – 150  - - - 
Zuclopenthixol 6 4 – 50  4 – 50  - - - 
 
108 plasma levels of control patients have been analysed (table 21). 17 (16%) were higher than the 
upper limit of the TDM reference value, 9 (8%) were 120% or higher.  33 (31%) controls had lower 
plasma concentrations than the lower limit of the TDM reference, 20 (19%) were 80% or lower. 
Comparison of cases and control 
Considering the low number of matched case-control groups we abandoned the analysis of a matched 
control study and compared all cases with all controls which led to the following results: 
Cases and controls are similar for gender, age, weight, BMI, renal function, and smoking behaviour.  
The diagnose frequencies differ somewhat; in the control group the two main diagnosis groups F2 plus 
F3 sum up to 80%, in the cases to70%; more control patients suffered from an F1, and more cases 
from an F6 diagnosis.  
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A preliminary analysis of the data suggests that the CYP3A activity as measured by the midazolam 
test seems somewhat lower in the cases (mean 6.8 ± 5.7, median of 3.6 (0.28-68.4)) than controls 
(mean 8.9 ± 6.8, median 5.4 (0.25-69.6)). 
The two groups seem also to differ in CYP2D6 genotype frequencies with an odds ratio of 2.84 CI95, 
calculated according to the method explained in table 2: 0.58-13.69 (p=0.20) for PM, and for UM 0.33 
CI95: 0.05-2.3 (p=0.3) but this does not reach statistical significance. 
In the cases the 4 PM were under treatment with drugs being at least partly metabolised by CYP2D6: 
clomipramine, olanzapine, fluoxetine and venlafaxine. The 2 PM of the controls did get drugs which 
are not metabolised by CYP2D6: trazodone and clozapine.  
Drug plasma concentrations of the cases compared to those of the controls seem to be more often 
higher than the upper reference level. The odds ratio for high plasma levels is: 1.95 CI95: 0.97-3.92 
(p=0.045), restricting the analysis to plasma levels of 120% or more the odds ratio reaches 3.49 CI95: 
1.42-8.57 (p=0.005). 
Comparing the number of cases (n=17) with that of the controls (n=8) having drug levels higher than 
120% of the upper reference level, the odds ratio is 3.11 CI95: 1.35-7.17 (p=0.006).  
 
Discussion 
This first analysis of the results of this study shows some positive but also negative aspects which 
hindered the full realisation of all the aims. To select matched control patients turned out to be much 
more difficult than anticipated. There was the problem of obtaining written informed consent, which is 
recognized to be a challenge in psychiatry since the first obligation is to evaluate a mentally ill 
patient's competence to consent (339). In the case of psychotic patients, they were not able to give 
informed consent, and often no tutor was appointed. In cases where the patient was able to give 
informed consent or where a tutor was available, the challenge of explaining the reasons for 
pharmacogenetic tests had to be met. Another hurdle was the phenotyping with the midazolam test. In 
our experience, psychiatric patients are not easily willing to drink test substances like the midazolam 
solution. Further many potential control patients were very ill, and they were not willing to consent to 
in their opinion unnecessary procedures such as taking extra blood samples for tests they were not 
interested in.  
A study in a naturalistic setting of a large psychiatric inpatient clinic seems on first sight easier to 
perform than clinical trials with stringent in- and exclusion criteria. However, that is not necessarily 
true. First we are confronted with a broad heterogeneity of the patient population, with many different 
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diagnoses, drug treatments and co-morbidities. In-patients of such a clinic are very ill and their 
medication is mostly complex. 
When an SADR occurs, they naturally tend to occur in patients with heavy drug treatments or with 
drugs with a less favourable side effect profile. Often these patients do not respond to other better 
tolerated medication and represent a special patient selection (selection bias). Matching control 
patients with the same medication proved sometimes impossible. In case of carbamazepine treatment 
this was prominent.  
Some ADR such as heavy weight gain were common under certain medications such us olanzapine or 
clozapine (in line with the literature (340-342), matching these cases was not easy because the ADR is 
so common with these drugs, but also because of the time component of gaining weight.  
Some drug combinations were so rare (e.g. haloperidol and clozapine) that we could not find matched 
controls, amongst other combinations with interaction risks such diclofenac with lithium. However, in 
some cases it might be acceptable to match only for the plasma concentration of the SADR causative 
agent and not for the interacting substance as well. No comparable pharmacovigilance study could be 
found where ADR cases have been compared in a matched control design with control patients under 
the same medication (combination) but without the ADR.  
Another problem is the latency between the moments a SADR appears and the plasma concentrations 
are measured. Side effects are a major factor leading to non-compliance, and there are some cases 
where we suspect at least partial mal-compliance at the moment the blood sampling was taken. 
Therefore the number of patients with a high drug plasma concentration may be underestimated. 
Comparison of the cases and controls showed similar characteristics. However, for the targeted risk 
factors such as high plasma levels or CYP2D6 genotypes associated with low CYP2D6 activity 
differences appeared. CYP2D6 PM are expected to have higher plasma levels of drugs being substrate 
of CYP2D6 and therefore might be more vulnerable to concentration dependent side effects. In a 
retrospective matched case control study (343) 18 CP2D6 PM were matched each with one CYP2D6 
IM and on CYP2D6 EM. The risk for extrapyramidal symptoms or tardive dyskinesia, and for mal-
compliance, was significantly higher in CYP2D6 poor metaboliser than in patients with another 
CYP2D6 genotype. Another study showed that the CYP2D6 genotype had a significant and clinically 
relevant influence on risperidone plasma concentrations and that average plasma concentration of the 
active moiety of risperidone was significantly higher in persons suffering from dystonia or 
parkinsonism (344). In our population the 4 SADR cases with a CYP2D6 poor metaboliser genotype 
were all under medication (clomipramine, olanzapine, fluoxetine, venlafaxine) which was at least 
partly metabolised by CYP2D6, 3 had higher than recommended plasma levels of these drugs, the 
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patient under venlafaxine treatment at the time of the blood sampling not. This could be due to poor 
compliance as consequence of intolerability. In contrast to the 4 cases the 2 CYP2D6 PM control 
patients were not treated with a medication metabolised by CYP2D6 (trazodone, clozapine) and their 
drug levels were not exceeding the recommended plasma concentrations. Although the odds ratios for 
CYP2D6 genotype did not reach statistical significance, CYP2D6 PM seem to have a higher SADR 
risk, while CYP2D6 UM seem to have a protective effect. One can expect that with a higher number 
of patients and controls these odds ratios become statistically significant. In order to estimate the 
importance of certain genetic factors in drug safety, more and larger prospective studies in drug 
development and post marketing must examine this potential risk (345). 
A recent review (346) summarises the results of studies on the effect of certain genotype on 
therapeutic efficacy and side effects of antipsychotics. Most of these were case-control or cohort but 
not matched control studies. CYP2D6 poor metaboliser showed in the majority a higher risk for 
extrapyramidal side effects (EPS); for tardive dyskinesia this relation was less clear. The studies 
showing a significant CYP2D6 genotype dependent risk for EPS/tardive dyskinesia comprised 50 or 
more cases. 
Up to today we do not know the number of patients to genotype to prevent a serious side effect, a 
prerequisite for routine testing. And we do not yet have sufficient data to support or reject genotype 
based dosing as proposed by Kirchheiner et al (154;156;238). 
High plasma levels (120% or more of the upper reference level) could be identified as a risk factor, in 
analysing the number of patients/controls with high plasma concentrations or in comparing the number 
of high plasma levels between the two groups. Other groups found also a higher risk with higher 
plasma levels with certain antipsychotics such as risperidone (344), clozapine (289) or tricyclic 
antidepressants (37).  
In our feasibility study we had not enough matched case-control-pairs so that an unmatched case-
control analysis has been performed and odds ratios were calculated. With our limited number of cases 
and controls this showed statistically significant results for high plasma levels and a trend for CYP2D6 
polymorphisms. A more extensive analysis about the influence of high plasma levels will be 
performed at a later stage adding more SADR cases to the current study cohort including plasma 
concentration information but without genotype determination and using more (unmatched) control 
patients (patients without an SADR).  
Heterogeneity of the cohort 
Although a case-control study seems an adequate study design for a heterogenic patient population, 
the nested case-control study was limited by the relative low number of cases and controls within one 
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in-patient hospital cohort. A case-control study in the entire AMSP cohort would generate far more 
cases but most of the clinics who participate in the AMSP project do this mainly for reasons of quality 
assurance and are not always interested in or able to perform research, many times also because there 
are no personnel resources for clinical research.  
 
TDM plus 
On the base of the experience gained in the AMSP+ study and the fact that we have only sparse data 
indicating that routine drug plasma concentration monitoring and/or pharmacogenetic testing (347) in 
psychiatry are justified to minimize the risk for ADR, we developed a test algorithm - which could be 
named “TDM plus” (TDM plus interaction checks plus pharmacogenetic testing) - on how to proceed 
in presence of an ADR (fig. 18) (64). 
 
Figure 18: TDM plus algorithm 
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When a patient experiences an adverse drug effect, especially when serious or unexpected, drug 
plasma levels of suspected drugs are analysed. When the plasma levels are expected (dependent on the 
administered dose) a pharmacodynamic explanation is probable. If unexpectedly high or low a 
pharmacokinetic explanation should be considered.  
Firstly the possibility of a pharmacokinetic drug interaction is examined. It is important to know all 
drugs taken, also oral contraception or over-the-counter preparations and herbal medication. Also prior 
medication, depending on its half-life, can be important. Furthermore lifestyle and diet should be taken 
into account: most importantly smoking, grapefruit, and consumption of alcohol or illegal drugs. All 
this information is checked in a drug interaction program reliable for its pharmacokinetic information 
(see chapter 5). Alternatively, the pharmacokinetic characteristics such as metabolism and transport 
pathways of the suspected drug or drug combination are looked up in the summary of product 
characteristics of each drug or in text books and the interaction potential is estimated.  
If no pharmacokinetic drug interaction is found and the suspected drug(s) are metabolised by a 
polymorphic enzyme (e.g. CYP450) a pharmacogenetic test should be proposed. As explained in the 
introduction, genotyping is a trait marker but not available for all CYP450 enzymes. Phenotyping 
shows the activity of the tested enzyme, is a state marker and dependent on environment (here e.g. the 
drug taken). When genotyping is done, the information should be written in the patient’s history and 
also given to the patient for all future treatment. Important tested alleles should be mentioned (fig.11). 
Pharmacogenetic tests exist also for other enzymes such UGT or for transporter proteins e.g. Pgp but 
the interpretation of their results is more difficult since less is known about substrate specificity and 
the clinical relevance of their different genotypes (64;348). 
For some drugs routine TDM is recommended such as for lithium or clozapine (41), for other drugs 
with a narrow therapeutic index such as tricyclic antidepressants, TDM can prevent serious side effects 
(e.g. cardiac conduct disturbances, epileptic seizures, anticholinergic delirium), for all other drugs the 
proposed TDM plus algorithm seems, especially in the light of the health economical situation, more 
realistic. 
Recommendations for further studies 
A case-cohort study might help to overcome the problems we encountered to match controls to our 
cases, and inclusion of more cases will probably generate a clearer result concerning CYP2D6 
genotype dependent (S)ADR risk. Limiting the heterogeneity of the cases in choosing either for a 
certain ADR group such as EPS or for a certain drug or drug group such as antipsychotics or 
antidepressants would be advisable as well. If one chooses a matched control design a more 
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homogenous patient group is advisable in order to reach the necessary number of matched case-control 
pairs to perform a more detailed risk analysis by logistic regression tests.  
Written informed consent for drug plasma level monitoring, pharmacogenetic testing and use of these 
data for research purposes is ideally obtained of all patients of the clinic as soon as possible after 
admission. Blood samples for pharmacogenetic tests of all patients are taken; however, analyses are 
only done when needed. In this way costs are limited. 
In conclusion, case-control or case-cohort studies seem appropriate to study drug safety risk factors 
such as pharmacokinetics’ influencing genotypes or too high plasma concentrations of psychotropic 
medication. A recent state of the art paper on pharmacogenetic studies concluded that in rare and 
severe adverse drug reactions, case-control studies might be the sole feasible design (349). 
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7 mediQ.ch,  a Web based Drug-Drug Interaction Database  
Summary 
The internet based drug interaction program mediQ.ch (www.mediQ.ch) meets the need of the 
clinicians for an easily accessible tool to rapidly check the risks of drug and drug combination 
therapies. Different levels of information depth allow rapid checks for significant interaction risks for 
uncomplicated treatments as well as more detailed information for complex cases. The information 
source for drug information and for the risk estimation is referenced and direct links to Pubmed allow 
access to the abstract of the source publications. 
Risk estimation of drug combinations is mostly made for drug pairs, based on published data of 
clinical studies, case reports and drug characteristics. Pharmacokinetic and –dynamic as well as the 
side effect profile are taken into account. 
Risk estimation is also provided for the influence of diet, lifestyle or pharmacogenetic factors. In the 
summary of the drug profile, mainly based on the summary of product characteristics, the clinician 
finds also information on the need of dose adaptation in case of renal or hepatic insufficiency, the 
potential for QT prolongation and for lowering the seizure threshold. In addition detailed and 
referenced information is given on the metabolic and transport pathways of the active substances 
described. 
The main difference with other drug interaction programs is risk estimation for each drug pair in 
contrast to risk estimations based on class effects. This has the advantage to be more accurate and the 
disadvantage of generating a large amount of data which has to be, and is, regularly updated.  
The program was originally set up by the author of this thesis to serve the clinicians of the psychiatric 
in-patient hospital Königsfelden but in the meantime it is implemented in over 100 hospitals in 
Switzerland, Germany and Austria and several hundred private practices. 
 
Introduction 
Unintended adverse drug effects are a more frequent cause of death than traffic accidents in developed 
countries(350). It is estimated that 200 to 700 cases of unintended adverse drug reactions occur in a 
hospital with 500 beds per year, and the extra costs per year reach an amount of 400 million EUR in 
Germany alone (351). In Switzerland, a study from 1999 estimated the costs of drug-related hospital 
admissions to 70-100 million Swiss francs (352).  
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The main reasons for serious adverse drug reactions are prescription errors, e.g. to incorrect dosage, 
double prescription, wrong medication and harmful drug-drug interactions (DDI) (353-356) which are 
either unknown or not considered. About 10% of all severe unintended adverse drug effects are due to 
adverse DDIs, in the elderly this increases to 15-20% (357;358). DDI are a major medical problem. 
This becomes more important as polypharmacy becomes more common; patients are treated for 
several conditions in parallel and more therapies build on combination therapy (e.g. HIV, cancer, 
infectious diseases, cardiovascular, and psychiatric disorders). Polypharmacy is also driven by the 
increase of age of the population in the developed world (i.e. more patients with multiple conditions to 
be treated), and the increased number of available drugs.  Therefore, at the same error rates, harmful 
DDI will increase if no tools are developed to support the prescription process in order to prevent 
harmful effects to patients.  
Combination pharmacotherapy is most common today in psychiatry. According to different studies 
only 20% of the hospitalised patients get a psychotropic monotherapy (8;359)(data from the AMSP 
database), the mean being 3.5 and 5 for patients under 65 and over 65 years old, respectively (data 
from the AMSP database). Besides the aimed benefit there is also the risk of potentially harmful DDI. 
It is estimated that clinicians identify 20 to 40 % of potentially hazardous interactions (360;361). 
Taking into account that the Swiss market comprises about 6000 medicinal drugs with about 2000 
active substances there are 2 million combination pairs (2 drugs) possible. Cautious calculations 
estimate the number of potentially harmful combinations to 40’ – 70’000 (Chistoph Hiemke, personal 
communication) taken all medication together and about 7000 in psychiatry only. These calculations 
do not take additive risks of multiple drugs’ combinations into account, nor interactions with food, 
lifestyle, genetic background and health status of the patient. 
Pharmacogenetic factors further complicate the prescription process 
Comparison of the list of drugs most commonly implicated in adverse drug reactions with the list of 
metabolizing enzymes with known polymorphisms shows that drugs commonly involved in adverse 
drug reactions were also those that were metabolized by enzymes with known polymorphisms (162). 
For certain new drugs pharmacogenetics is already part of standard practice for prescriptions 
(64;362;363). Thus, the clinician ideally knows the patient history, effects of food and life style, the 
exact medication with potential DDI, and in addition the potential effect of a certain pharmacogenetic 
status to determine whether a prescription is safe.  
Information Technology (IT) support systems 
To manage the overwhelming amount of data on potential drug effects, health professionals use more 
and more IT-based decision support systems when making prescriptions. Current databases which are 
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included in IT-based decision support systems list drug-drug interactions on one hand based on past 
observations of adverse effects in clinical practice, on the other hand, drugs are not treated individually 
but as members of an “effectors’ class”.  
The volume and complexity of knowledge and information e.g. through extended drug innovations or 
front line research insights such as in the above mentioned pharmacogenetics require the use of IT-
systems to support the prescription process. In general, medical practitioners lack behind other 
professions in implementing IT to support processes and share information. For example, only 14 % of 
all General Practitioners in Switzerland use electronic patient files (personal communication from e-
mediat at e-health conference 2010). Estimations from the US say that that the use of IT could prevent 
2 million adverse drug interactions and subsequent 190’000 hospitalisations a year (364).  
The US government therefore plans regulations to make electronic prescriptions (as opposed to paper 
prescriptions) mandatory by 2011. Prescription devices or systems will have to include an automatic 
check for interaction risk assessments. In Europe, similar regulation is likely to follow. Several 
initiatives are underway in Switzerland to overcome this systemic weakness, with the electronic 
patient files (e.g. a “patient smart card”) as one of the steps.  
Concept of the interaction program mediQ.ch 
The program has been designed and built to meet the need of the clinicians for an easily accessible 
source of reliable information where they can rapidly check the risks of drug and drug combination 
therapies. Different levels of information depth does allow the rapid check for significant interaction 
risks for uncomplicated treatments as well more detailed information for complex cases. The user of 
the program should always be able to know on which source the information of the risk estimation is 
based on, so information is referenced. 
The program does also inform (at least partly) on the interactions of patient factors such as 
pharmacogenetic status, renal and hepatic insufficiency, and the risk for long Qt syndrome or lowered 
convulsion threshold with a certain drug or drug combination treatment. 
The mediQ.ch database is built “bottom-up” on pharmacological data (fig. 19), which allows 
integrating pharmacogenetic and other new information as it is established. Thus, the data base can be 
extended easily by the “genetics” dimension or e.g. by the influence of co-morbidities, which is not 
possible – or very laborious – in other data bases. In addition, new drugs can be easily assessed for 
potential interactions when their metabolism and mode of action are known. 
For this deductive and mechanistic approach, mediQ.ch has filled an outstanding database on the 
pharmacological profile of pharmaceutical compounds and pharmacogenetic data, including detailed 
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information for about 20’000 interactions, 5’000 drugs, 2’000 substances, 400 indication classes, 150 
metabolic/transport pathways and 25 genotypes, including links to original scientific literature. 
The mediQ.ch source data is retrieved from the summary of medicinal product characteristics for 
healthcare professionals and published medical literature, based wherever possible on clinical data. 
The corresponding literature references are indicated. In order to keep up with the new research 
results, mediQ.ch’s data-base is continuously online updated and extended. Furthermore, several 
research collaborations help mediQ.ch to stay abreast of the scientific development (Unité de 
Biochimie et Psychopharmacologie Clinique, Centre des Neurosciences Psychiatriques of the 
University of Lausanne, IKC of the University of Zürich, and Psychiatric University Institute in 
Munich amongst others). 
Thus, the mediQ.ch system is an easy to use tool to access the fundamental data relevant to assess drug 
interaction risks with the ability to integrate new biomedical insights in a dynamic and intuitive way. 
Figure 19: Estimation of interactions potential on pharmacological bases (Number of potential 
interaction pairs of “n” drugs: n*(n-1)/2: At 2’000 known compounds this yields 2 millions 
interactions, not taking into account genotypes.) 
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Information Sources 
Besides the prescriber’s information or Summary of product characteristics (SPC) the following 
sources are used: 
1. Drug interaction/combination studies in patients: these studies can give a proper insight in the 
expected interactions in the studied patient population. Importantly, one has to consider that drugs 
are sometimes used in different indications, with a different patient population and therefore 
different risks. If these studies show no clinically relevant interaction, vulnerable patients could 
still be at risk. 
2. Drug interaction studies in healthy volunteers: These studies are mostly performed to study 
pharmacokinetic interactions, pharmacodynamic effects are sometimes neglected. Healthy 
volunteers are in general less vulnerable to adverse drug reactions than patients. 
3. Case reports: case reports are a valuable source of clinical information on the potential risk for rare 
adverse events of a drug combination.  
4. Pharmacological information is retrieved from the prescriber’s information and pharmacological 
studies, mainly found through literature search in Pubmed or in other drug interaction programs 
such as Micromedex (Thomson Micromedex, Thomson Reuters 1974-2010) or Genelex 
(www.genemedrx.com). 
4.1. Pharmacokinetic information (absorption, distribution, metabolism, excretion)  
4.1.1. In vivo: it is important to extensively search for in vivo data, since it is difficult from in 
vitro data to predict the in vivo activities.  
4.1.2. In vitro: where no in vivo data are available in vitro information is taken. However, the 
interpretation is done more cautiously than with in vivo data.  
4.2. Pharmacodynamic information (e.g. receptor affinity, agonistic/antagonistic action): 
pharmacodynamic information is sometimes difficult to find and interpret. In 2010 this 
information is still mostly missing in mediQ.ch.  
5. Side effect profile: the risk for certain drug reactions can substantially increase (accumulated risk) 
when more than one drug bears this risk (e.g. prolongation of QT-interval and risk of torsade de 
pointes; liver enzyme disturbances; electrolyte disturbances; neurotoxicity etceteras.)  
Literature searches are mostly done in Pubmed, supported by e-alerts from scientific journals and 
alerts from drug safety authorities such as FDA, EMEA and Swissmedic 
Concise risk estimation 
Concise risk estimation comments are written by experienced health professionals (pharmacists, 
physicians, pharmacologists…) and corrected by at least one peer (minimum 4 eyes).  All information 
is updated as new data become available and periodically, normally all 2 years. 
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In cases where no clinical information is found, mediQ’s risk estimation is compared to the 
information in other drug interaction programs, e.g. Micromedex, Genelex, Pharmavista 
(www.pharmavista.net), PSIAC (www.psiac.de). 
 
Structure of the mediQ.ch interaction program 
The program is web-based in order to be easily accessible, always updated, dynamic with links to 
other information sources and interactive with online advice on specific questions 
Core of the program is the interaction-check where two or more substances can be combined, also with 
information on genetic polymorphisms. The answers will be presented in different ways and amount 
of details (see examples with screen shots below).   
In addition each substance is described with a summary of the prescriber’s information, important 
safety information (dose decrease in renal or hepatic insufficiency, potential for QT-prolongation, 
lowering of seizure threshold), pregnancy category , and detailed information on metabolism and 
transport of the drug,  
There is also information in which galenic formulation under which trade name a substance is 
available.  
All information is accessible via the name of the active substance or the trade name of the medicinal 
drug. 
As a supplement a glossary with useful definitions and links to other information sources in the field 
of drug interactions are given. 
The user guide explaining all the features is accessible on www.mediQ.ch under “So funktioniert es.... 
Screenshots und Präsentationen”. 
 
Examples 
Example 1 
A 40 year old male patient suffering from schizoaffective disorder, under olanzapine treatment needs 
an antidepressant, paroxetine being the first choice. The same patient suffers from a dry cough and he 
asks for a cough syrup containing dextromethorphan. He also mentions that he considers stop 
smoking.  No other health problems are known. 
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Figure 20: First page after log in of the drug interaction program mediQ 
 
 
 
The entry page (fig. 20) displays on the left side different search categories, most important in blue the 
page which leads to the interaction check of drug combinations. We choose “Interaktions-Check”. 
 
 
 
 
 
  
 
 
101 
   
Figure 21: Drug entry page for the interaction check in mediQ.ch 
 
On the page “Interaktions-Check” (fig. 21) active substances (“Substanzen”) and/or drugs with their 
trade name (“Medikamente”) and/or a pharmacogenetic status (“Genetik”) can be combined. The 3 
drugs of our example and smoking (“Rauchen”) are chosen for checking the interactions under „Jetzt 
checken“.  
First an overview (fig. 22) of the clinical relevance of a potential interaction per drug pair is found. 
Red, meaning “highly relevant interaction, often also contra-indicated”, orange: “clinically 
meaningful”, yellow: “might be relevant in special clinical situations or vulnerable patients”, gray: no 
clinically relevant interaction expected. Besides that the user can see if there are relevant issues around 
liver (L) or renal (N) insufficiency, potential for QT-prolongation (Q) or lowering of the seizure 
threshold (K). 
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Figure 22: graphic overview of the relevance of potential interactions between the chosen substances 
 
 
In our example we find a highly relevant interaction between dextromethorphan and paroxetine, a 
clinically relevant interaction between smoking and olanzapine, two weak interactions between 
olanzapine and dextromethorphan and paroxetine respectively. We further see that for paroxetine and 
olanzapine we need to adapt the dose in cases of renal or hepatic insufficiency; further that both drugs 
have a certain potential for QT prolongation and that olanzapine lowers the seizure threshold. 
We now have the choice to click on one of combinations either in the first, or as seen in the next slide 
(fig. 23), second overview. We want to know what effect smoking has on olanzapine and click on the 
second combination comment. 
 
 
 
 
 
 
In English:                                                                  
N = dose adaptation in case of renal insufficiency       
L = dose adaptation in case of hepatic insufficiency   
Q = QT prolongation                                                    
K = lowering of seizure threshold 
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Figure 23: Second overview with summary of the potential interaction per drug pair is listed under the 
first overview.  
 
 
We click on the second combination “olanzapine and smoking” in order to obtain the detailed 
description of this combination comment (fig. 24).  
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Figure 24: Detailed combination comment on the influence of smoking on olanzapine treatment with 
information source references  
 
The comment explains that smoking (not nicotine) induces CYP1A2 and that sudden smoking 
cessation without dose adaptation can lead to high olanzapine plasma concentration and high risk for 
adverse drug reactions. It also mentions that the induction effect comes with latency. Clicking on a 
reference (e.g. Zullino DF et al 2002) brings us to the abstract of the source information (fig. 25). 
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Figure 25: abstract of source reference from the open access literature service “Pubmed” 
 
Under the second overview we find a rough overview of CYP450 interactions (fig.26). The variation 
in bioavailability is not yet taken into account or some other factors such as where different CYP450 
isoforms are active (e.g. intestinal vs. hepatic...). 
Figure 26: Rough overview of CYP450 interactions 
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Below an overview of metabolic and transport pathways with importance of substrate affinity and 
strength of modulating activity is found (fig. 27). 
Figure 27: Overview of metabolic and transport pathways with substrate affinity and modulating 
effects 
 
In case we want to know on what information sources mediQ relies for e.g. CYP2D6 and paroxetine 
we will find that in clicking on the right information button under details (fig. 28). 
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Figure 28: Source references, all with direct link (click on the author name in green) to their abstract 
in the open access literature service “Pubmed” or link to the journal, especially in case where free 
full text is available. 
 
 
 
Example 2 
A 54 year old female bipolar patient consults because she fears experiencing another manic episode. 
She presents with profuse and for her untypical sweatening; she feels restless, suffers from 
handicapping tremor (cannot handle the computer mouse, cannot hold a cup without spilling...). A 
month ago she added some new drugs to her existent medication after consulting a gynaecologist for 
menopausal complaints and weight gain. Her medication presented as follows: since several years:  
paroxetine 20mg/d, lithium 660mg/d, and levothyroxine 0.05mg/d; since 4 weeks tibolone 2.5mg/d 
against menopausal symptoms and sibutramine 10mg/d to reduce her weight gain. 
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The result of the interaction check presents as follows with the first graphic overview (fig. 29), below 
the second overview with the summaries of the most relevant information for each combination pair 
(fig. 30) and finally a detailed comment for the combination of lithium with paroxetine (fig. 31).  
Figure 29: Graphic overview of the interaction risk of the combination pairs in the combination 
treatment of paroxetine, lithium, levothyroxine and sibutramine 
 
 
The 3 orange flagged combination pairs show a serotonin agonistic potentiation of the sibutramin, 
paroxetine and lithium and warn of the risk of serotonin toxicity. mediQ.ch only displays comments 
on drug pairs; therefore clinician should read all the comments in order to get the full picture. 
The summaries of the next overview (fig. 30) mention the most important symptoms of a serotonergic 
overstimulation such as hyperreflexia, myoclonus, agitation, confusional state, hyperthermia, 
sweatening, ataxia and diarrhoe, it shows also an increased risk for QT prolongation and 
hyponatriemia.  
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Figure 30: Summary overview for the drug pairs of the combination treatment with paroxetine, 
lithium, levothyroxine and sibutramine. 
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In figure 31 the details for the combination pair lithium and paroxetine is displayed. It mentions that 
this combination is used as augmentation therapy in patients with a difficult to treat depression but it 
bears a certain increased risk for serotonin toxicity and QT prolongation. 
 
Figure 31: Detailed comment on the combination of paroxetine with lithium 
 
 
 
For further information on serotonin toxicity a link will bring you to the glossary, as shown in figure 
32. 
 
 
 
111 
   
 
Figure 32: Glossary text on serotonin toxicity 
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Realisation 
First we built a standalone program based on Microsoft Access in collaboration with Stefan Kunz 
from the mathematical institute of the University of Berne. The complexity of the tasks and the high 
amount of data exceeded the capacity of this program quickly. It also became clear that an internet 
based program which is easily accessible and regularly updated would better cover the clinicians’ 
needs. 
Based on the gained experience from the prototype mediQ.ch was designed and subsequently 
implemented  in close collaboration with Pierre Gumy from Pronaos GmbH by using open source 
software Zope and Plone. The platform is hosted by Stephan Göldi from Goeldi.com. 
 
Discussion 
Validation of mediQ.ch: Medical Thesis of A. Vieth, Mainz, 2008 (365) 
One validation has been realized with data from 8/2007 in a medical thesis by Anna Vieth of the 
University of Mainz from 2008. She compared 4 German speaking drug interaction programs: PSIAC 
(www.psiac.de), mediQ (www.mediQ.ch), ifap (ifap index®KLINIK, on CD-ROM version 5/07 with 
data from ABDATA) and the interaction check from the Arznei-Telegramm (http://arznei-
telegramm.de). In a Pubmed search she identified 40 clinically relevant drug interactions and 30 not 
clinically relevant drug interactions, examined them in each of the programs with the following 
criteria: 
• Interaction pair in the program described? 
• Mechanism of interaction described? 
• Source reference of primary literature? (summary of product characteristic was not counted as 
such, neither were review articles or similar) 
• Recommendations for the clinicians? 
• Was the information to the interaction pair useful? E.g. was the relevance of the interaction 
adequately described? Was the information complete? And as most relevant, was the 
recommendation to the clinician helpful?   
In 8/2007, the index time of the data capture for the medical thesis, the mediQ program had less than 
4000 drug pairs described and stood at its beginning (although some evaluations concerning the 
program in general were made later when around 8000 drug combinations were described). End of 
2009 almost 20’000 drug pairs are described. This meant that relevant information at the index period 
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was missing and sensitivity was rated as low (in 2009 all the examined drug pairs were described). 
The information found, however, was correct; the source information good with direct access to the 
abstracts of Pubmed, and as only program there was detailed information on the pharmacokinetics 
displayed as well. In 2007 only few recommendations to the clinicians were given, which was seen as 
drawback. This indeed was not an omission but at that time wanted. The mediQ team would only 
made risk estimations and the clinicians would then take the necessary measures. Three years 
experience with many different users of the mediQ program and the critique of A. Vieht, showed 
however, that many clinicians, especially young doctors or e.g. psychiatrists who rarely prescribe 
medication “cocktails” needed recommendations on what to do, and if necessary and possible, wished 
to get examples of alternative medications.   
At the index period the user- friendliness was rated as suboptimal since not the whole information was 
displayed on the first page of the results. This might seem a disadvantage when only asking for the 
combination of 2 drugs; however, is a clear advantage when asking for more complex combinations, 
where mediQ in a graphical overview shows the available information with a first rating of the clinical 
relevance. This graphical display has been realised after the index period of 8/2007. 
If the same validation would have been realised in 2009 or 2010, the mediQ program would have been 
rated high which according a personal communication of Christoph Hiemke from Mainz will be 
shown in a second thesis by Martina Hahn “Vermeidung von Interaktionen in der 
Psychopharmakotherapie“.  
Research project by Stefan Russmann et al, Zürich, 2009 - 2011 
A research project on the clinical utility of clinical information programs such as mediQ and Theraopt/ 
ID PHARMA CHECK® has been performed by the Clinical Pharmacology Unit of the University of 
Zurich (Stefan Russman et al). They have filled in AMSP prescription data of almost 85’000 
psychiatric in-patients in the mediQ-program and checked for the number and nature of alerts 
generated. A first manuscript on the results has been submitted in spring 2011. In a second step they 
plan to repeat this analysis with the medication of ADR cases of the AMSP project. 
Comparison with other drug interaction programs 
The use of dedicated software system in medical practice allows integrating automatic interaction 
checks directly into the work flow of the physician. These drug-interactions-checker-programs warn of 
the potential risks, give the level of significance of the interaction (major, moderate or minor), and in 
certain cases, provide the recommended course of action to manage the interaction. 
However, conventional databases have a number of shortcomings, including: 
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- They are often empirical only, i.e. based on collections of clinical observations whose 
underlying causes usually are explained ex-post. This means that new drugs are not assessed, 
and that new biochemical and genetic information are not integrated. 
- They assess interactions on the level of effectors classes of drugs, e.g. SSRIs, antipsychotics, 
etceteras. This can lead to dangerous misjudgements if combinations of drugs with an atypical 
compound included are assessed, e.g. a combination of clozapine and citalopram or clozapine 
with fluvoxamine is both rated as moderate interaction; however, fluvoxamine-clozapine can 
raise the plasma concentration of clozapine 10times and more, citalopram will probably have 
no effect at all.  
- Novel concepts like the use of genetic profiling to stratify patients are not integrated in the 
data sets. The potential of pharmacogenetics for the risk-assessment of drug-drug interactions 
is foregone.  
- Important information on diet or recreational drugs is not included. 
- They are often based on linear (“conventional”) texts and do not use the capabilities of 
electronic texts (such as hyperlinks inside the text, or links to references). These data sets tend 
to be heavy and cumbersome to use. 
Some of the above mentioned tools are available online or are downloadable as personal digital 
assistants on Black Berry or iPhone. In many cases, though very interactive and with the promise of 
regular up-dated information, there is no knowledge about the source of the information which may 
pose an error risk. 
Furthermore, with the exception of Genelex (www.genemedrx.com), pharmacogenetics and 
information on diet and recreational drugs are not integrated in the tools and new information-sets are 
very difficult to integrate without reprogramming the tools.  
The analysis in table 22 is based on the 5 programs: Micromedex (Thomson Micromedex, Thomson 
Reuters 1974-2010: www.thomsonhc.com ), Genelex (www.genemedrx.com), Pharmavista 
(www.pharmavista.net ), mediQ (www.mediQ.ch), PSIAC (www.psiac.de) which all reference the 
source of their information. 
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Table 22: Comparison of 5 drug interaction programs (Micromedex, Genelex, Pharmavista, mediQ, 
PSIAC). pk = pharmacokinetic 
abilities YES Partly NO 
Risk estimation of 
combination >2drugs 
 Genelex, mediQ  Micromedex, Pharmavista, 
PSIAC 
Pharmacokinetic 
information 
Genelex, mediQ PSIAC, Micromedex, 
Pharmavista 
 
Pharmacodynamic 
information 
Micromedex, Pharmavista, 
mediQ, PSIAC 
Genelex  
Side effect profile Micromedex, Pharmavista, 
mediQ, PSIAC 
Genelex  
Pharmacogenetics Genelex, mediQ  Micromedex, Pharmavista, 
PSIAC 
Age, gender, co-
morbidities 
  None, sometimes in the text 
a warning 
Diet/lifestyle Genelex, mediQ, PSIAC  Micromedex, Pharmavista 
Recommendations to the 
clinician 
Micromedex, Pharmavista, 
mediQ, PSIAC 
 Genelex 
Risk estimation without 
clinical cases 
mediQ, PSIAC Genelex pk, Micromedex/ 
Pharmavista class effects 
 
 
A broader overview is given in the table 23; it compares mediQ and the following databases/drug 
interaction programs on different features: 
• e-mediat / ABDATA databases: today the most used interaction databases used in German 
language clinical decision support systems. Its origin comes from the “Deutsche 
Apothekerverband” (www.dimdi.de) 
• Pharmavista (www.pharmavista.net): a standalone interaction program based on ABDATA 
• Medical Letter's Adverse DID (http://secure.medicalletter.org ): this program is currently 
overhauled and is expected to be available with more features mid of 2011.  
• Micromedex (Thomson Micromedex, Thomson Reuters 1974-2010: www.thomsonhc.com ) 
• PSIAC (www.psiac.de) 
• Genelex (www.genemedrx.com) 
• Epocrates (www.epocrates.com) 
•  PEPID (www.pepid.com) 
• Davis Drug Guide (www.unboundmedicine.com) 
• Lexicomp (www.lexi.com) 
• Skyscape (www.skyscape.com) 
• Drugs.com (www.drugs.com) 
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Table 23: Comparison of electronic information sources on drug interactions 
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 emediat/ABDATA 
Data collection 
health prof YES NO NO NO NO PARTLY YES YES PARTLY NO YES YES 
 Pharmavista (data 
from e-mediat) 
health prof YES NO NO NO NO PARTLY YES YES NO NO YES PARTLY
 Medical Letter's 
Adverse DID 
health prof YES PARTLY NO NO NO PARTLY YES PARTLY NO YES YES PARTLY
 Micromedex  health prof YES YES NO NO NO PARTLY YES YES NO NO YES PARTLY
 PSIAC (only 
psychiatry) 
health prof YES YES NO NO NO PARTLY YES YES NO YES YES YES 
 Genelex health prof YES YES YES YES PARTLY YES PARTLY PARTLY NO YES NO PARTLY
 Epocrates Rx health prof NO YES NO NO NO no info no info YES YES PARTLY PARTLY YES 
PEPID health prof NO YES NO YES NO PARTLY YES YES NO YES YES YES 
 DavisDrugGuide health prof NO PARTLY NO NO NO no info no info no info YES PARTLY YES YES 
 Lexi-Comp health prof  NO no info NO NO NO no info no info no info no info no info PARTLY YES 
 Skyscape (data from 
Medical letter) Patients:  simple warning 
NO no info NO NO NO no info no info no info NO no info NO no info 
 Drugs.com 
Patients:  
with 
explanations 
NO PARTLY NO NO NO no info no info YES NO PARTLY YES YES 
 mediQ.ch health prof YES YES YES YES PARTLY YES YES YES PARTLY YES YES YES 
 
Other authors looked from a different angle to several drug interaction programs and rated e.g. time to 
retrieve the relevant information, accessibility through mobile devices, or studied the “signal to noise 
ratio”, the problem of too many alerts leading to ignoring given alerts (361;366-374). The risk of 
ignoring the alerts of an interaction program because there are too many alerts can lead to build in 
filters for seeing only the interaction bearing a major risk. However, this can be misleading by 
overlooking an accumulation of equal or similar effects in a drug combination with more than 2 drugs. 
Better than filters are short graphical overviews where the clinician gets on first eyesight an 
impression of the interaction potential, and from there he or she can decide to go more into details. 
Further points of critique were that patient factors are not taken into account, that there are no 
standards of how clinical relevance is rated and in mobile devices but also some pharmacy programs 
117 
   
the quality of information seems to be at times suboptimal, partly because no automatic updates were 
available. 
Drug interactions programs: clinician’s needs and program’s realities 
Electronic programs to aid the physician with prescribing drugs can be valuable tools for the safety of 
patients and may become integrated in the quality assurance in medical practice. Drug interactions 
programs give risk estimations of drug combinations, which dependent on the factors considered – 
also patient characteristics - will be more or less accurate. Currently there exists no program which is 
able to predict the outcome of a drug (combination) treatment, the interplay of a multitude of 
influencing variables being too complex. This is also true for mediQ.ch. 
Clinicians wish a precise risk prediction of a drug combination therapy, not only for the combination 
of two drugs but also for more. The program should also take into account patient factors such as renal 
or hepatic insufficiencies, age, gender, illnesses, pharmacogenetic factors, diet, and lifestyle.  
However, the complexity of the interplay between drugs and the patient variables represent a 
seemingly insurmountable challenge at least as of today. One can imagine that new mathematical 
models to combine all these variables will allow a more precise outcome prediction one day. The 
clinician has to be aware of the advantages but also of the shortcomings of today’s drug interaction 
programs. 
Financial and legal aspects 
As of today clinicians are not obliged to consult drug information programs but they have the duty to 
care and to prevent harm.  Being knowledgeable of the interaction risk of a drug combination might 
also legally belong to this duty. In Switzerland there is no court case known, where a doctor has been 
convicted because he or she has overlooked a drug interaction risk (personal communication with 
Ursula Eggenberger Stöckli, Bern, lic. Iur. and dipl. Pharm.). It will be interesting to see how this will 
change when electronic prescribing with an integrated drug interaction checker will become part of 
standard care. The situation in the USA is different. There exist lawyers who are specialised in 
medical malpractice and some are specialised in injuries as consequence of drug interactions.  Courts 
might view a drug interaction due to a pharmacokinetic interaction as excessive dosing or as failure to 
appropriately monitor plasma levels (375); some case of death or permanent injury resulted in high 
financial damage compensations, as e.g. in a case 1999 in Oregon where ciprofloxacin (strong 
CYP1A2 inhibitor) and theophylline (CYP1A2 substrate) were co-prescribed resulting in permanent 
brain damage because of theophylline intoxication (375).  
Another legal aspect is the liability of the authors of drug information programs.  Users must exercise 
their independent professional judgment and should always consider the latest manufacturer's legal 
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information. A drug interaction or information program has to be used as a clinical decision support 
system, it cannot be more.  Nevertheless the authors of drug information programs should be aware of 
their obligation to offer the most accurate information possible since clinicians will rely on their 
information and patients’ wellbeing might depend on it.  This also implies regular updates on one hand 
and dated information on the other hand.   
Costs play a role in the decision of doctors and pharmacist to consult drug information programs but 
costs are also important in building up and maintain high quality programs. Nowadays cost differences 
are high. Some programs such as www.drugs.com are freely accessible and are paid by advertisement. 
Others are expensive such as Micromedex Drug Reax where a single user licence for a clinician costs 
approximately 5000 Euros, Pharmavista costs around 650 CHF, more often the costs sum up to 100-
250 Euros per single user (PSIAC; Genelex, mediQ.ch...). For the moment, these programs are 
competing with each other, and each of them has high salary costs for qualified personnel to pay. In 
the case of mediQ.ch, salaries are paid by the clinic Königsfelden and the income generated by the 
mediQ.ch licences, no pharmaceutical sponsoring is allowed.  
Collaboration could be useful, as could be a governmental support to make high quality programs 
available to all.  
Future Challenges for mediQ.ch 
Challenges for the mediQ.ch program will be to become integrated in the (electronic) prescribing 
process, to keep all the information regularly updated in order to maintain a high quality database and 
to provide continuously clinically relevant information and recommendations to the clinician. The risk 
of over-alerting must be kept in mind. When a clinician considers the information too abundant and 
not enough relevant, he or she will discard the alerts and the interaction program loses its purpose. A 
multi-lingual program would serve more persons and would on the long-term become more cost-
effective.  mediQ.ch has a structure which would allow a multi-lingual approach.  If enough financial 
resources are to be found a translation in other languages is probable.   
Interfaces to clinical information systems are currently being programmed and first tests seem 
promising. Since most clinical information systems already have a more general drug interaction 
program such as Pharmavista integrated, the problem of too much and sometimes contradicting 
information will have to be addressed.  
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8 Pharmacovigilance in Psychiatry: case studies 
 
Case reports are important documentations of uncommon events – clinical studies are most often not 
large enough to document rare adverse drug reactions therefore post marketing surveillance is essential 
– case reports can illustrate theoretical assumptions and often serve didactic purposes as well. 
They are of particular interest as “real life” documentation of drug effects in patients where only 
studies in healthy volunteers or clinical studies with stringent in- and exclusion criteria exist.  
However, case reports can only be used for signal generation. False conclusions can be drawn when 
unexpected events are wrongly interpreted, sometimes because not all pieces of the puzzle are known. 
E.g. a drug B is added to a drug A, plasma levels of drug A raise: obvious conclusion: drug B inhibits 
drug metabolism of A – but: shortly before adding drug B a drug C had been stopped, this drug C is an 
inducer of the metabolism of drug A and that fact has been overlooked. A cause to effect relationship 
needs pharmaco-epidemiological studies.  
The following case (series) reports are examples; a brief summary of their publication is given here. 
 
Metabolic syndrome associated to clozapine and olanzapine (266) 
A case-series of three chronic schizophrenic patients are presented who responded only to clozapine or 
olanzapine but suffered from massive weight gain and developed a (partial or full) metabolic 
syndrome. A change of medication was not an option since treatment changes resulted in exacerbation 
of their schizophrenic symptomatology. Therefore pharmacological and non-pharmacological 
strategies to counteract the weight gain under these antipsychotics were searched.  
The first case describes a 34 years old man who developed tardive dyskinesia under zuclopenthixol 
and was therefore changed to olanzapine. He had a body mass index (BMI) of 29 before first intake of 
olanzapine 10mg/d, within 10 months of this treatment his BMI raised to over 35 and he developed a 
full metabolic syndrome (fig. 33).  As counteractive measure a galenic change to dispersible 
olanzapine tablets and diet and fitness counselling was installed. With this the patient lost 6kg within 4 
months. 
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Figure 33: Time course of weight and metabolic changes of case A during treatment with olanzapine 
 
The second case describes a 33 years old woman who gained 44 kg (76 kg to 120kg, BMI 37.5) within 
5 years of clozapine treatment, most of the time in combination with valproate. This massive weight 
gain corresponding to 58% of her original weight caused walking problems with pain and urinary 
stress incontinence. She began to develop a metabolic syndrome with lipid changes and partially high 
blood pressure. Change to another pharmacotherapy was several times tried but always failed. 
The third case describes a 33 years old male patient who almost doubled his weight (67 to 128kg) 
under clozapine treatment in less than 4 years. As counteractive measure combinations with 
topiramate (-8 kg) and later with fluvoxamine (-18kg) helped to lose weight. During his massive 
weight gain his blood pressure was high and lipids and glucose parameter were suboptimal which 
partially normalised following weight loss. 
Discussion:  
Weight gain is a common but often underestimated health problem with many antipsychotics, most 
important with clozapine and olanzapine. Sometimes, especially in the cases of massive weight gain, it 
is accompanied by a metabolic syndrome. The reader should get sensitised to the clinical impact of 
such weight gain and learn strategies to prevent or minimize it. 
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Electric sensations: neglected symptom of escitalopram discontinuation (376) 
Treatment with citalopram (20 mg/d) was initiated in a depressive patient, which was soon replaced by 
escitalopram (10 mg/d, as monotherapy), the pharmacological active enantiomer of citalopram. 
Responding well, the patient reduced after 2 months first this dose to 5 mg/d and three weeks later 
stopped treatment completely. About a week later, she experienced electric shock-like sensations or 
flashes which were also visual, lasting for about one second each. This was followed by a phase of 
spatial disorientation that lasted for about 30 seconds and was experienced as highly unpleasant and 
frightening. The sensations were only felt in an upright position; the patient has no history of loss of 
tonicity. These episodes occurred up to three times a day over a period of two weeks. Prodromal 
symptoms or specific triggers were not reported. While the patient was on citalopram/escitalopram, no 
side-effects were observed. About 6 weeks later her depressive symptoms returned, resulting in 
another therapy with escitalopram (10 mg). After feeling better she stopped again taking her 
antidepressant escitalopram and experienced another withdrawal syndrome with the same symptoms 
as the first time, although this time they were less intense. 
 
Discussion:  
This case describes in detail - including dechallenge and rechallenge of the drug treatment - the 
symptomatology of an SSRI withdrawal syndrome after cessation of an escitalopram treatment. This 
was then the first case about a withdrawal syndrome published with this specific SSRI.  
 
 
Smoking not nicotine (377) 
A 50-year-old female inpatient, a heavy smoker, was treated for organic psychotic disorder and 
epilepsy with clozapine 75 mg/day, fluvoxamine 150 mg/day and valproate 1.5 g/day. After smoking 
cessation, because of bronchitis with elevated CRP, and supported by nicotine substitution 
(transdermal patch), her serum level of the CYP1A2 substrate clozapine increased by factor 2, while 
dosage and co-medication with valproate and the strong CYP1A2 inhibitor fluvoxamine stayed the 
same. CYP1A2 is induced by polycyclic aromatic hydrocarbons (not nicotine) in tobacco smoke and 
probably inhibited by infect related cytokines. The lack of induction (smoking cessation) and transient 
inhibition of CYP1A2 (bronchitis) caused a marked increase of clozapine level, even in presence of 
the strong CYP1A2 inhibitor fluvoxamine. Smoking cessation and infections with elevated CRP while 
on clozapine therapy require evaluation of dose reduction, monitoring of serum levels and screening 
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for signs of overdosing. It is important to note that an increase of clozapine level is not prevented by 
nicotine substitution (cf. above). 
Discussion:  
This case illustrates how co-medication and patient factors can affect the plasma concentration of a 
drug with a relatively narrow therapeutic index. CYP450 modulation (induction and inhibition) are 
discussed as well as the fact that clozapine has not a linear concentration-dose relationship. 
 
Clonus, hyperreflexia and agitation in a patient with increased fluvoxamine plasma level: signs 
of serotonin toxicity (378) 
This case report describes a 28 years old woman with mild mental retardation and significant 
behavioral impairment resulting from anxiety and obsessive-compulsive symptoms. She was admitted 
to the psychiatric clinic Königsfelden. Neither her neurological examination including MRI and EEG 
nor laboratory values revealed any abnormalities. Her treatment with 200mg/d fluvoxamine was 
stepwise increased to 400mg/d and valproate 2000mg/d was added. She showed signs of sedation and 
her initially light tremor under fluvoxamine 200mg/d became more severe. She also complained about 
cramps in her legs. Neurological examinations showed a middle frequent tremor of all extremities, a 
marked hyperreflexia of the legs and an Achilles tendon reflex clonus of 3-5 contractions. Fever, 
tachycardia, excessive sweatening, and high blood pressure were not observed. Trough plasma levels 
were for fluvoxamine 620ng/ml (ref. 150-300ng/ml) and for valproate 154 μg/ml (ref. 50-100 μg/ml) 
(41).  Valproate was stopped and fluvoxamine stepwise reduced and with that the neuromuscular 
hyper-excitability disappeared gradually, after stopping fluvoxamine no hyperreflexia was noted 
anymore.  
Adverse drug reactions as a result of increased central serotonin levels are best described by the term 
”serotonin toxicity” (ST) implicating concentration dependent effects. ST is characterized by the triad 
of neuromuscular signs, changes of mental status and autonomic symptoms, clonus being a key 
symptom. Severe ST at therapeutic doses mainly occurs, when inhibitors of monoamine oxidase type 
A (MAOI-A) are combined with serotonin reuptake inhibitors (SRI) of any kind. In Switzerland 
irreversible nonselective MAOI antidepressants are not marketed. Nevertheless a number of drugs 
have MAO-A inhibiting properties: moclobemide (reversible, selective MAOI-A) and the antibiotics 
linezolid (reversible, nonselective) and isoniazid (irreversible, nonselective). The antiparkinson drug 
selegiline (irreversible, selective MAOI-B) loses MAO selectivity at higher doses, an effect which also 
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has been shown for rasagiline. A number of drugs and combinations can - even in absence of MAOI - 
precipitate mild to moderate ST, a condition which can be difficult to recognize and impair 
compliance: (S)SRI, tricyclic and ”dual action” antidepressants (and sibutramine), serotonin 
precursors, some opioids, stimulants and antihistamines. Treatment options are dose reduction (mild 
ST), treatment discontinuation, benzodiazepines and 5-HT2A-antagonists (severe ST). 
Discussion:  
With the description of this case under a high dosed SSRI, the symptomatology of serotonin toxicity 
which can comprise only some typical serotonergic symptoms up to a full serotonin syndrome is 
presented. Diagnostic criteria as well as precipitative agents and counter measures are discussed. 
 
 
Adverse drug reactions following non-response in a depressed patient with CYP2D6 deficiency 
and low CYP 3A4/5 activity: a pharmacovigilance case report (379) 
A 47-year-old male taxi driver experienced multiple adverse drug reactions during therapy with high-
dose clomipramine and quetiapine for major depressive disorder, after having been unsuccessfully 
treated with adequate doses of mirtazapine and venlafaxine. Drug serum concentrations of 
clomipramine and quetiapine were unusually high. Pharmacogenetic testing showed a poor 
metaboliser status for CYP2D6, low CYP3A4/5 activity and normal CYP2C19 genotype. After 
reduction of the clomipramine dose and discontinuation of quetiapine, all ADRs subsided except for 
the increase in liver enzymes. The latter improved but did not normalize completely, even months 
later, possibly due to concomitant cholelithiasis.  
Discussion:  
This patient showed an unusual combination of CYP2D6 *4/*6 and a probably genetically determined 
very low CYP3A activity comparable to inhibition by ketoconazole (a very strong CYP3A-inhibtor). 
Clinical effects, preventive and correcting measures are discussed, Therapeutic Drug Monitoring - re- 
or better proactive - being given special attention. 
 
Misinterpretation of a venlafaxine blood level (380) 
A 42 years old depressed female patient was admitted to the psychiatric clinic Königsfelden pre-
treated with an SSRI. Her treatment was changed to a regimen of 75mg/d venlafaxine, mirtazapine 
15mg/d and valproate 1000mg/d. Blood levels of venlafaxine (V) and its active metabolite O-
124 
   
desmethylvenlafaxine (ODV) were measured because she suffered of an adverse event. The results 
showed an unusual high concentration/dose (488ng/ml V + ODV with a venlafaxine dose of 75mg/d) 
and a very low metabolic ratio ODV/V of 0.1. Subsequently the dose was lowered to 37.5mg/d which 
finally led to a depression relapse. Further investigations revealed that the low metabolic ratio was due 
to a CYP2D6 inhibition by the formerly taken fluoxetine. Interestingly, two weeks after the last intake 
of fluoxetine 40mg the plasma levels (determined from a frozen serum probe) were still in the 
recommended therapeutic range: fluoxetine 136 ng/ml, norfluoxetine 136 ng/ml, ref. for the sum 120-
300 ng/ml. This unusual metabolic rate is also seen in CYP2D6 poor metabolisers, but this patient was 
in an earlier hospitalisation genotyped and genetically (CYP2D6*1/*1) a CYP2D6 EM. ”After 
readmission (10 weeks later) the patient’s venlafaxine doses was increased to 150mg/d, the plasma 
levels of venlafaxine plus O-desmethylvenlafaxine were with 349ng/ml lower than before and the 
metabolic ratio ODV/V was now 1.9 (fig. 34). 
Figure 34: metabolic ratio of O-desmethylvenlafaxine (ODV)/venlafaxine (V) with and without 
influence of the co-medication fluoxetine 
 
Discussion:  
This case illustrates how discontinuation of medication with a long half life can continue its effects 
including CYP450 modulation. The reader is invited to thoroughly judge the patient’s medication 
history. Further possible interpretations of the metabolic ratio including pharmacogenetics are 
discussed. 
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Blood levels of extended-release quetiapine: beware of misinterpretation (48) 
A patient treated with extended-release quetiapine showed an unusual high blood level (1204 ng/ml, 
therapeutic range 70-170 ng/ml). On the basis of this example and a further three cases the specific 
pharmacokinetics of extended-release quetiapine and problems concerning the interpretation of its 
blood levels are discussed. Plasma levels measured 12-16 hours after last drug intake are valid for 
quetiapine immediate but not for quetiapine extended release. Trough levels are not yet reached in the 
latter case.  Plasma levels measured 10 hours after drug intake were about 5 times higher than levels 
measured after 20 hours. 
Discussion:  
In many psychiatric clinics blood drawing for plasma level analysis is only done in the morning before 
first drug intake. Quetiapine is a drug which is mostly prescribed as an evening or night dose and 
therefore plasma levels are taken after about 12 hours. This common practice is acceptable for many 
psychopharmacological agents but as shown in the case series not for quetiapine (and probably other) 
extended release medication where trough levels are better taken after 20-24 hours. 
 
Combination of clozapine with fluvoxamine (69;331)  
 A 48-year-old smoker with chronic schizophrenia was treated with a very high dose of clozapine 
(1200 mg/day) in order to obtain plasma levels within the recommended range of 350-600 ng/ml and 
to attain a therapeutic response (the patient was phenotyped as a rapid CYP1A2 metaboliser due to a 
high smoking-related CYP1A2 inducibility). After 2 years of this high-dose treatment he experienced 
several grand mal epileptic attacks. It was hypothesized that the use of such a high dose of clozapine 
produced high peak plasma levels, which could be a risk factor for his epileptic attacks. Treatment was 
therefore changed to a combination of a strong CYP1A2 inhibitor, i.e. fluvoxamine (150 mg/day) + 
125 mg/day clozapine, in order to decrease peak plasma levels, while maintaining the trough levels. 
The therapeutic response remained stable and trough plasma levels stayed within the same range as 
those observed with high dose clozapine treatment. However, the patient did not experience any 
further epileptic fits. 
Discussion: 
Adding fluvoxamine to clozapine treatment can increase plasma levels of clozapine by up to 10-fold 
(69;315;381-383), which can be highly effective (69;315;382-384) but is not without risk of 
intoxication (drowsiness, epileptic seizures, delirium and cardiac problems). Regular TDM control 
during the treatment switching period is necessary, as well as an immediate adaptation of the clozapine 
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dose. It is important to remember that the extent of the inhibitory effect is dependent on the baseline 
metabolic activity of the enzyme to be blocked and on the dose of the blocking agent (320;385). 
Another effect will be a shift of the concentration relationship between the parent compound clozapine 
and the metabolite norclozapine, which might represent a certain advantage in the tolerability of the 
treatment since norclozapine seems to be more sedative. It has also been postulated that combination 
therapy with fluvoxamine causes less weight gain than monotherapy with clozapine alone (315). 
 
Drug interaction leading to loss of therapeutic effect  
A 38-year-old patient with a history of drug abuse, psychotic episodes and human immunodeficiency 
virus (HIV) infection was admitted to hospital in an aggressive psychotic state. Treatment with a high 
dose of zuclopenthixol 400 mg depot, diazepam 60 mg/day and methadone 90 mg/day improved his 
condition. Because of his HIV-infection he subsequently received lamivudine and efavirenz. Five days 
after starting the new HIV treatment the patient deteriorated rapidly and became highly aggressive 
again. TDM of methadone showed a decrease in the methadone concentration to 55% of the baseline 
value, resulting in methadone withdrawal symptoms. HIV treatment with efavirenz was stopped and 
the patient recovered after about one week; the methadone plasma levels concomitantly returned to 
baseline values.  
Discussion: 
The described case (unpublished observation) and similar published cases (386;387) demonstrate a 
drug metabolism-inducing effect leading to methadone withdrawal. Efavirenz (388) and nevirapine 
(389) are strong inducers of CYP3A4, a major pathway in the metabolism of methadone. A 
prospective stepwise increase of the methadone dose (in general about 25%) together with multiple 
daily dosing and TDM are recommended.  
 
Interaction with concomitant illness 
A 54-year-old obese diabetic non-smoking patient with chronic schizophrenia was treated with a 
stable clozapine dose (and stable plasma levels in the therapeutic range) for several months. She 
became drowsy and partly disoriented during a symptom free pericarditis. Her clozapine plasma levels 
were at 250% of the recorded levels before the pericarditis without any change in medication dose.  
 
127 
   
Discussion: 
Similar cases, mainly with respiratory infections like pneumonia have been described (390;391). The 
clinicians should be aware of potential clozapine intoxication in presence of a severe inflammatory 
process, measure clozapine plasma levels and adapt accordingly the dose. This might be valid for other 
drugs which are mainly metabolised by CYP1A2 such as olanzapine and theophilline. 
 
Conclusion 
Although case reports cannot be generalized they are issued from clinical “real life”. Sometimes they 
illustrate what previously existed only as a theoretical hypothesis (pharmacodynamic interaction) or as 
a prediction from in vitro data (e.g. pharmacokinetic interaction). Sometimes their events are 
completely unexpected and further systematic research with pharmaco-epidemiological tools can 
confirm or refute an unknown adverse drug reaction. Sometimes they also show how normally well 
tolerated drug combinations can be harmful in vulnerable patients with risk factors such as low renal 
function, pharmacogenetic mutations, or an electrolyte abnormality. 
Case reports containing information on confirmed or suspected drug interactions are useful in the 
estimation of drug interaction risks and are referenced in the drug interaction program mediQ.ch. 
Often this is the only published clinical information available.  
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9 Concluding remarks and outlook 
 
During the past decade, Therapeutic Drug Monitoring, drug interaction checking programmes and 
pharmacogenetic tests have become more integrated in the clinician’s prescription process. A major 
step forward was the publication of the TDM consensus paper for psychiatry in 2004 (41), which 
provides guidelines for plasma level analysis and reference plasma levels. Thanks to the experiences 
made in pharmacovigilance programmes such as AMSP, where drug plasma levels have become an 
important factor to assess causality, and from published case reports linking observed ADRs or 
therapeutic failures to unusual and/or unexpected plasma levels, awareness is increasing. In 2011, 
updated and extended TDM guidelines will be published for therapeutic and dose related reference 
levels and including, for the first time, the notion of an alert plasma level, since the upper value of the 
recommended levels is often misinterpreted as the toxic threshold. This can, in some cases, lead to 
unnecessary dose adaptations and subsequent treatment failure.  
Although in 2011 clinicians are more familiar with therapeutic drug monitoring than they were 10 
years ago, efforts to teach the correct handling and interpretation of drug plasma levels to ensure 
meaningful results must continue. At the Psychiatric Clinic Königsfelden, it seems that involuntary 
intoxications due to unrecognised drug interactions or pharmacogenetic vulnerability are being 
detected earlier and are becoming less common. To confirm this assumption, we plan to compare drug 
plasma level results and drug combination data from 2000-2002 with those of 2009-2011. However, 
the introduction of regular TDM is not the only factor that has contributed to a lower number of 
harmful drug interactions: the introduction of our drug interaction programme mediQ.ch in the autumn 
of 2006 has also had a significant impact, as did the introduction of our test algorithm TDM plus, 
following which pharmacogenetic test results explained a number of unusual plasma levels. 
 
How  did the work in connection with this thesis contribute to improve drug 
safety  for the psychiatric  patient? 
Psychiatric patients are often exposed to polypharmacy of different psychotropic and somatic drugs 
their whole life, whereby the latter are sometimes administered to combat adverse effects of the first. 
The chronic use of drugs bears extra risks (e.g. weight gain and metabolic syndrome with modern, 
tardive dyskinesia, in the case of classic antipsychotics), risks which are hardly detected before a drug 
reaches the market. In phases of symptom exacerbation, the psychiatric patient might be medicated 
against his or her will in an emergency situation, be given high doses of different psychotropic drugs 
while being unable to communicate negative side effects. It is important to recognize and understand 
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ADR risk factors by undertaking clinical trials, case-control studies and by learning from well-
analysed case reports. It is necessary to raise awareness of these risks and to offer a tool that helps 
clinicians assess risks quickly. 
AMSP is a pharmacovigilance programme which helps finding risk factors and generates safety 
signals for new ADR in psychiatric patients under naturalistic conditions. It represents an instrument 
of quality assurance and continuous education of medical doctors in psychiatric wards. By discussing 
the cases of the AMSP+ study, TDM and pharmacogenetics have been introduced to members of the 
AMSP programme during the different case conferences. In the course of the last decade, TDM has 
become a valuable tool for causality assessment of SADR, and pharmacogenetic variation is now 
generally recognized as a risk factor. The AMSP+ study was able to confirm that high drug plasma 
levels represent a risk factor for experiencing an SADR with a statistically significant odds ratio of 3.5 
for drug plasma levels >120% of the upper recommended reference level. AMSP data show that the 
hospitalisation period doubles when a psychiatric patient experiences a serious adverse reaction. If 
drug plasma levels are measured at an earlier stage, we are able to prevent a number of SADR. We can 
furthermore guide the clinician in his or her choice of reducing the dose or changing the drug. 
However, for economical reasons we cannot recommend routine TDM. The indications for TDM 
given in the consensus guidelines should be followed.  
The situation concerning pharmacogenetic tests is more complex. On the one hand, more research, 
such as our clinical trials with mirtazapine and clozapine, is needed to understand which genotypes 
influence the effects of which drugs. On the other hand, we have to understand the nature of genotype-
related risks. We were able to show that the case-control study design is appropriate to identify rare 
events such as SADR and their risk factors. A state-of-the-art paper on pharmacogenetic studies also 
mentions the case-control design as suitable for studying SADR and pharmacogenetics (349). We will 
continue our research into risk factors of SADR in psychiatry and will analyse a larger case-control 
group for the impact of high plasma levels and more CYP450, and possibly ABCB1, genotypes.  
Based on our experience gained during the AMSP+ study and on the fact that we have only sparse data 
to support routine TDM and/or pharmacogenetic testing, we developed the test algorithm “TDM plus”. 
This algorithm is followed at the Psychiatric Clinic Königsfelden and has been instrumental in 
avoiding unnecessary pharmacogenetic tests. It has also become part of many continuing medical 
education lectures in and outside Switzerland. It is our firm belief that TDM and pharmacogenetic 
tests are valuable instruments of pharmacovigilance, not only in the causality assessment of ADR, but 
also in limiting harmful effects and in preventing them in future treatments.  
It is not enough to study and publish pharmacological characteristics of drugs or ADR related risk 
factors, this knowledge must be available to the treating physician at the moment of prescribing the 
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medication for the patient. A variety of electronic drug information programmes have become 
available, with the most successful programmes being accessible through the internet, which allows 
information retrieval at any time from almost every location. Future prescribing will most probably be 
done electronically on a handheld device.  
mediQ.ch has taken another approach than most of the current drug interaction programmes by being 
designed “bottom up”, meaning that risk assessment is based on the clinical and pharmacological data 
available for the combination of two specific drugs. It allows easy updating and combining interaction 
risks with other factors such as specific genotypes, diet, lifestyle or co-morbidity. Medical 
professionals from more than 130 hospitals, and 400 independent physicians in the German-speaking 
countries, consult this programme regularly. Their feedback is taken into account to fine-tune the 
programme to meet the users’ needs. mediQ.ch gives more detailed and more in-depth information 
than most other programmes. However, this detailed information rather meets the needs of hospital 
doctors and pharmacists than those of doctors or pharmacists in the field. One might consider 
developing a “light” version for them and adapting it for use with mobile devices such as smart phones 
or the I-Pad. This may also meet the needs of patients. 
mediQ.ch will be developed further, ideally to cover all clinically significant interactions, although 
such a goal might seem ambitious considering the vast number of possible drug pairs. Each user has 
the possibility to request information about such drug pairs of a drug combination therapy that have 
not yet been described. Answers will be provided within 48 hours, and the missing information is 
added to the programme. All information has to be periodically re-examined and, if necessary, 
updated. To support this task, the programme has an automatically generated reminder for information 
that is older than 2 years.  
Another challenge will be the integration of the drug interaction check of mediQ.ch into the electronic 
prescribing process and to make this large information database available in other languages. In 
general, more collaboration and consensus between different drug information providers should be 
attained and information from different sources combined, so that drug prescribing becomes safer. In 
order to avoid possible medication errors, several governmental bodies are considering guidelines for 
electronic prescription programmes which would include an interaction check. This may eventually 
lead to a certain level of harmonisation between the information from different providers. 
Finally, has the target of avoiding high-risk drug combinations been reached? Are there fewer SADR 
due to drug interactions? A recent publication on AMSP data has shown that although polypharmacy 
has increased between 1993 and today, the number of high-risk combinations (as measured by 
mediQ.ch) has in fact decreased (392). This may indicate that high-risk combinations are avoided 
more often and replaced by low-risk drug combinations. Our impression based on the AMSP project is 
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that the severity of Type A ADR has decreased. Serotonin toxicity e.g. is being recognised early and a 
dramatic course is thus being prevented. Also, more targeted laboratory or ECG controls are carried 
out in high-risk drug combinations, which can prevent serious ADR. Very high drug plasma levels 
resulting from a pharmacokinetic drug interaction have also become less frequent. 
 
Our hope 
Increasing knowledge of drug characteristics, pharmacogenetics and environmental factors, together 
with more advanced and less costly laboratory and information technologies, will enable us to find a 
way to practice a (more) personalised medicine, ensure safer and better tolerated drug treatments and a 
higher therapy success rate.  
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